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 ABSTRACT 
MITOCHONDRIAL LIPIDOME AND GENOME ALTERATIONS IN MOUSE 
BRAIN AND EXPERIMENTAL MURINE BRAIN TUMORS 
Michael A. Kiebish 
Thesis Advisor: Thomas N. Seyfried 
 Mitochondria are the key regulators of the bioenergetic state of the cell.  
Damage to mitochondrial protein, DNA, or membrane lipids can result as the 
cause or affect of disease pathology.  Regardless, this damage can impair 
mitochondrial function resulting in a decreased ability to produce ATP to support 
cellular viability.  This thesis research examined the mitochondrial lipidome by 
shotgun lipidomics in different populations of C57BL/6J (B6) brain mitochondria 
(non-synaptic and synaptic) and correlated lipid changes to differences in 
electron transport chain (ETC) activities.  Furthermore, a comparison was made 
for non-synaptic mitochondria between the B6 and the VM mouse strain.  The 
VM strain has a 1.5% incidence of spontaneous brain tumors, which is 210 fold 
greater than the B6 strain.  I determined that differences in the brain 
mitochondrial lipidome existed in the VM strain compared to the B6 strain, likely 
corresponding to an increased rate of spontaneous brain tumor formation.  
Analysis of the mitochondrial genome in the CT-2A, EPEN, VM-NM1, and VM-
M3 brain tumors compared to their syngeneic controls mouse strains, C57BL/6J 
(B6) and VM mice, was examined to determine if mutations existed in 
experimental brain cancer models.  No pathogenic mtDNA mutations were 
discovered that would likely cause a decrease in the mitochondrial functionality.  
A novel hypothesis was devised to examine the tumor mitochondrial lipidome to 
determine if quantitative or molecular species differences existed that could 
potentially alter the functionality of the ETC.  Brain tumor mitochondria were 
examined from tumors grown in vivo as well as in vitro.  Numerous lipid 
differences were found in the mitochondria of brain tumors, of which the most 
interesting involved the unique molecular speciation of cardiolipin.  ETC activities 
were significantly decreased in the primary ETC complexes which contribute 
protons to the gradient as well as the linked complexes of brain tumor 
mitochondria compared to controls.  Taken together, it is likely that differences in 
the mitochondrial lipidome of brain tumors results in severe impairment of the 
mitochondria’s ability to produce ATP through the ETC.  This research has 
provided a new understanding of the role of mitochondrial lipids in brain as well 
as brain cancer and offers an alternative explanation for metabolic dysfunction in 
cancer. 
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 CHAPTER ONE 
INTRODUCTION 
 
Mitochondria 
 Mitochondria are a key cellular component, which maintain and regulate 
the bioenergetic state of the cell.  After one billion years of cellular evolution, 
mitochondria have acquired countless roles in the cell, not only as the guardian 
of the cells’ bioenergetic status, but also as the regulator of programmed cell 
death.  Over 10 quadrillion (1015) mitochondria exist in the human body providing 
it with the currency of energy, adensine triphosphate (ATP), to support biological 
function (Lane 2005).  This thesis investigates alterations in mitochondrial 
function that contribute to bioenergetic dysfunction in cancer (Warburg 1956). 
 Mitochondria were first discovered in the mid-1800’s by microscopists. 
The organelle was uniquely autonomous and existed within the cytoplasm.  At 
first, mitochondria were referred by countless names, yet the description referring 
to the thread (Greek mitos) and small grain like structure (Greek chondrin), 
seemed to take precedence (Scheffler 1999).  The mitochondrion was described 
as a bimembraneous organelle, containing an inner and an outer membrane.  
The inner mitochondrial membrane contained numerous membraneous folds, 
termed cristae, which differ dramatically in organization in different tissues, 
organisms, or diseased states.  Mitochondria also contain electron dense 
1 
 
particles within the inner membrane, later believed to be components of the 
electron transport chain (ETC) (Munn 1974). 
 The recognition of mitochondrial function evolved slowly over the first 100 
years after their discovery.  Seminal work by enzymologists and biochemists 
such as Otto Warburg, Britton Chance, Peter Mitchell, Hans Krebs as well as 
countless others characterized the enzyme activities, oxidation and reduction 
reactions, as well as the electrochemical properties contained within 
mitochondria (Lehninger 1964).  As our understanding of mitochondria increased, 
the level of complexity and interconnection between metabolic pathways became 
clearer regarding the bioenergetic capacity of the mitochondrion.  The connection 
between oxygen utilization linked with Mitchell’s chemiosmotic hypothesis of a 
proton motive force driving the synthesis of ATP caused the greatest 
developments toward the understanding of the ETC.  Two models are proposed 
to describe the mitochondrial ETC.  These are the random collision model, which 
described the ETC complexes arranged as individual components in a random 
order.  The second model described the ETC complexes existing in a solid state 
electron channeling or as a ‘respirasome’ in which multiple complexes form a 
multicomplex organization (Lenaz and Genova 2007; Schagger 2002).  Each 
complex performs a designated function either through the transfer of protons 
and electrons from metabolites, through the membrane, or acts as an ionic 
selective pore to couple the reaction (Wainio 1970).   
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 The mitochondrial ETC consists of five unlinked complexes to include 
NADH-ubiquinone oxidoreductase (Complex I), succinate ubiquinone 
oxidoreductase (Complex II), ubiquinol-cytochrome c reductase (Complex III), 
cytochrome c oxidase (Complex IV), and F1Fo ATPase (Complex V).  The two 
linked complexes are NADH cytochrome c reductase (Complex I / III) and 
succinate cytochrome c reductase (Complex II / III) (Scheffler 1999).  Each ETC 
complex performs a designated reaction to contribute to the ETC and is 
composed of subunits encoded by the mitochondrial and/or the nuclear genome 
(Table 1).   
 The enzyme activities of the ETC can be measured as individual 
complexes (unlinked) or as a combined measurement of multiple complexes 
(linked) activities as mentioned previously (Ellis et al. 2005; Pon and Schon 
2001).  Measurement of the unlinked activities determines if differences exist in 
ETC functionality in pathological states.  Differences in activities can be the result 
a loss of an ETC complex subunit, a change in the distribution of phospholipids 
that dock into the enzyme to regulate its activity of electron transfer, or due to 
damage by free radicals as the result of a pathological process (Shinzawa-Itoh et 
al. 2007; Lenaz et al. 2002; Starkov et al. 2002) (Figure 1A).  The linked activity 
measurements can determine if alterations exist in the membrane, supercomplex 
formation, or the combined individual activities.  Differences in linked activity 
could be due a change in carrier proteins and lipids (cytochrome c and 
ubiquinone), mitochondrial lipid alterations resulting in uncoupling or a change in 
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fluidity of the membrane, or a loss of supercomplex formation (Lenaz et al. 2007; 
Lenaz and Genova 2007; Hoch 1998; Paradies et al. 2002) (Figure 1 B-E).  
Linked activities also measure the electron flux through the pathway.  These 
conditions make it necessary to measure both unlinked and linked activities to 
determine if alterations exist in mitochondrial physiology. 
  
The Mitochondrial Genome 
 Mitochondria are also unique since they harbor their own genome 
localized in the mitochondrial matrix.  The mitochondrial genome is a ~16,500 bp 
circular piece of DNA, which encodes 37 genes on the L and H strand.  These 
genes include 22 tRNAs, 2 rRNAs, and 13 components of the ETC 
(Wolstenholme 1992; Copeland 2002).  Since, mtDNA contains few non-coding 
regions (~5% of the total genome) it is vulnerable to pathogenic mitochondrial 
mutations, since genes reside on both the 5’ Æ 3’ end of the sequence as well as 
the 3’ Æ 5’ end of the coding sequence.  The mitochondrial genome is localized 
adjacent to the ETC, which can produce vast amounts of reactive oxygen 
species (ROS).  This localization has resulted in much spectulation that mtDNA 
is likely mutated at a higher rate than nuclear DNA.  Also, the mitochondrial 
genome does not contain protective histones or a high fidelity polymerase, 
resulting in a ten-fold increase in the rate of mutation compared to nuclear DNA 
(Kunkel and Loeb 1981; Croteau and Bohr 1997; Backer and Weinstein 1980). 
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Fortunately, the mitochondrial genome has evolved to compensate for constant 
assault by containing 2-8 copies per mitochondrion, to allow for selection against 
damaged mtDNA (Khaidakov and Reis 2005; Fan et al. 2008). The mitochondrial 
genome also has a slightly different genetic code compared to the nuclear 
genome in regards to amino acid synthesis (Barrell et al. 1979).  Taken together, 
these factors have created interest into the role of mtDNA mutations in 
neurodegenerative, neurological diseases, as well as cancer (Wallace 2001; 
Wallace 2005). 
 There are between 1,000 to 2,000 different protein components of the 
inner and outer mitochondrial membrane (Frazier et al. 2006; Stojanovski et al. 
2003).  Mitochondrial proteins encoded by mtDNA are synthesized in the matrix 
and imported into the inner mitochondrial membrane.  Other proteins encoded by 
the nuclear genome are first localized to the mitochondria by their targeting 
sequence and imported through TOM/TIM protein import machinery through the 
outer and the inner mitochondrial membrane depending on their outer, inner, or 
matrix sorting sequence (Hartl 1996).  Interestingly, differences in mitochondrial 
membrane lipid composition can alter the import of mitochondrial proteins 
through TOM/TIM machinery (Jiang et al. 2000; Ostrander et al. 2001). 
 
The Mitochondrial Lipidome 
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 The mitochondrial lipidome is the least studied of the mitochondrial 
structural components, yet it represents almost half of the entire mitochondrial 
membrane.  The lipid composition of the mitochondrial membrane has evolved to 
conform to a specific distribution for the purpose of energy production (Haslam et 
al. 1973; Mileykovskaya et al. 2005; Else and Hulbert 2003).  Changes to the 
lipid composition of the mitochondrial membrane will dramatically affect the ability 
of the mitochondria to produce ATP (Hoch 1992; Chicco and Sparagna 2007).  
The fluid mosaic model of membranes has established the role of lipids in 
membrane function and dynamics (Singer and Nicolson 1972).  In the fluid 
mosaic model, membranes are composed of proteins (integral, peripheral, and 
transmembrane), which are embedded in a lipid bilayer membrane (Cooper 
2000).  The fluidity of lipids are expressed by the phase gel to liquid crystalline 
transition temperature (Tt), which is dependent upon the chain length, number of 
double bonds, and polar head groups of lipids (Packer and Gomez-Puyou 1976).  
Also, depending on the specific lipids as well as the effect of ionic strength and 
interaction with Ca2+, lipids can transform into different phases and molecular 
shapes, such as micellar, bilayer, or hexagonal (HII) phase, which can change 
the shape and fluidity of membranes (Vance and Vance 1996).  Thus, changes in 
the distribution, degree of saturation or unsaturation, as well as chain length, will 
have dramatic effects of the fluidity as well as structure of biological membranes. 
 The mitochondrial membrane is unique since it contains two membranes 
with distinctive lipid compositions in both the inner and the outer membrane 
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(Munn 1974; Comte et al. 1976).  The lipid composition of the mitochondrial 
membrane primarily consists of ethanolamine glycerophospholipids (EtnGpl), 
choline glycerophospholipids (ChoGpl), cholesterol, cardiolipin (Ptd2Gro), 
phosphatidylinositol (PtdIns), phosphatidylglycerol (PtdGro), phosphatidylserine 
(PtdSer), sphingomyelin (CerPCho), and ceramide (Cer).  Mitochondrial EtnGpl 
and ChoGpl can also be composed of lipid subclasses, such as phosphatidyl 
(Ptd), plasmenyl (Pls), and plasmanyl (Pak) glycerophospholipids depending on 
the linkage found at the sn-1 position.  Plasmenyl glycerophospholipids 
(plasmalogens) are unique to heart and brain mitochondria and have been 
hypothesized to act as antioxidant as well as fusogenic lipids aiding in membrane 
fusion (Getz et al. 1968; Morand et al. 1988; Gorgas et al. 2006).  Most lipids in 
the mitochondrial membrane are imported by mitochondrial/microsomal-
associated membrane complex.  These lipids include: ChoGpl, EtnGpl, 
cholesterol, PtdIns, PtdSer, and Cer (Daum and Vance 1997; Vance et al. 1997).  
PtdEtn can also be synthesized by the decarboxylation of PtdSer on the outer 
leaflet of the mitochondrial membrane (Zborowski et al. 1983).  Also, Cer has 
been proposed to be synthesized by the mitochondria (Ardail et al. 2001).  The 
only lipids solely synthesized in the mitochondria are PtdGro and Ptd2Gro. 
 Ptd2Gro is exclusively found in the mitochondrial membrane.  Ptd2Gro was 
originally discovered based on its abundance in beef heart, hence its common 
name ‘cardio’ lipin, the heart lipid (Hoch 1992; Pangborn 1942).  Ptd2Gro is 
synthesized by the condensation of PtdGro and cytidine diphosphate-
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diacylglycerol (CDP-DAG) in the mitochondrial inner membrane.  Ptd2Gro is 
unique since it contains two phosphate head groups and four acyl tails (Fig. 2) 
(Daum 1985).  These characteristics allow Ptd2Gro to contribute to the integrity of 
the mitochondrial membrane, dock into membrane complexes as well as interact 
with calcium (Grijalba et al. 1999; Shinzawa-Itoh et al. 2007; Chicco and 
Sparagna 2007; Hoch 1992).  The acyl composition of Ptd2Gro molecular 
species also appears to be stringently regulated by acyl transferases that 
reacylate newly synthesized Ptd2Gro.  This process is referred to as Ptd2Gro 
remodeling and has been proposed to use EtnGpl and ChoGpl sn-2 acyl tails as 
donors to reacylated Ptd2Gro (Xu et al. 2003; Hauff and Hatch 2006).  Based on 
the distribution of Ptd2Gro molecular species post-remodeling, it has also been 
proposed that specific molecular species of Ptd2Gro have selective functionality.  
In addition, the enzyme that performs the acyl transferase has fatty acid acyl 
specificity due to the predominance of tetralinoleic Ptd2Gro (18:2-18:2-18:2-18:2) 
as the most abundant Ptd2Gro in most tissues (Schlame et al. 2005; Chicco and 
Sparagna 2007). 
 
Electron Transport Chain 
 The activities of ETC complexes have demonstrated a requirement of 
Ptd2Gro content as well as specific molecular species (Chicco and Sparagna 
2007; Gohil et al. 2004; Paradies et al. 1997).  Complex I, III, IV, and V have 
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demonstrated a requirement of Ptd2Gro for their activity (Fry and Green 1981; 
Goormaghtigh et al. 1986; Fry et al. 1980; Robinson 1993).  Changes in Ptd2Gro 
content have also been implicated in alterations in supercomplex formation 
(McKenzie et al. 2006; Pfeiffer et al. 2003a; Pfeiffer et al. 2003b).  However, 
Ptd2Gro is not the only lipid known to interact with the ETC or other enzymes. 
 Cer, cholesterol, EtnGpl, ChoGpl, as well as PtdGro can also intereact 
with enzyme complexes of the mitochondrial membrane.  Specific molecular 
species of Cer can inhibit Complex I and III activities (Di Paola et al. 2000).  
PtdGro, EtnGpl, and ChpGpl have also been found to regulate the activity of 
Complex IV at key docking sites for electron transfer (Shinzawa-Itoh et al. 2007).  
Also, cholesterol in the outer mitochondrial membrane specifically interacts with 
the voltage dependent anion channel (VDAC), which regulates anionic transfer 
between the intermembrane space and the cytosol (Rostovtseva et al. 2006).  
Numerous other enzymes involved in ketone metabolism, ATP transport, creatine 
synthesis are also regulated by mitochondrial membrane lipids (Daum 1985; 
Sawyer and Greenawalt 1979; Jurtshuk et al. 1963; Cheneval and Carafoli 
1988). 
  
Brain Mitochondria 
 Mitochondrial metabolism can differ between organs, based on 
specialized metabolic functions or bioenergetic requirements of tissues (Scheffler 
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1999; Lemasters et al. 1988; Benard et al. 2006).  The brain is unique in terms of 
mitochondria since multiple populations exist due to brain heterogeneity (Villa et 
al. 1989b).  The two predominant populations include non-synaptic (NS) 
mitochondria, which originate from neuronal and glial cell bodies, and synaptic 
(Syn) mitochondria, which originate from nerve endings (Lai and Clark 1989).  
These mitochondrial populations demonstrate differences in ETC activities as 
well as other metabolic processes (Lai et al. 1977; Battino et al. 1991; Lai et al. 
1994; Brown et al. 2006).  Differences in mitochondrial lipid composition could 
underlie the metabolic heterogeneity of the brain (Berl et al. 1975; Boulton et al. 
1989; Daum 1985). 
 
Mitochondria and Cancer 
 Alterations in mitochondrial metabolism are most notably associated with 
metabolic dysfunction in cancer.  Deficiencies in oxidative phosphorylation were 
originally characterized by Otto Warburg in the 1920’s and 1950’s (Warburg 
1931; Warburg 1956).  Warburg determined that tumors derived most of their 
energy from aerobic glycolysis and stated that tumors had irreversible damage to 
their respiratory capacity (Warburg 1956).  This concept became known as the 
‘Warburg hypothesis’ and has spawned research for the past 80 years to test this 
hypothesis regarding mitochondria’s role in tumorigenesis or abnormal 
metabolism in tumors (Racker and Spector 1981; Chance 2005; Pedersen 2007; 
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Wallace 2005).  The Warburg hypothesis has not yet been proven incorrect, due 
to the fact that Warburg never defined what abnormalities actually existed in 
tumor metabolism, therefore it is now considered a theory (Warburg 1931; 
Warburg 1956).   Researchers have focused on mtDNA mutations, alterations in 
glycolytic enzymes, abnormalities in energy stress signals, mitochondrial 
signaling factors or content, as well as reactive species (Bui and Thompson 
2006; Thompson et al. 2005; Kirsch et al. 1972; Kroemer 2006; Pelicano et al. 
2006; Aisenberg 1961; Fantin et al. 2006).   
 It is well established that brain tumors have an abnormal glycolytic and 
oxidative metabolism (Lichtor and Dohrmann 1986; Meixensberger et al. 1995; 
Oudard et al. 1997; Galarraga et al. 1986; Seyfried and Mukherjee 2005).  The 
role of mtDNA mutations has been extensively studied in brain tumors, with no 
evidence proving that mtDNA mutations contributed to the dependence on 
glycolysis (Kirches et al. 2001; Kirches et al. 2003; Wong et al. 2003; Kiebish and 
Seyfried 2005).  Mitochondrial membrane lipids regulate mitochondrial function in 
regards to its bioenergetic capacity (Hoch 1992; Ellis et al. 2005; Fleischer et al. 
1967).  Previously, brain tumor mitochondrial lipids have been examined, 
however, the mitochondrial fraction contained excessive organelle and 
membrane contamination resulting in a misinterpretation of the lipid distribution 
relative to functional differences (Sun 1973).  Hepatoma mitochondrial lipids have 
also been examined, however, there was no association regarding the functional 
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implications of the altered mitochondrial lipid distribution (Park and Wenner 1970; 
Reitz et al. 1977; Hartz et al. 1982; Crain et al. 1983; Bergelson et al. 1970).   
 This thesis provides new evidence to support the Warburg theory of 
altered energy metabolism in tumors.  The mitochondrial genome as well as the 
lipidome were investigated in conjuction with ETC activities to determine if 
alterations in mitochondrial metabolism exist in brain tumors.  Investigation of the 
mitochondrial lipidome in brain cancer is a novel interpretation of the Warburg 
theory, which might be able to explain the irreversible damage of mitochondria in 
cancer.  A new understanding of brain metabolic compartmentation, in regards to 
mitochondrial lipids, was also developed based on the discoveries made in this 
dissertation research.  Furthermore, this thesis provides new evidence regarding 
the importance of brain and brain tumor mitochondrial lipidome in regards to 
bioenergetic efficiency. 
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           Complex Reaction
Nuclear 
encoded 
subunits
mtDNA 
encoded 
subunits
I NADH-ubiquinone oxidoreductase NADH + Q + 5Hi+ −> NAD+ + QH2 + 4Ho+ 39 7
II Succinate decylubiquinone oxidoreductase succinate + Q −> fumarate + QH2 4
III Ubiquinol-cytochrome c oxidoreductase QH2 + 2 cyt c3+ + 2H+i −> Q + 2 cyt c2+ + 4 H+o 10 1
IV Cytochrome c oxidase 4 cyt c2+ + 8H+i + O2 −> 4 cyt c3+ + 4H+0 + 2H20 10 3
V F1F0 – ATPase ADP + Pi −> ATP + H20 14 2
I / III NADH cytochrome c reductase NADH + Q + 5Hi+ −> QH2 + 2 cyt c3+ −> Q + 2 cyt c2+ 
II / III Succinate cytochrome c reductase succinate + Q −> QH2 + 2 cyt c3+ −> Q + 2 cyt c2+
Table 1   Components of the electron transport chain
     Unlinked
    Linked
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Figure 1.  The electron transport chain in the inner mitochondrial membrane.  (A)  
The ETC spans across the inner mitochondrial membrane and is organized into 
five individual complexes.  The ETC utilizes the unique properties of the inner 
mitochondrial membrane to create an impermeable barrier as well as shuttle 
electrons through ubiquinone (Q) and cytochrome c (c) between complexes.  
Complexes I, III, and IV contribute protons to the gradient, where as complex V 
utilizes protons for the synthesis of ATP. Linked measurements of the electron 
transport chain can be interpretated in numerous ways: either measurement of 
the individual complexes or as a measurement of the supercomplex formed in 
the mitochondrial membrane.  Complex I / III and Complex II / III can be 
measured as the span over the membrane (B, D) or as a supercomplex (C, E), 
respectively. 
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Figure 2. Structure of cardiolipin.   Cardiolipin contains two phosphate head 
groups and four fatty acid tails.  The molecular species displayed is tetraoleic 
cardiolipin, which is one of the most abundant species in brain.  (Cardiolipin 
structure created on www.lipidmaps.org) 
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Cardiolipin 
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CHAPTER TWO 
Absence of pathogenic mitochondrial DNA mutations in mouse brain tumors 
 
INTRODUCTION 
 
Mitochondrial Genome 
Mitochondrial DNA (mtDNA) is essential for the production of subunits for the 
ETC, since it encodes peptides for Complex I, III, IV, and V.  The mitochondrial 
genome consists of a 16.5 kb piece of circular DNA encoding 37 genes on the L 
and H strands.  These include 22 tRNAs, 2 rRNAs, and 13 respiratory chain 
subunits (Wolstenholme 1992).   The mitochondrial genetic code varies slightly 
from the nuclear genetic code (Barrell et al. 1979).  The mutation rate is 10 fold 
higher in the mitochondrial genome, than in the nuclear genome (Neckelmann et 
al. 1987; Wallace et al. 1987).  This higher mutation rate is due to a lack of 
protective histones and reduced fidelity of polymerase γ (Backer and Weinstein 
1980; Allen and Coombs 1980; Kunkel and Loeb 1981).  The higher mutation 
rate of the mitochondrial genome might also be explained by its localization to 
the inner mitochondrial membrane, which contains an increased level of 
damaging reactive oxygen species (ROS) (Croteau and Bohr 1997; Bianchi et al. 
2001).  mtDNA defects may also contribute to a decrease in metabolic efficiency 
that enhances aging, promotes neurodegeneration, and is conducive to 
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carcinogenesis (Brown et al. 1979; Cavalli and Liang 1998; Augenlicht and 
Heerdt 2001). 
 
mtDNA Mutations in Cancer 
mtDNA mutations have been studied in various types of cancers, including breast 
(Tan et al. 2002), bladder, lung, head and neck (Fliss et al. 2000), gastric 
(Maximo et al. 2001), esophageal (Hibi et al. 2001), pancreatic (Jones et al. 
2001), and colon (Polyak et al. 1998).  The majority of the mutations in the 
mitochondrial genome of human tumors were found in the hypervariable regions 
of the displacement loop (D-loop) (Okochi et al. 2002; Ha et al. 2002; Kumimoto 
et al. 2004).  These hypervariable regions correspond to the OL and Arg tRNA in 
mouse mtDNA (Bayona-Bafaluy et al. 2003).  Studies of human tumors have 
demonstrated an association between mtDNA somatic mutations and tumor 
progression (Shay and Werbin 1987; Baggetto 1992; Cavalli et al. 1997). 
 
mtDNA Mutations in Brain Cancer 
Few studies have evaluated mtDNA mutations in brain cancer.  
Mitochondrial genome instability was found in the hypervariable regions in the D-
loop of human gliomas, meningiomas, schwannomas, gliomatosis cerebri, 
glioblastomas, astrocytomas, and neurofibromas (Kirches et al. 1999; Kirches et 
al. 2001; Kirches et al. 2003; Vega et al. 2004; Kurtz et al. 2004).  Other studies 
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of the mitochondrial genome focused on mtDNA copy number in brain tumors 
(Liang and Hays 1996).  In the only study examining the entire mitochondrial 
genome, Wong et al. found that the majority of mtDNA somatic mutations in 
medulloblastomas existed in regions of mononucleotide repeats, rather than in 
genes encoding proteins for the respiratory complexes (Wong et al. 2003).   
 
Mitochondrial Heterogeneity in Brain 
In contrast to most tissues where mitochondrial morphology and function 
is relatively homogeneous, mitochondria in brain are heterogeneous and exist as 
non-synaptic free mitochondria (FM), synaptic light mitochondria (LM), and 
synaptic heavy mitochondria (HM) (Battino et al. 1995; Genova et al. 1997).  This 
morphological heterogeneity is thought to reflect the metabolic heterogeneity of 
mitochondria within and between the various neuronal and non-neuronal (glial) 
cell populations (Lai 1992).  We examined the entire mitochondrial genome in 
chemically induced and spontaneous mouse brain tumors that differ in 
metastasis, malignancy, and vascularity.  To our knowledge, this is the first study 
examining the entire mitochondrial genome for mutations in tumors cells 
compared to their syngeneic host strain.  Direct sequencing was used to examine 
mtDNA from isolated normal brain mitochondrial populations and from tumor cell 
mitochondria.  
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 MATERIALS AND METHODS 
Mice  
The inbred VM and C57BL/6J (B6) mouse strains were obtained originally 
from F. C. Frazer, University of Edinborough, and from the Jackson Laboratory, 
Bar Harbor, ME, respectively.  All mice used in the study were propagated in the 
animal care facility at Boston College using animal husbandry conditions 
described previously (Ranes et al. 2001).  All animal use procedures were in 
accordance with the NIH Guide for the Care and Use of Laboratory Animals and 
were approved by the Institutional Animal Care Committee. 
Experimental Murine Brain Tumors 
The EPEN and CT-2A brain tumors were produced originally from 
implantation of 20-methylcholanthrene into the brains of B6 mice as previously 
described (Seyfried et al. 1992; Zimmerman and H. 1941; Zimmerman and 
Arnould 1941).  The EPEN tumor arose in the cerebral ventricle and was 
characterized as an ependymoblastoma, whereas the CT-2A tumor arose in the 
cerebral cortex and was characterized as an anaplastic astrocytoma (Seyfried et 
al. 1992; Rubin et al. 1969).  The morphological, biochemical, and angiogenic 
characteristics of these mouse brain tumors have been described previously 
(Ranes et al. 2001; Ecsedy et al. 1998; Seyfried et al. 1992; Seyfried et al. 1987; 
Cotterchio and Seyfried 1993; Mukherjee et al. 2004).  The nonmetastatic (VM-
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NM1) and the metastatic (VM-M3) tumors arose spontaneously in the brains of 
VM mice as previously described for other VM brain tumors (Fraser 1986; El-
Abbadi et al. 2001).   
 
Tumor cell culture 
Cultured cell lines were prepared from each tumor as the Seyfried laboratory 
previously described (Bai and Seyfried 1997; el-Abbadi and Seyfried 1994).  The 
tumor cells were grown in Dulbecco's modified Eagle medium (DMEM) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) in a 
humidified atmosphere containing 95% air and 5% CO2 at 370C.  Upon reaching 
confluency, the cells were trypsinized and collected. 
 
Mitochondrial Isolation from Brain Tissue and Cultured Tumor Cells 
Mitochondria were isolated from VM and B6 cerebral cortex according to 
previously described procedures (Genova et al. 1997; Pon and Schon 2001).  
Cerebral cortex mitochondria were separated into three populations following 
ficoll gradient centrifugation.  These populations included non-synaptic free 
mitochondria (FM), synaptic light mitochondria (LM), and synaptic heavy 
mitochondria (HM).  Mitochondria were isolated from the tumor cell lines as a 
single enriched mitochondrial fraction as previously described (Yang et al. 1997; 
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Pon and Schon 2001).  Mitochondria were isolated in duplicate independent 
samples from each of the brain tumor cell lines for sequence comparison. 
 
Isolation and Amplification of Mouse mtDNA 
mtDNA from cerebral cortex and cultured tumor cells was isolated using the 
DNeasy Tissue Kit (QIAGEN, Valencia, CA, USA) and was amplified in 12 
overlapping segments covering the entire mitochondrial genome.  PCR reactions 
were performed in a volume of 50 μl using the Eppendorf Master Taq system 
(Brinkmann Eppendorf, Westbury, NY).  Primers used for mtDNA amplification 
are given in Table 2.  PCR conditions for all primer pairs consisted of an initial 
denaturation at 94°C for 2 min followed by 34 cycles of 94 °C for 1 min.  
Extension time for all primers pairs, except primer pair 1, was 72 °C for 1:10 +3 
s/cycle with a final extension at 72°C for 5 min.  Primer pair 1 had an extension at 
72 °C for 1 min with a final extension time of 5 min.  Optimal annealing 
temperatures were determined by performing gradient PCR on each of the 
primer sets.   
 
mtDNA Sequencing 
Amplified regions of mtDNA were purified using a PCR purification kit (MO BIO 
Laboratories, Solana Beach, CA) and were then visualized by 1% agarose gel 
electrophoresis.  DNA concentration was estimated using a Low DNA Mass 
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Ladder (Invitrogen, Carlsbad, CA) by gel electrophoresis.  Approximately 25 fmol 
of the purified PCR product was used in the sequencing reaction following 
manufacturer’s instructions for the CEQ DTCS kit (Beckman Coulter, Fullerton, 
CA).  The amount of DNA used varied depending on the size of the PCR 
fragment.  The primers in Table 2, together with nested primers, were used in the 
sequencing reactions to obtain double-stranded sequence.  Nested primer 
information can be found in Table 3 and description of primer location can be 
found in Figure 3.   
Sequencing reactions were performed at 96°C for 20 s, 50°C for 20 s, and 60°C 
for 4 min based on a 32 cycle reaction.  Sequencing products were precipitated 
in cold 95% ethanol, washed twice with cold 70% ethanol, dried in a speed vac 
for 20 minutes, and then re-dissolved in sample loading solution provided by the 
manufacturer (Beckman Coulter, Fullerton, CA).  The samples were then 
transferred to a Beckman 96-well plate and the plate loaded into a CEQ 8000 
automated sequencer (Beckman Coulter).  The mtDNA sequence alignments 
were then compared to those from Mus Musculus (Accession no. V00711) (Bibb 
et al. 1981) and from B6 mice (Accession no. AY172335) (Bayona-Bafaluy et al. 
2003). 
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RESULTS 
Analysis of mtDNA Variation in B6 and VM Mouse Strains 
 Sequence analysis of the entire mitochondrial genome of the VM and B6 
mouse strains revealed a single nucleotide base pair change at position 11774, 
found in both strains, compared to the republished B6 sequence (Bayona-
Bafaluy et al. 2003). This resulted in a T->A transversion, causing an amino acid 
change of an isoleucine to methionine in the ND5 gene (Table 4).  This 
transversion was found in all three brain mitochondrial populations for both 
strains and existed in all brain tumor cell lines corresponding to the host strain.  
This was the only variation found between the B6 strain sequence and the 
republished B6 sequence (Bayona-Bafaluy et al. 2003).  The VM strain also had 
two additional nucleotide variations compared to the B6 strain.  The first variation 
was found in the ND3 gene at position 9461. This caused a C->T transition, but 
resulted in no amino acid change. A second variation existed in the poly-A tract 
of the Arg tRNA, where an adenine was inserted at position 9825 (Table 4).  The 
data show that few mtDNA variations exist between the B6 and VM inbred 
mouse strains. 
 
mtDNA Somatic Mutations in Mouse Brain Tumor Cell Lines Compared to 
Syngeneic Host mtDNA Sequence 
 Analysis of the EPEN brain tumor cell line revealed two somatic mutations 
compared to the syngeneic B6 host strain.  One mutation involved an insertion of 
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two adenines in the Arg tRNA at position 9825 (Table 5).  This is not expected to 
alter Arg tRNA function because the mutation occurred in a highly variable site in 
mouse strains (Bayona-Bafaluy et al. 2003).  A second mutation involved a T->C 
transition in the ND3 gene at position 9461, but did not change the amino acid.  
Analysis of the CT-2A brain tumor cell line revealed only a single mutation 
compared to the syngeneic B6 host strain.  This involved an insertion of an 
adenine in the OL at position 5182 (Table 5).  This mutation is also not likely to 
have functional consequence (Bayona-Bafaluy et al. 2003). 
 As in the chemically induced EPEN and CT-2A brain tumor cell lines, only 
a few somatic mutations were found in the spontaneous VM brain tumor cell lines 
(VM-NM1 and VM-M3) compared to the syngeneic VM host (Table 5).  Two 
somatic mutations were found in the nonmetastatic VM-NM1 cell line.  One 
mutation involved a deletion of an adenine in the OL at position 5182.  This is the 
same location where the only variation was found in the CT-2A tumor and is 
consistent with hypervariability in this region (Bayona-Bafaluy et al. 2003).  The 
second mutation in the VM-NM1 cell line involved a T->C transition in the D-loop 
at position 15466.  Neither of these mutations have functional consequence.  A 
single mutation was found in the metastatic VM-M3 cell line involving an A->G 
transition in the 16srRNA gene at position 2159.  In contrast to the other mtDNA 
mutations found in either the B6 or the VM tumor cell lines, the A->G transition in 
the VM-M3 cell line was heteroplasmic (Fig. 4).  This heteroplasmic mutation, 
however, was unstable since it was not found in later passages of this cell line 
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(data not shown).  Viewed together, these data indicate that only a few mtDNA 
somatic mutations exist in either chemically induced or spontaneous mouse brain 
tumors.  Also, three of these mutations were found in hypervariable regions and 
none were pathogenic.  
 
 
DISCUSSION 
The purpose of this study was to determine if mtDNA mutations existed in 
chemically induced and spontaneous mouse brain tumors and whether such 
mutations might provide insight on the development or progression of 
experimental brain tumors.  To reduce the probability of detecting spurious 
pathogenic mutations, we compared the mtDNA sequence of each brain tumor 
cell line with that of normal mtDNA from the syngeneic mouse host strains.  
Furthermore, to avoid the coamplification of mitochondrial pseudogenes that 
exist in nuclear DNA, we amplified only large mtDNA fragments (1-1.8 kb in 
length) in isolated mitochondria (Heerdt et al. 1994; Polyak et al. 1998; Parfait et 
al. 1998).  Several mtDNA mutations were found in the mouse brain tumor cell 
lines, but most of these were located in hypervariable mononucleotide hotspot 
regions, such as in the OL and in Arg tRNA for mouse mtDNA.  Moreover, none 
of these mutations were considered pathogenic since they did not change amino 
acid sequence or alter gene function. 
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Our findings that most mtDNA changes in the mouse brain tumors were in 
hypervariable regions of mononucleotide repeats are in general agreement with 
previous studies in human brain tumors (Table 6).  We detected a single 
heteroplasmic mutation in the 16srRNA gene of the VM-M3 metastatic cell line, 
which was determined by sequence analysis (Taylor et al. 2001).  This mutation 
was unstable since it could not be found in other independent isolates from this 
brain tumor cell line in later passages.  The EPEN cell line contained a nucleotide 
variation compared to the B6 genotype at position 9461 in the ND3 gene. This 
nucleotide variation in the EPEN cell line also existed in the VM-NM1 and VM-M3 
cell lines.  This polymorphism could be due to a base pair wobble at that location 
or could result from a nucleotide variation in the original mouse from which the 
tumor arose (Rubin and Sutton 1968).  Viewed together, our findings suggest 
that mtDNA mutations are unlikely to contribute to the development or 
progression of these diverse experimental mouse brain tumors. 
With the exception of a single variation at nucleotide 11774 in the ND5 gene, our 
whole mitochondrial genome sequence for the B6 strain was in complete 
agreement with the recently republished for this mouse strain (Bayona-Bafaluy et 
al. 2003).  This single nucleotide difference involved a T->A transversion that 
changed isoleucine to methionine.  This difference was also found in the VM 
mouse strain as well as in all examined mouse brain tumor cell lines.  It is not yet 
clear if this variation represents an error in the republished B6 mtDNA sequence 
or a population genetic variation among the B6 mouse strain.   
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In summary, our results show that the mitochondrial genome of mouse brain 
tumor cell lines contains mutations in regions of mononucleotide repeats.  These 
mtDNA mutations in the mouse brain tumors are similar to those found previously 
in hypervariable regions of the D-loop in human brain tumors.  However, none of 
the mouse mutations were pathogenic suggesting that mtDNA changes do not 
contribute to the carcinogenic progression of these mouse brain tumors. 
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Primer 
Pair MtDNA bp           Forward Primer              Reverse Primer
    1 15309-00040  GGTCTTGTAAACCTGAAATGAAG  GCATTTTCAGTGCTTTGCTTTG
    2 16173-01436  CTGATCAATTCTAGTAGTTCC  CAAGCTCGTTAGGCTTTTCAC
    3 01314-02880  GAATTACAGCTAGAAACCCCG  CGTATGGACCAACAATGTTAGG
    4 02673-03873  GTTATTAGGGTGGCAGAGCCAG  GCCCGATAGCTTAATTAGCTGAC
    5 03731-05324  CTTTGATAGAGTAAATTATAGAGG  TAAAATGGCTGAGTAAGCATTAG
    6 05194-06593  GTCTTAGTAGAGATTTCTCTACAC  GTTTACTCCTACGAATATGATGG
    7 06477-07996  GGAGCAGTGTTTGCTATCATAGC  TGATGGCTACAACGATTGGGAATC
    8 07847-09438  GTCTCATCACAAACATTCCCAC  CAGAATCTACTAATTGGAAGTCAG
    9 09307-10806  GATTTGAAGCCGCAGCATGATAC  GTCATAGGTGAACTCCATATAATGG
  10 10647-12399  GCCCTCATCTTAATCCAAAACC  CTGTAGCTGCGATTAATAGGC
  11 12247-13788  CAATCCTCTATAACCGCATCG  GTATTGGGGGTGATTATAGAG
  12 13670-15498  CCAACATCATCAACCTCATAC  GTACTAGCTTATATGCTTGGG
Table 2  Primers used for amplification of Mus Musculus mitochondrial genome
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Primer name Sequence (5' to 3') Size gene location Location Amp or S
ThrF100     GGTCTTGTAAACCTGAAATGAAG    23-mer Thr tRNA 15309-15332 A
PheR101 GCATTTTCAGTGCTTTGCTTTG 22-mer Phe tRNA 18-40 A
ControlRegF102 GACATCTGGTTCTTCTTACTTCAG 24-mer C R 15776-15800 S
ControlRegR103 CTGAAGTAAGAAGAACCAGATGTC 24-mer C R 15776-15800 S
ControlRegF104 GTCCGCAAAACCCAATCACCTAAG 24-mer C R 16003-16027 S
ND6F105 CCAACATCATCAACCTCATAC 21-mer ND6 13670-13691 A
ControlRegR106 GTACTAGCTTATATGCTTGGG 21-mer CR 15477-15498 A
ControlRegF107 CTGATCAATTCTAGTAGTTCC 21-mer CR 16173-16194 A
16SrRNAR108 CAAGCTCGTTAGGCTTTTCAC 21-mer 16srRNA 1415-1436 A
CytBR109 GGCTAAGAAAAGACCTGTAATG 22-mer CytB 14272-14294 S
CytBR111 GATTGAGCGTAGAATGGCGTATGC 24-mer CytB 14966-14990 S
CytBF112 CCAGCTAATCCACTAAACACCC 22-mer CytB 14910-14932 S
12srRNAR113 GTGTATTATAAATGACTAGAATTAC 25-mer 12srRNA 447-470 S
12srRNAF114 CGTGTCAACTATAAATAAATAAATAG 26-mer 12srRNA 360-386 S
12srRNAF115 GAGCTTAATTGAATTGAGCAATG 23-mer 12srRNA 870-892 S
12srRNAR116 CGACTTATCTCCTCTCATAAACG 23-mer 12srRNA 962-985 S
ND1R118 CGTATGGACCAACAATGTTAGG 22-mer 16srRNA 2858-2880 A
ND6R119 GTATTGGGGGTGATTATAGAG 21-mer ND6 13767-13788 A
ND5F120 CAATCCTCTATAACCGCATCG 21-mer ND6 12247-12268 A
CYTBF121 CACTCATTCATTGACCTACCTG 22-mer CytB 14185-14206 S
16srRNAF122 CTCCAGACATACGCGTATAAC 21-mer 16srRNA 1761-1781 S
16srRNAR123 GGATCTTTCCTTTAGGCATTC 21-mer 16srRNA 1873-1893 S
16srRNAF124 CCTCCGAATGATTATAACCTAG 22-mer 16srRNA 2277-2299 S
ND5F126 CACCTAGCATTCCTACACATCTG 23-mer ND5 12701-12724 S
ND5R127 GGATGTCTTGTTCGTCTGCCAG 22-mer ND5 12783-12804 S
ND5F128 CCACAGCCCTAATTATTTCAG 21-mer ND5 13198-13218 S
ND5R129 GAGAAGGATGAATATGGATTTGC 23-mer ND5 13281-13303 S
MetR131 GCCCGATAGCTTAATTAGCTGAC 23-mer ND1 3851-3873 A
ND1F132 CCAATACCACACCCATTAATTAA 23-mer ND1 3018-3040 S
ND1F133 CCATTCGCGTTATTCTTTATAGC 23-mer ND1 3404-3427 S
ND1R134 GCTATAAAGAATAACGCGAATGG 23-mer ND1 3404-3427 S
IleF135 CTTTGATAGAGTAAATTATAGAGG 24-mer ND2 3731-3754 A
ND2F137 AACGGTCTTATCCTTAACATAAC 23-mer ND2 4184-4206 S
ND2R138 GTCATGTAAGAAGAATAAGTCC 22-mer ND2 4292-4313 S
ND2F139 CCAAAATGAATTATCATCACAG 22-mer ND2 4696-4718 S
ND2R140 GTTGGAAATATTGTTAGTGAAGTGG 25-mer ND2 4809-4833 S
CytBR141 GAATTAAGATGATTGAGAAGTATG 24-mer CytB 15208-15231 S
CytBR142 GTCTTGGGTTAGCATTAAAGCC 22-mer CytB 13997-14018 S
ND1R143 GCTCCGAATAGTGAGTATTTGGAG 24-mer ND1 3122-3145 S
LeuF144 CTTGTTCCCAGAGGTTCAAATCC 23-mer ND1 2717-2739 S
ND2F145 GCAACACTCATAGCAATAATAGC 23-mer ND2 4748-4770 S
AsnF146 GTTAACAGCTAAATACCCTATTAC 24-mer Cox1 5122-5146 A
Cox1R147 GTTTACTCCTACGAATATGATGG 23-mer Cox1 6571-6593 A
CysF148 GTCTTAGTAGAGATTTCTCTACAC 24-mer Cox1 5194-5217 S
Cox1F149 GAGCCCCAGATATAGCATTCCC 22-mer Cox1 5590-5610 S
Cox1R150 GTGGGTAGACTGTTCATCCTGTTC 24-mer Cox1 5695-5718 S
Cox1F151 CCAGAAGTTTATATTCTTATCCTCC 25-mer Cox1 6049-6072 S
Cox1R152 TAGACATTATTGCTCATACTATTCC 25-mer Cox1 6141-6165 S
Cox1F153 GGAGCAGTGTTTGCTATCATAGC 23-mer Cox2 6477-6499 A
ATPase6R154 TGATGGCTACAACGATTGGGAATC 24-mer Cox2 7973-7996 A
SerF155 CAAGCCAATCTCATATCCTATATG 24-mer Cox2 6907-6930 S
Cox2R156 GTAGACCAAGTTGGAATGGGTAGG 24-mer Cox2 7017-7040 S
Cox2F157 CGACTGCTAGAAGTTGATAACCG 23-mer Cox2 7412-7434 S
Cox2R158 GTCGGCCTGGGATGGCATCAG 21-mer Cox2 7527-7547 S
URFA6LF159 GTCTCATCACAAACATTCCCAC 22-mer ATP6 + Cox3 7847-7868 A
GlyR160 CAGAATCTACTAATTGGAAGTCAG 24-mer ATP6 + Cox3 9415-9438 A
ATPase6F161 GCCCACTTCCTTCCACAAGG 20-mer ATP6 + Cox3 8302-8321 S
ATPase6R162 GTCCTGCAGTAATGTTAGCTGTAAG 25-mer ATP6 + Cox3 8404-8428 S
Cox3F163 GCCTCGTACCAACACATGATCTAG 24-mer ATP6 + Cox3 8920-8943 S
Cox3R164 CATGTAATTGAAACACCTGATGC 23-mer ATP6 + Cox3 9021-9043 S
Cox3F165 GATTTGAAGCCGCAGCATGATAC 23-mer ND3 + ND4 9307-9329 A
ND4LR166 GTCATAGGTGAACTCCATATAATGG 25-mer ND3 + ND4 10782-10806 A
ND3F167 CTCTAGGCCTAGCATATGAATGAAC 25-mer ND3 + ND4 9751-9775 S
ArgR168 GAACAGCATCATAATCTAATGAGTC 25-mer ND3 + ND4 9837-9861 S
ND4F169 GTTTAACCAGCCTAACACTTCTATG 25-mer ND3 + ND4 10264-10288 S
ND4R170 ATATTAGTGGCAGTAATCAGGCTG 24-mer ND3 + ND4 10366-10389 S
ND4F171 GCCCTCATCTTAATCCAAAACC 22-mer ND4 + ND5 10647-10668 A
ND5R172 CTGTAGCTGCGATTAATAGGC 21-mer ND4 + ND5 12379-12399 A
ND4F173 CACATGGCCTCACATCATCACTCC 24-mer ND4 + ND5 11113-11136 S
ND4R174 GACTTGCTATCAGTCATCATGTGG 24-mer ND4 + ND5 11227-11250 S
SerF175 GATTGCAAGAACTGCTAATTCATG 24-mer ND4 + ND5 11613-11636 S
LeuR176 CTTTTATTTGGATTTGCACCAAGG 24-mer ND4 + ND5 11710-11733 S
ND5F177 CTATCCTGTTTACATCTGTAGCCC 24-mer ND4 + ND5 11992-12215 S
16srRNAR178 CCCTAATTGTCGATATGAACTC 22-mer 16srRNA 2398-2419 S
ND4LR180 GTGAGGTTGAAGAAGGTAGATGG 23-mer ND4 9877-9899 S
16srRNAF181 GAATCAACTCGTCTATGTGGC 21-mer 16srRNA 1367-1387 S
Table 3  Primer list for sequencing of the mouse mitochondrial genome
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Mouse Strain
Nucleotide 
Position      Gene
DNA 
Change
Amino Acid 
Change
C57BL/6J 11774       ND5      T->A      Ile->Met
VM 11774       ND5      T->A      Ile->Met
VM   9825       Arg tRNA      InsA      NAb
VM   9461       ND3      C->T      Ile->Ile
b NA, not applicable
Table 4  Summary of mtDNA nucleotide variations in C57BL/6J and VM mouse strainsa
a Nucleotide variation compared to the republished C57BL/6J mtDNA sequence from Bayona-
Bafaluy et al. 2003
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Brain Tumor 
Cell Line Metastatic
Host Genetic 
Background
Nucleotide 
Position Gene
DNA 
Change Stateb
Amino Acid 
Change
   EPEN - B6   9461 ND3    T->C Homo  Ile->Ile
  9825     Arg tRNA    InsAA Homo NAc
   CT-2A - B6   5182 OL    InsA Homo NA
   VM-NM1 - VM   5182 OL    DelA Homo NA
15466       D-loop    T->C Homo NA
   VM-M3 + VM   2159      16srRNA    A->G  Hetero NA
a Tumor cell lines mtDNA sequences were compared to host strain brain mtDNA populations
b Homo=Homoplasmy, Hetero=Heteroplasmy
c NA, not applicable
Table 5  Summary of mtDNA mutations in experimental murine brain tumor cell linesa 
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Type of tumor
Number of 
tumors
Number of tumors 
with mtDNA 
somatic mutationsa
Number of somatic 
mutations causing 
amino acid 
substitutionsc Region of mutation Reference
Neurofibroma     37 23/37  NAd D-loop
Glioma     53 20/53 NA HVRII
Meningioma     11 5/11 NA
Schwannoma      5 2/5 NA
Medulloblastoma     15 6/15 2/18
Gliomatosis cerebri      6 2/6 NA HVRII
Glioma     55 7/55 NA HVRII, D-loop
    
Astrocytoma     12 11/12b NA HVRII
a Number of tumors with mutations/Number of tumors
b 2 of the 12 astrocytomas were compared to adjacent brain tissue, the remaining 10 were aligned 
to Anderson et al. 1981 for mutation analysis
c Number of mutations causing amino acid substitutions/Total number of mutations found in all tumors
d NA, not applicable because in hypervariable region of the D-loop (HVR)
Table 6  mtDNA alterations in human brain tumors compared to matched tissue controls
D-loop, Asp tRNA, COXI, 
CoxII, Thr tRNA, ND4
Kirches et 
al. 2001
Kirches et 
al. 1999
Kirches et 
al. 2003
Wong et al. 
2003
Vega et al. 
2004
Kurtz et 
al. 2004
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Figure 3.  Primer constructs for the amplification of the entire mouse 
mitochondrial genome.  The mitochondrial genome was amplified into 12 
overlapping fragments and sequenced using nested primers in designated 
positions. 
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Figure 4.   Heteroplasmy in the metastatic VM-M3 tumor cell line. Mitochondrial 
16srRNA revealed a heteroplasmic mutation at position 2159 of an A to G.  The 
three VM brain mitochondrial populations (LM, HM, and FM) displayed the same 
chromotagraph profile.  The same level of heteroplasmy was observed in 
duplicate independent samples for the VM-M3 cell line.  Arrow indicates 
heteroplasmic nucleotide at position 2159 compared to control. 
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CHAPTER THREE 
Lipidomic Analysis and Electron Transport Chain Activities in C57BL/6J Mouse 
Brain Mitochondria 
 
INTRODUCTION 
 
Brain Mitochondrial lipids 
Lipids of the mitochondrial membrane can influence numerous mitochondrial 
functions to include ETC activities, nucleotide transport, mitochondrial protein 
import, membrane fluidity/permeability properties, and ATP synthesis (Petrushka 
et al. 1959; Daum 1985; Hoch 1992; Brand et al. 2003a; Shinzawa-Itoh et al. 
2007).  Brain contains at least two major populations of mitochondria, based on 
cellular localization (Lai and Clark 1989).  These include the non-synaptic (NS) 
mitochondria, which originate from neuronal and glial cell bodies, and the 
synaptic (Syn) mitochondria, which primarily originate from the synaptic bouton of 
neurons.  These mitochondrial populations express differences in specific ETC 
activities, believed to contribute to the metabolic compartmentation of the brain 
(Lai et al. 1977; Battino et al. 1991).  The origin of this metabolic 
compartmentation could arise from differences in lipid composition of the 
mitochondrial membrane.  However, contamination from subcellular membranes 
including myelin has hindered past attempts to accurately characterize the lipid 
composition of brain mitochondria (Cuzner and Davison 1968; Lai and Clark 
1989; Villa et al. 1989b; Bangur et al. 1995).  
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Cardiolipin 
Shotgun lipidomics by electrospray ionization mass spectrometry 
(ESI/MS) can provide a rapid and detailed analysis of lipids in biological 
membranes (Han and Gross 2005a).  This approach recently identified nearly 
100 molecular species of brain cardiolipin (1,3-diphosphatidyl-sn-glycerol, 
Ptd2Gro), a mitochondrial specific lipid (Cheng et al., unpublished observation).  
The origin of brain Ptd2Gro heterogeneity is not well defined, but may be related 
to the unique synthesis of Ptd2Gro (Hauff and Hatch 2006; Schlame and Ren 
2006).  Ptd2Gro is synthesized as immature Ptd2Gro through the condensation of 
phosphatidylglycerol (PtdGro) and cytidine diphosphate-diacylglycerol (CDP-
DAG).  Ptd2Gro is then deacylated to monolysocardiolipin and reacylated to form 
mature Ptd2Gro (Hauff and Hatch 2006).  This Ptd2Gro remodeling process uses 
fatty acyl groups from the sn-2 position of donor choline (ChoGpl) and 
ethanolamine (EtnGpl) glycerophospholipids (Xu et al. 2003; Schlame and Ren 
2006).  No prior studies have evaluated Ptd2Gro heterogeneity in purified NS and 
Syn mitochondrial populations. 
The objective of this study was to analyze the lipid composition of NS and 
Syn mitochondria.  We designed a modified Ficoll and sucrose discontinuous 
gradient system for the isolation and purification of mitochondria from mouse 
brain free of contaminating myelin or organelle and plasma membranes (Lai et al. 
1977; Dagani et al. 1983).  Shotgun lipidomics and HPLC connected to an 
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electrochemical detector (HPLC/ECD) were used to determine if quantitative or 
qualitative differences in lipid composition existed between these two brain 
mitochondrial populations.  Moreover, ours is the first comprehensive 
examination of the brain mitochondrial lipidome, including molecular species and 
mass content of ceramide (Cer), PtdGro, and lysophosphatidylcholine 
(LysoPtdCho).   ETC activities were measured to determine if differences in 
enzyme activities correlated with differences in the lipid composition of 
mitochondrial populations.  Our results provide new insight into the importance of 
brain mitochondrial lipids, which could contribute to metabolic compartmentation 
of the brain. 
 
MATERIALS AND METHODS 
Mice 
   C57BL/6J (B6) mice were obtained from the Jackson Laboratory (Bar Harbor, 
ME, USA).  All mice were propagated at the Boston College Animal Facility and 
were housed in plastic cages with filter tops containing Sani-Chip bedding (P.J. 
Murphy Forest Products Corp., Montville, NJ, USA).  The room was maintained 
at 22 ºC on a 12 hr light/dark cycle.  Food (Prolab RMH 3000; PMI LabDiet, 
Richmond, IN, USA) and water were provided ad libitum.  This study was 
conducted with the National Institutes of Health Guide for the Care and Use of 
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Laboratory Animals and was approved by the Institutional Animal Care 
Committee.   
 
Non-synaptic and Synaptic brain mitochondrial isolation 
   B6 mice (4 months of age) were sacrificed by cervical dislocation and the 
cerebral cortex was dissected.  Mitochondria were isolated in a cold room (4 ºC) 
and all reagents were kept on ice.  The isolation procedure employed a 
combination of gradients and strategies as previously described (Lai and Clark 
1976; Lai et al. 1977; Mena et al. 1980; Dagani et al. 1983; Rendon and 
Masmoudi 1985; Battino et al. 1991; Brown et al. 2006) (Fig. 5). The cerebral 
cortexes (a pool of 6/sample) were diced on an ice cold metal plate and then 
placed in 12 mL of mitochondria isolation buffer (MIB; 0.32 M sucrose, 10 mM 
Tris-HCl, and 1 mM EDTA-K (pH 7.4)).  The pooled cerebral cortexes were 
homogenized using a Potter Elvehjem homogenizer with a Teflon coated pestle 
attached to a hand-held drill.  Samples were homogenized using 15 up and down 
strokes at 500 rpm.  The homogenate was centrifuged at 1,000 x g for 5 min.  
The supernatant was collected and the pellet was washed twice by 
centrifugation, collecting the supernatants each time.  The supernatants were 
pooled and centrifuged at 1,000 x g for 5 min.  The collected supernatant was 
then spun at 14,000 x g for 15 min.  The supernatant was discarded and the 
pellet, which contained primarily NS mitochondria, synaptosomes and myelin, 
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was resuspended in 12 mL MIB and was layered on a 7.5%/12% discontinuous 
Ficoll gradient.  Each Ficoll gradient layer contained 12 mL for a total volume of 
36 mL.  The Ficoll gradients were made from a 20% Ficoll stock with MIB.  The 
gradient was centrifuged at 73,000 x g for 36 min (4 ºC) in a Sorvall SW 28 rotor 
with slow acceleration and deceleration (Optima L-90K Ultracentrifuge).  The 
centrifugation time used permitted sufficient acceleration and deceleration to 
achieve maximum g force (Battino et al. 1991), and to prevent synaptosomal 
contamination of the mitochondrial fraction below the 12% Ficoll layer.  Crude 
myelin collected at the MIB/7.5% Ficoll interface was discarded.  Synaptosomes 
were collected at the 7.5%/12% interface and were resuspended in MIB and 
centrifuged at 16,000 x g for 15 min.  The Ficoll gradient purified NS 
mitochondria (FM) were collected as a pellet below 12% Ficoll.  
  
Purification of NS Mitochondria - The FM pellet, containing NS mitochondria, 
was resuspended in MIB containing 0.5 mg/mL bovine serum albumin (BSA) and 
was centrifuged at 12,000 x g for 15 min.  BSA was used in the isolation buffer at 
this stage to bind free fatty acids.  The resulting pellet was collected and 
resuspended in 6 mL of MIB.  The resuspended FM pellet was layered on a 
discontinuous sucrose gradient containing 0.8 M/ 1.0 M/ 1.3 M/ 1.6 M sucrose.  
The volumes for the sucrose gradient were 6 mL/ 6 mL/ 10 mL/ 8 mL, 
respectively.  The gradients were made from a 1.6 M sucrose stock containing 1 
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mM EDTA-K and 10 mM Tris-HCl (pH 7.4).  The discontinuous sucrose gradient 
was centrifuged at 50,000 x g for 2 hr (4 ºC) in a Sorvall SW 28 rotor using slow 
acceleration and deceleration to prevent disruption of the gradient.  Purified NS 
mitochondria were collected at the interface of 1.3 M and 1.6 M sucrose.  NS 
mitochondria were collected and resuspended in (1:3, v/v) TE buffer  (1 mM 
EDTA-K and 10 mM Tris-HCl, pH 7.4) containing 0.5 mg/mL BSA and 
centrifuged at 18,000 x g for 15 min.  The pellet was then resuspended in MIB 
and centrifuged at 12,000 x g for 10 min.  The pellet was again resuspended in 
MIB and centrifuged at 8,200 x g for 10 min. 
 
Purification of Syn mitochondria - Synaptosomes were burst by 
homogenization in 6 mM Tris-HCl (pH 8.1) using 5 up and down strokes.  The 
homogenized synaptosomes were transferred to a 15 mL conical tube and then 
placed on a rocker for 1 hr (4 ºC).  The burst synaptosomes were centrifuged at 
10,000 x g for 10 min.  The pellet was resuspended in 6 mL of MIB.  The 
resuspended pellet was layered on a discontinuous sucrose gradient and 
centrifuged following the same procedure as described above for NS 
mitochondria. 
 
Western blot analysis of subcellular fractions 
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Protein concentration of isolated subcellular fractions was determined by the Dc 
Protein Assay using BSA standards (Bio-Rad, CA, USA).  Total protein (2 to 20 
μg) from fractions were loaded on 4-12% NuPage Bis-Tris gradient gels using 
MES SDS running buffer (Invitrogen, CA, USA) and electrophoresed.  Proteins 
were transferred to an immobilon TM-P membrane (Millipore, MA, USA) for 2 hr 
at 80 volts at 4 ºC.  The TM-P membrane was then washed with Tris-buffered 
saline or phosphate buffered saline (PBS), depending on manufacturers’ 
instructions for primary antibody and then blocked in 5% nonfat powdered milk in 
Tris-buffered saline or PBS with Tween 20 (pH 7.6) for 1 hr or overnight.  Primary 
antibodies were used at the dilutions suggested by the manufacturers’ protocols 
and included Complex IV, subunit IV (1:1250) (clone 20E8, Molecular Probes, 
OR, USA), monoamine oxidase-A (1:200) (clone T-19, Santa Cruz, CA, USA), 
SNAP25 (1:10,000) (clone, SMI 81, Sternberger monoclonal, Lutherville, MD, 
USA), β-actin (1:7000) (AC-15, Abcam, Cambridge, UK), tuberin (1:400) (clone 
C-20, Santa Cruz, CA, USA), proliferating cell nuclear antigen (1:100) (clone 
PC10, DAKO, CA, USA), calnexin (1:500) (clone C8.B6, Cell Signaling, MA, 
USA), and myelin proteolipid protein (1:200) (clone AA3).   Also, proteins 
representative of individual ETC complexes (I-V) were evaluated using the 
Rodent Total OXPHOS Complexes Detection Kit (1:500) (MS604, Mitosciences, 
OR, USA).  The kit consisted of antibodies to Complex I (ND6), Complex II (FeS 
30 kD), Complex III (Core 2 subunit), Complex IV (subunit I), and Complex V (α 
subunit).  Blots were incubated with corresponding secondary antibody 
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conjugated with horseradish peroxidase.  Bands were visualized using the Pierce 
chemiluminescence detection system (Pierce, Rockford, IL, USA).  Band 
densities were quantified using a densitometer (Molecular Dynamics) and IQ Mac 
software (version 1.2).  Protein was loaded in incremental amounts to confirm 
that the signal detected was not saturated.  
 
Ganglioside GM1a analysis using cholera toxin b immunostaining 
Gangliosides were isolated and purified from subcellular fractions as we 
previously described (Hauser et al. 2004).  The ganglioside fraction was desalted 
by LH-20 Sephadex column chromatography.  Purified gangliosides were spotted 
on a plastic backed Nagel PolyGram Sil G Thin Layer Chromatography (TLC) 
plate (Macherey-Nagel, Germany) based on 100 μg protein, as previously 
described (Hirabayashi et al. 1990).  Immunostaining for GM1a was performed 
as previously described (Brigande et al. 1998).  Approximately 1.6 ng of purified 
GM1a was spotted as a standard.  The concentration of GM1a standard used 
was calculated based its level of immunoreactivity with cholera toxin b.  The TLC 
plate was developed in one ascending run for 45 min in CHCl3/CH3OH/0.2% 
CaCl2 (55:45:10).  The plate was thoroughly dried after development and was 
then blocked in PBS containing 1% BSA for 2 hr at 37 ºC on a rocker.  The plate 
was then washed with PBS for 5 min.  Next, the plate was incubated with the β-
subunit of cholera toxin/peroxidase conjugated (1 μg/mL) (List Biological 
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Laboratories, Inc.) in PBS containing 1% BSA for 2 hr at 37 ºC.  Post-incubation, 
the plate was washed 5 times (5 min each time) with PBS and was then 
developed using 10 mL PBS, 2 ml 4-chloro-1-napthol (3 mg/mL in CH3OH) and 
20 μL 30% H2O2 at room temperature for 15 min. 
 
Materials for mass spectrometry 
Synthetic phospholipids including 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine 
(14:1-14:1 PtdCho), 1,2-dipalmitoleoyl-sn-glycero-3phosphoethanolamine (16:1-
16:1 PtdEtn), 1,2-dipentadecanoyl-sn-glycero-3-phosphoglycerol (15:0-15:0 
PtdGro), 1,2-dimyristoyl-sn-glycero-3-phosphoserine (14:0-14:0 PtdSer), N-
lauroryl sphingomyelin (N12:0 CerPCho), 1,1’,2,2’-tetramyristoyl cardiolipin 
(T14:0 Ptd2Gro), heptadecanoyl ceramide (N17:0 Cer), 1-heptadecanoyl-2-
hydroxy-sn-Glycero-3-phosphocholine (17:0 LysoPtdCho) were purchased from 
Avanti Polar Lipids, Inc. (Alabaster, AL, USA).  It should be noted that the prefix 
“N” denotes the amide-linked acyl chain.  Deuterated cholesterol (d6-chol) was 
purchased from Cambridge Isotope Laboratories, Inc. (Cambridge, MA, USA).  
All the solvents were obtained from Burdick and Jackson (Honeywell 
International Inc., Burdick and Jackson, Muskegon, MI, USA).  All other 
chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).   
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Sample preparation for mass spectrometric analysis 
An aliquot of the mitochondrial preparation was transferred to a disposable 
culture borosilicate glass tube (16 x 100 mm).  Internal standards were added 
based on protein concentration and included 16:1-16:1 PtdEtn (100 nmol/mg 
protein), 14:1-14:1 PtdCho (45 nmol/mg protein), T14:0 Ptd2Gro (3 nmol/mg 
protein), 15:0-15:0 PtdGro (7.5 nmol/mg protein), 14:0-14:0 PtdSer (20 nmol/mg 
protein), 17:0 LysoPtdCho (1.5 nmol/mg protein), N12:0 CerPCho (20 nmol/mg 
protein), N17:0 Cer (5 nmol/mg protein).  This allowed the final quantified lipid 
content to be normalized to the protein content and eliminated potential loss from 
the incomplete recovery.  The molecular species of internal standards were 
selected because they represent < 0.1% of the endogenous cellular lipid mass as 
demonstrated by ESI/MS lipid analysis. 
A modified Bligh and Dyer procedure was used to extract lipids from each 
mitochondrial preparation as previously described (Cheng et al. 2006).  Each 
lipid extract was reconstituted with a volume of 500 μL/mg protein (which was 
based on the original protein content of the samples as determined from protein 
measurement) in CHCl3/MeOH (1:1, v/v).  The lipid extracts were flushed with 
nitrogen, capped, and stored at -20 ºC for ESI/MS analysis.  Each lipid solution 
was diluted approximately 50-fold immediately prior to infusion and lipid analysis. 
 
Instrumentation and mass spectrometry 
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A triple-quadrupole mass spectrometer (Thermo Scientific TSQ Quantum Ultra, 
Plus,  San Jose, CA, USA), equipped with an electrospray ion source and 
Xcalibur system software, was utilized as previously described (Han et al. 2004).  
The first and third quadrupoles serve as independent mass analyzers using a 
mass resolution setting of peak width 0.7 Thomson while the second quadrupole 
serves as a collision cell for tandem MS.  The diluted lipid extract was directly 
infused into the ESI source at a flow rate of 4 μL/min with a syringe pump.  
Typically, a 2-min period of signal averaging in the profile mode was employed 
for each mass spectrum.  For tandem MS, a collision gas pressure was set at 1.0 
mTorr, but the collision energy varied with the classes of lipids as described 
previously (Han et al. 2004; Han and Gross 2005b).  Typically, a 2- to 5-min 
period of signal averaging in the profile mode was employed for each tandem MS 
spectrum.  All the mass spectra and tandem MS spectra were automatically 
acquired by a customized sequence subroutine operated under Xcalibur 
software.  Data processing of 2D MS analyses including ion peak selection, data 
transferring, peak intensity comparison, and quantitation was conducted using 
self-programmed MicroSoft Excel macros (Han et al. 2004). 
 
Mathematical computation for predicting the distribution of cardiolipin molecular 
species 
A PERL script was developed for predicting the distribution of molecular species 
in mouse brain Ptd2Gro.  This script calculated the expected concentration 
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F×c1×c2×c3×c4 for each Ptd2Gro species, given the concentration of each fatty 
acid found in Ptd2Gro.  C represents a given concentration of fatty acids in any 
one of the four possible fatty acid tails of Ptd2Gro.  F was calculated for each 
possible Ptd2Gro molecular species using an enumerative approach, with trivial 
computation time. 
 
Isolation and quantification of coenzyme Q 
Aliquots of NS and Syn mitochondria were subjected to lipid extraction and 
analyzed for Q content as previously described (Jonassen et al. 2002).  Q6 was 
used to gauge coenzyme Q recovery in the lipid extracts and was added to all 
standards and samples.  Lipids were extracted by adding 0.05 mL water, 0.9 mL 
methanol, and 0.6 mL petroleum ether to each sample.  The mixtures were 
vortexed for 1 min, centrifuged at 1,422 x g, and the top layer of petroleum ether 
was removed from each mixture and saved in a separate vial.  Fresh petroleum 
ether (0.6 mL) was added to each vial containing the aqueous phase and 
vortexed for 1 min.  The vials were subjected to centrifugation as before and the 
second petroleum ether layer removed.  The process was repeated once more, 
and the three pooled petroleum ether fractions were dried under nitrogen and 
resuspended in 150 μL methanol.  The Q6 and Q10 standards were from Sigma-
Aldrich, and Q9 was a gift from Dr. Youssef Hatefi. 
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The coenzyme Q present in extracted standards and samples was separated 
and quantified by HPLC/ECD as previously described (Jonassen et al. 2002), 
with the following exceptions: the precolumn electrode was the only electrode 
used and was set at +650 mV to oxidize all coenzyme Q, and a Gilson 118 
UV/Vis detector was utilized to detect coenzyme Q as they eluted from the 
column.  The amounts of Q9 and Q10 in the standards and samples were 
normalized to the amount of Q6 recovered in the individual lipid extracts. 
 
Electron transport chain enzyme activities 
Purified mitochondrial samples were freeze-thawed three times before use in 
enzyme analysis to give substrate access to the inner mitochondrial membrane.  
All assays were performed on a temperature controlled SpectraMax M5 plate 
reader (Molecular Devices) and were done in triplicate.  Specific enzyme 
activities were calculated using ETC complex inhibitors in order to subtract 
background activities. 
 
Complex I (NADH-ubiquinone oxidoreductase) activity was determined by 
measuring the decrease in the concentration of NADH at 340 nm as previously 
described (Birch-Machin and Turnbull 2001; Ellis et al. 2005).  The assay was 
performed in buffer containing 50 mM potassium phosphate (pH 7.4), 2 mM 
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KCN, 5 mM MgCl2, 2.5 mg/mL BSA, 2 μM antimycin, 100 μM decylubiquinone, 
and 0.3 mM K2NADH.  The reaction was initiated by adding purified mitochondria 
(20 μg).  The enzyme activity was measured for 5 min and values were recorded 
30 sec after the initiation of the reaction.  Specific activities were determined by 
calculating the slope of the reaction in the linear range in the presence or 
absence of 1 μM rotenone (Complex I inhibitor).   
 
Complex II (succinate decylubiquinone DCIP oxidoreductase) activity was 
determined by measuring the reduction of 2,6-dichloroindophenol (DCIP) at 600 
nm as previously described (King 1967; Ellis et al. 2005).  The Complex II assay 
was performed in buffer containing 25 mM potassium phosphate (pH 7.4), 20 mM 
succinate, 2 mM KCN, 50 μM DCIP, 2 μg/mL rotenone, and 2 μg/mL antimycin.  
Purified mitochondria (10 μg) were added prior to initiation of the reaction.  The 
reaction was initiated by adding 56 μM decylubiquinone.  Specific activities were 
determined by calculating the slope of the reaction in the linear range in the 
presence or absence of 0.5 mM thenoyltrifluoroacetone (Complex II inhibitor).  
 
Complex III (ubiquinol-cytochrome c reductase) activity was determined by 
measuring the reduction of cytochrome c at 550 nm.  The Complex III assay was 
performed in buffer containing (25 mM potassium phosphate (pH 7.4), 1 mM 
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EDTA, 1 mM KCN, 0.6 mM dodecyl maltoside, 32 μM oxidized cytochome c) 
using purified mitochondria (2.5 μg).  The reaction was initiated by adding 35 μM 
decylubiquinol.  The reaction was measured following the linear slope for 1 min in 
the presence or absence of 2 μM antimycin (Complex III inhibitor).   
Decylubiquinol was made by dissolving decylubiquinone (10 mg) in 2 mL 
acidified ethanol (pH 2) and using sodium dithionite as a reducing agent.  
Decylubiquinol was further purified by cyclohexane extraction (Degli Esposti 
2001; Birch-Machin and Turnbull 2001; Ellis et al. 2005).   
 
Complex IV (cytochrome c oxidase) activity was determined by measuring the 
oxidation of ferrocytochrome c at 550 nm.  The Complex IV assay was performed 
in buffer containing (10 mM Tris-HCl and 120 mM KCl (pH 7.0)) using purified 
mitochondria (5 μg).  The reaction was initiated by adding 11 μM reduced 
ferrocytochrome c and monitoring the slope for 30 sec in the presence or 
absence of 2.2 mM KCN (Complex IV inhibitor) (Yonetan 1967; Ellis et al. 2005).  
Cytochrome c oxidase was additionally measured by a multiplexing assay 
(MS446 – Mitosciences – Eugene, OR, USA).   
 
Complex I/III (NADH cytochrome c reductase) activity was determined by 
measuring the reduction of cytochrome c at 550 nm.  The Complex I/III assay 
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was performed in buffer (50 mM potassium phosphate (pH 7.4), 1 mM EDTA, 2 
mM KCN, 32 μM oxidized cytochrome c, and 105 μM K2NADH) and was initiated 
by adding purified mitochondria (10 μg).  The reaction was measured for 30 sec 
with a linear slope in the presence or absence of 1 μM rotenone and 2 μM 
antimycin (Complex I and III inhibitors) (Birch-Machin and Turnbull 2001; Degli 
Esposti 2001; Ellis et al. 2005).   
 
Complex II/III (succinate cytochrome c reductase) activity was measured 
following the reduction of cytochrome c at 550 nm.  The Complex II/III assay was 
performed in buffer (25 mM potassium phosphate (pH 7.4), 20 mM succinate, 2 
mM KCN, 2 μg/mL rotenone) using purified mitochondria (10 μg).  The reaction 
was initiated by adding 40 μM oxidized cytochrome c in the presence or absence 
of 2 μM antimycin (Complex III inhibitor) (Birch-Machin and Turnbull 2001; Ellis et 
al. 2005).  
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RESULTS 
Analysis of mitochondrial purity 
Ficoll as well as sucrose discontinuous gradients were used to purify NS and Syn 
mitochondria (Fig. 5).  As Ficoll gradient purified NS mitochondria (FM) contained 
markers for cytoskeletal (β-actin) and membrane (SNAP25, PCNA, tuberin, PLP, 
and calnexin) contamination, we further purified mitochondria using a 
discontinuous sucrose gradient.  None of these markers were present in the 
Ficoll and sucrose discontinuous gradient purified mitochondria, which contained 
only mitochondrial-enriched markers representing the inner mitochondrial 
membrane (Complex IV, subunit IV) and the outer mitochondrial membrane 
(MAO-A) (Fig. 6A).  Cholera toxin b immunostaining is a sensitive procedure for 
detecting gangliosides with the GM1a structure in cells and tissues (Brigande et 
al. 1998).  The toxin can have slight cross reactivity with GD1a.  GM1a and a low 
amount of GD1a was found in the TH, My, and FM fractions, indicating the 
presence of myelin and microsomal membranes in these subcellular fractions 
(Fig. 6B).  Only a trace amount of GM1a was detected in the NS mitochondria 
and no GM1a was detected in Syn mitochondria.  These finding attest to the high 
degree of mitochondrial purity achieved with the isolation procedure and also 
indicate that GM1a is not present in C57BL/6J mouse brain mitochondria. 
 
Lipid composition of C57BL/6J mouse brain mitochondria  
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We used shotgun lipidomics to evaluate lipid content and distribution of fatty acid 
molecular species in the NS and Syn mitochondria.  The lipid classes are listed 
according to their relative abundance (Table 7).  Although the content of most 
lipids was similar in the NS and Syn mitochondria, the content of Ptd2Gro was 
lower whereas the content of PtdSer and Cer were higher in the Syn 
mitochondria than in the NS mitochondria.  The myelin-enriched lipids, sulfatides 
and cerebrosides, were not detected in either NS or Syn mitochondria.   
The distribution of fatty acid molecular species within each major lipid of the NS 
and the Syn mitochondria is shown in Figures 7 and 8 and in Tables 9-17.  The 
individual phospholipids were arranged according to the number of molecular 
species with PtdIns having the fewest and Ptd2Gro having the greatest number.  
PtdIns contained predominantly 18:0-20:4, with lower amounts of 16:0-20:4 (Fig. 
7A and Table 12).  CerPCho contained predominantly N20:0 and N18:0 (Fig. 7B 
and Table 14).  PtdSer contained predominantly 18:0-22:6 (Fig. 7C and suppl. 
Table 15).  PtdGro contained predominantly 16:0-18:1 (Fig. 7D and Table 13).  
LysoPtdCho consisted of a range of fatty acids, but predominantly 16:0, 18:1, 
18:0, and 22:6 (Fig. 7E and Table 16).  ChoGpl contained predominantly D16:0-
18:1, D18:2-18:2/D16:0-20:4, D16:0-22:6/D18:2-20:4, D18:2-20:2/D18:0-20:4, 
D16:0-16:0, and A16:0-20:0 (Fig. 7F and Table 10). EtnGpl contained 
predominantly D18:0-20:4/D16:0-22:4 and D18:0-22:6/D18:1-22:5 (Fig. 7G and 
Table 9).  Cer consisted primarily of N18:0 (Table 17).   
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 Cardiolipin composition in NS and Syn mitochondria 
Despite a lower amount of Ptd2Gro in the Syn than in the NS mitochondria, the 
mole percentage of Ptd2Gro molecular species was remarkably similar for NS 
and Syn mitochondria (Fig. 8 and Table 11).  Both NS and Syn mitochondria 
contained Ptd2Gro species enriched in 18:1, 20:4, 22:6, 18:2, and 16:1 fatty acids 
(Table 11).  The predominant molecular species of Ptd2Gro were 18:1-18:1-18:1-
18:1, 20:4-18:1-18:1-18:1, 20:4-20:4-18:1-18:1, 22:6-20:4-18:1-18:1, 22:6-18:1-
18:1-18:1/20:4-20:3-18:1-18:1, and 20:4-18:2-18:1-18:1/22:6-18:1-18:1-16:0 (Fig. 
8).  A unique pattern was discovered comparing mole percentage based on the 
mass to charge ratios.  The unique pattern consisted of seven major molecular 
species groups, with group I having the shortest chains and the least 
unsaturation, and group VII having the longest chains and the greatest 
unsaturation.   
 
Mathematical Model for the distribution of mouse brain cardiolipin molecular 
species 
We hypothesized that the unique distribution of Ptd2Gro molecular species 
detected with shotgun lipidomics could be explained by a mathematical model in 
which Ptd2Gro fatty acids are at equilibrium with respect to the available 
quantities of each fatty acid chain. In other words, we expected that the 
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concentration C of a given species of Ptd2Gro (specified by its four fatty acids) 
would be proportional to the product of the concentrations of its four fatty acids 
(c1×c2×c3×c4).  Since there are multiple permutations in which fatty acids can be 
arranged in the four Ptd2Gro fatty acid positions, C should also be proportional to 
a combinatorial prefactor F.  For example, if there are four distinct fatty acids 
attached to the Ptd2Gro, there are F = 4! = 24 possible permutations in which 
these fatty acids can be arranged.  However, if the four fatty acids are identical, 
there is only one way to arrange them, i. e. F = 1. The F×c1×c2×c3×c4 data were 
summed in groups of Ptd2Gro species with identical numbers of carbons and 
double bonds. This grouping allows the predictions of the model to be compared 
directly with the observed data from shotgun lipidomic analysis.  Our results 
show that the distribution of Ptd2Gro fatty acid molecular species predicted by the 
mathematical model fell into 7 major groups that corresponded closely with data 
obtained from shotgun lipidomic analysis (Fig. 9).  Data were condensed from 
about 1800 possible Ptd2Gro molecular species to 54 species that represented 
greater than 99% of the total Ptd2Gro species.  Subtle differences between the 
theoretical and observed distribution of cardiolipin molecular species, as 
demonstrated in the molecular species between 72:7 and 72:4, could be the 
result of a slight difference in the rate of Ptd2Gro synthesis or remodeling.  Our 
analysis showed that the unique pattern of Ptd2Gro molecular species could arise 
from a simple process of random fatty acid incorporation.   
 
61 
 
Coenzyme Q content in NS and Syn mitochondria 
Coenzyme Q content was measured since this is a lipid constituent and involved 
in mitochondrial ETC activities (Lenaz 2001).  The relative amounts of Q9 and 
Q10 were approximately 24% lower in the Syn mitochondria than in the NS 
mitochondria.  The Q9:Q10 ratio was about 3:1 in both the NS and Syn 
mitochondria (Fig. 10).   
 
ETC activities of brain mitochondrial complexes 
ETC activities have been used to characterize the metabolic properties of NS 
and Syn mitochondrial populations (Lai and Clark 1976; Lai et al. 1977; Hevner 
and Wong-Riley 1989; Villa et al. 1989a; Gorini et al. 1989; Battino et al. 1991).  
We examined the activities of the individual ETC complexes (Complex I, II, III, 
and IV) as well as those of the linked enzyme complexes (Complex I/III and II/III) 
(Table 8).  The activities of Complex I, Complex II, Complex III, Complex II/III 
were 55%, 53%, 63%, and 69%, respectively, in Syn mitochondria of those 
activities observed in NS mitochondria (Table 8).  The activities of Complex IV 
and of Complex I/III were similar in the NS and the Syn mitochondria.  To 
determine whether differences in ETC enzyme activities might be associated with 
differences in protein content of complexes, we evaluated protein markers 
representative for ETC complexes using the Rodent OXPHOS Complexes 
Detection Kit.  No differences were found for the expression of ETC protein 
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markers for each of the complexes (Fig. 11).  These data indicate that the 
differences found between the NS and Syn mitochondria for ETC enzyme 
activities were not observed for the content of individual ETC protein markers. 
 
 
DISCUSSION 
 
The objective of this study was to characterize the lipidome and ETC 
activities in highly purified populations of NS and Syn mitochondria from B6 mice.  
Information on the lipid composition of NS and Syn mitochondria can provide 
insight into the metabolic compartmentation in brain (Sonnewald et al. 2004).  
However, subcellular contamination or technical limitations have hindered past 
attempts to accurately characterize the lipidome of brain mitochondria (Villa et al. 
1989b; Ruggiero et al. 1992; Bangur et al. 1995).  This has been due in large 
part to contamination from myelin, a lipid-rich membrane that is difficult to 
separate from mitochondria (Seminario et al. 1964; Villa et al. 1989b).  The 
failure to remove contaminating membranes or differences in experimental 
procedures could account for the variability in brain mitochondrial lipid 
composition found in previous studies (Ruggiero et al. 1992; Bangur et al. 1995).  
We used multiple discontinuous gradients to obtain highly enriched brain 
mitochondrial populations free from detectable contamination including that from 
myelin and cytoskeletal proteins.  Since the primary goal of this investigation was 
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to isolate highly enriched NS and Syn mitochondria free from any detectable 
level of contamination, the length as well as choice of discontinuous gradients 
employed was designed solely for the purpose of mitochondrial lipid analysis as 
well as assessment of ETC enzyme activities by standard biochemical 
procedures.  GM1a content of the isolated fractions was also evaluated as an 
independent marker for membrane contamination, since GM1a is enriched in 
myelin (Seyfried et al. 1979).  Our data show that the ganglioside GM1a, 
sulfatides, cerebrosides, and cytoskeletal proteins do not exist in neural cell 
mitochondria.  We suggest that the presence of glycosphingolipids in brain 
mitochondria would indicate contamination from non-mitochondrial subcellular 
membranes or a physiological environment different from that which exists 
normally in mouse cerebral cortex.   
We used mouse cerebral cortex in this study since previous studies in rats 
showed that the relative differences between NS and Syn mitochondria for ETC 
enzyme activities and Coenzyme Q content are generally similar across brain 
regions (Leong et al. 1984; Battino et al. 1991; Battino et al. 1995).  It is therefore 
likely that our findings for mitochondrial lipids and ETC activities in the cerebral 
cortex would be similar for other brain regions.  We chose to examine B6 mice 
because many existing neurological mutations that alter CNS function and 
behavior are expressed on this genetic background (Bedell et al. 1997a; Bedell 
et al. 1997b).  Consequently, our study will provide useful information on brain 
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mitochondrial function to a broad range of neurological and neurodegenerative 
diseases expressed in B6 mice. 
 Membrane lipids can influence the activity of mitochondrial enzymes to 
include those of the ETC (Daum 1985; Di Paola et al. 2000; Chicco and 
Sparagna 2007).  We found that the levels of Ptd2Gro, Coenzyme Q9, and Q10 
were lower and the levels of Cer and PtdSer were higher in the Syn mitochondria 
than in the NS mitochondria.  Additionally, we found that the ETC activities of 
complexes I, II, III, and II/III were lower in the Syn mitochondria than in the NS 
mitochondria.  Since, enzyme activities from individual (unlinked) complexes 
(Complexes I, II, and III) could include activities of the combined (linked) 
measurements (Complexes I/III and II/III), it is possible that these differences 
arise from the ETC existing in two states, a random collisions state or a solid 
electron channeling state (Lenaz and Genova 2007).  Linked ETC activities can 
represent the combined activity of individual complexes or the activity of the 
supercomplex (Schagger and Pfeiffer 2000).  Recently, it was shown that the 
Complex I/III linked activity in the α-synuclein knockout mouse brain was lower 
than that of normal mouse brain without corresponding changes in either the 
Complex I or the Complex III individual ETC activities (Ellis et al. 2005).  This 
suggests that the linked activity corresponded to the measurement of the ETC 
complexes in the supercomplex state.  Hence, differences in individual ETC 
activities may not always correspond to differences in linked ETC activities. 
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No differences were found between NS and Syn mitochondria for the 
content of major protein markers for the individual ETC complexes.  This 
suggests that other factors, such as differences in lipid content, may account the 
differences found between NS and Syn mitochondria for linked ETC activities.  
As Ptd2Gro is required for the enzymatic activities of Complex I and Complex III 
(Fry and Green 1981; Gohil et al. 2004; Chicco and Sparagna 2007), a lower 
Ptd2Gro content in Syn than in NS mitochondria could account for the lower 
activities of Complex I and III in Syn mitochondria.  We suggest that the 
differences found in ETC complex activities between the NS and Syn 
mitochondria might be due in part to quantitative differences in their lipid 
composition, which could differentially affect unlinked or linked enzyme activities. 
 It is interesting that Ptd2Gro content is lower, while PtdSer content is 
higher in Syn than NS mitochondria.  These lipid differences might be related to 
the greater susceptibility of Syn mitochondria to calcium overload and 
permeability transition than NS mitochondria (Brown et al. 2006; Naga et al. 
2007).  Although Ptd2Gro and PtdSer are both anionic lipids that can buffer 
calcium, PtdSer is less prone than Ptd2Gro to calcium-induced peroxidation, 
which would occur during intense synaptic activity (Grijalba et al. 1999; Brown et 
al. 2006).  Differences in Ptd2Gro content between Syn and NS mitochondria 
might also influence susceptibility to apoptosis,  cytochrome c retention, or lipid 
peroxidation (Kagan et al. 2004).  We do not exclude the possibility that the 
difference between NS and Syn mitochondria for PtdSer content is related to 
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differences in lipid synthesis, transport protein activity, or cellular heterogeneity 
related to synaptic activity (Daum and Vance 1997; Zborowski et al. 1983). 
 Plasmalogen glycerophospholipids contain a vinyl-ether linkage in the sn-
1 position and are hypothesized to function as antioxidants and facilitators of 
membrane fusion (Gross 1984; Zoeller et al. 1988; Farooqui and Horrocks 2001).  
The ESI/MS procedures we used can easily measure the content and 
composition of plasmalogens (Han et al. 2001; Han and Gross 2005a).  Only 
brain and heart mitochondria contain significant quantities of choline and 
ethanolamine plasmalogen glycerophospholipids suggesting a unique role for 
plasmalogens in these tissues (Getz et al. 1968; Eichberg et al. 1964).  We found 
that the content of plasmenylethanolamine and plasmenylcholine was similar in 
the NS and the Syn mitochondria.  Hence, the role of plasmalogens is likely 
similar in the NS and Syn mitochondria.  This role could involve management of 
free radicals or regulation of unique fusogenic properties of brain mitochondrial 
membranes.   
Almost 100 molecular species of Ptd2Gro were detected in the NS and 
Syn mitochondria of B6 mice.  Moreover, these molecular species formed a 
unique pattern consisting of 7 major groups when arranged according to mass to 
charge ratios.  Interestingly, this Ptd2Gro pattern in brain was also observed in 
human, rat, and rabbit, suggesting conservation across some mammalian 
species (Cheng et al., unpublished observation).  Molecular species 
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heterogeneity was greater in the most abundant groups (groups II - VI) than in 
the least abundant groups (groups I and VII).  This Ptd2Gro species pattern in 
brain differs markedly from those found previously in non-neural tissues, which 
contain predominantly tetralinoleic Ptd2Gro (18:2-18:2-18:2-18:2) (Schlame et al. 
2005).  Surprisingly, no tetralinoleic Ptd2Gro was found in brain mitochondria.  
Hence, Ptd2Gro composition from brain differs markedly from the Ptd2Gro 
composition found in non-neural tissues. 
We suggest that the unique brain Ptd2Gro pattern arises from the 
remodeling activities of phospholipases and acyl transferases, which remove and 
transfer, respectively, fatty acid species from the sn-2 position of the ChoGpl and 
EtnGpl to form mature Ptd2Gro from monolysocardiolipin.  This suggestion 
comes from finding an abundance of fatty acids in mature Ptd2Gro that match 
those expressed in the predicted sn-2 position of ChoGpl and EtnGpl.  Our 
findings also indicate that only a small percentage of mature Ptd2Gro contains 
fatty acids originating from the condensation of PtdGro and CDP-DAG, which 
contain predominantly shorter chain fatty acids. 
The mechanism by which the acyl transferases select the sn-2 fatty acids 
from either ChoGpl or EtnGpl remains unclear.  Taffazin is the only known 
Ptd2Gro acyltransferase that is highly expressed in brain (Bione et al. 1993; Ma 
et al. 1999; Lu et al. 2004).  Although taffazin may have specificity for linoleic 
acid in non-neural tissues (Xu et al. 2003), linoleic acid is a minor fatty acid in 
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mature Ptd2Gro of brain.  Our findings together with those of other groups 
indicate that brain Ptd2Gro contains predominantly oleic, arachidonic, and 
docosahexaenoic fatty acids (Yamaoka et al. 1988; Nakahara et al. 1992; Bayir 
et al. 2007).  Although other enzymes have been implicated in Ptd2Gro 
remodeling to include scramblase 3 (PLS3), acyl-CoA:Lysocardiolipin 
acyltransferase (ALCAT1), monolysocardiolipin acyltransferase (MLCL AT), and 
acylglycerol-3-phosphate acyltransferases (AGPATs), the acyltransferase(s) 
involved in the complex remodeling of brain Ptd2Gro have yet to be determined 
(Hauff and Hatch 2006).  Nevertheless, our mathematical model indicates that 
the unique Ptd2Gro pattern for normal brain can arise from a random 
incorporation of selected fatty acids during the Ptd2Gro remodeling process. 
The functional significance of the unique brain Ptd2Gro molecular species 
pattern remains unclear.  A greater ratio of PUFA to saturated fatty acids could 
cause Ptd2Gro to be more prone to form a non-bilayer HII hexagonal phase lipid 
(Sankaram et al. 1989; Kraffe et al. 2002).  This conformational change can 
create regions of small curvature within the membrane, which could affect cristae 
structure (Hoch 1992; Stuart et al. 1998).  Increased docosahexaenoic containing 
Ptd2Gro results in decreased complex IV activity, but increases F1 ATPase 
activities (Yamaoka et al. 1988).  This might explain the lower complex IV 
activities that we found in the NS and Syn mitochondria relative to those found in 
non-neural tissues (Benard et al. 2006).  Long-chain PUFA Ptd2Gro species 
could also enhance membrane phase transformations thus allowing optimal 
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activity of oxidative phosphorylation in response to environmental changes 
(Kraffe et al. 2002).  The prevalence of oleic fatty acids in Ptd2Gro could also 
enhance mitochondrial respiratory chain ratios and degree of coupling (Brand et 
al. 2003a).  The unique Ptd2Gro species pattern of brain might also be interesting 
with regard to the ‘respirasome’ formation, since Ptd2Gro can ‘glue’ the 
complexes together in an organized supercomplex to increase efficiency of ATP 
production (Zhang et al. 2002; Pfeiffer et al. 2003b).  Further studies are needed 
to resolve the role of the unique pattern of Ptd2Gro molecular species in brain 
mitochondrial function.   
Alterations in brain energy metabolism have been implicated in variety of 
neurological and neurodegenerative disorders including Parkinson’s disease, 
Alzheimer’s disease, Huntington’s disease, epilepsy, brain tumors, storage 
diseases, bipolar disorder, schizophrenia, and autism to name a few (Bowling 
and Beal 1995; Lombard 1998; Blass 2002; Seyfried and Mukherjee 2005).  
Abnormalities in NS and Syn mitochondrial lipids, at the quantitative as well as 
the molecular species level, may occur in these disorders as either a cause or an 
effect of disease pathogenesis. Although differences in lipid content as well as 
ETC activities exist between NS and Syn mitochondria, these differences likely 
represent metabolic compartmentation in the brain.  However, these populations 
of brain mitochondria might be affected differently in disease states.   We 
suggest that the integrity of the mitochondrial lipidome is critical for efficient ATP 
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production and that alterations in the lipidome will impair oxidative 
phosphorylation thus compromising normal neurological function. 
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  Lipid
  Ethanolamine glycerophospholipids 187.4 + 12.1 211.7 + 21.3
Phosphatidylethanolamine 164.9 + 10.0 184.6 + 20.3
Plasmenylethanolamine 22.5 + 2.2 27.0 + 1.0
  Choline glycerophospholipids 129.9 + 7.7 156.3 + 26.1
Phosphatidylcholine 119.6 + 5.3 137.4 + 17.2
Plasmenylcholine 1.2 + 0.1 2.4 + 1.1
Plasmanylcholine 9.1 + 3.2 16.5 + 8.5
  Cholesterol 139.0 + 46.7 126.7 + 31.2
  Cardiolipin 52.7 + 4.5 39.9 + 3.4 *
  Phosphatidylinositol 9.4 + 0.8 10.2 + 0.9
  Phosphatidylglycerol 7.1 + 0.5 6.4 + 0.7
  Sphingomyelin 5.3 + 1.2 6.5 + 0.6
  Phosphatidylserine 4.6 + 1.5 14.1 + 3.0 *
  Lysophosphatidylcholine 2.7 + 0.6 3.3 + 0.4
  Ceramide 0.7 + 0.2 1.6 + 0.2 **
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Significantly different values from NS mitochondria at *: P < 0.02; **: P <0.005 as determined from the two-tailed t -test
Non-synaptic Synaptic
Table 7  Lipid composition of C57BL/6J mouse brain mitochondria
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Non-synaptic Synaptic
Complex I 975 + 64   533 + 37***
NADH ubiquinone oxidoreductase
Complex II 292 + 18   177 + 27**
succinate decylubiquinone DCIP oxidoreductase
Complex III 437 + 71   235 + 47*
ubiquinol cytochrome c oxidoreductase
Complex IV 179 + 17   184 + 50 
cytochrome c oxidase
Complex I/III 269 + 59   244 + 40
NADH cytochrome c oxidoreductase
Complex II/III 309 + 30   212 + 22*
succinate cytochrome c reductase
a - Enzyme activities are expressed as (nmol/min/mg protein) + S.D. (N = 3)
Signficantly different values from NS mitochondria at *: P < 0.025; **: P < 0.01;
***: P < 0.005 as determined from the two-tailed t-test
Table 8  Electron transport chain activities of C57BL/6J mouse 
brain mitochondriaa
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[M-H]- Major Species
716.5 D16:0-18:1 5.11 + 1.14 4.82 + 0.68
742.5 D18:0-18:2 5.07 + 0.62 5.09 + 0.88
      D18:1-18:1
      D16:0-20:2
746.5 P16:0-22:6 9.03 + 1.39 9.89 + 1.72
      D18:0-18:0
      P18:2-20:4
762.5 D16:0-22:6 9.39 + 0.81 11.08 + 1.00
764.5 D16:0-22:5 8.78 + 0.52 8.35 + 0.86
      D18:1-20:4
766.5 D18:0-20:4 37.49 + 2.42 36.39 + 4.86
      D16:0-22:4
768.6 D18:1-20:2 11.49 + 2.19 16.42 + 1.11
      D16:0-22:3
      D18:0-20:3
774.5 P18:0-22:6 10.37 + 1.44 13.25 + 1.63
      P18:1-22:5
      D18:0-20:0
776.6 P18:0-22:5 7.29 + 2.19 8.24 + 2.24
      P18:1-22:4
778.6 P18:0-22:4 2.23 + 0.52 3.38 + 1.03
      P20:0-20:4
      P18:1-22:3
788.5 D18:1-22:6 5.95 + 0.44 6.47 + 0.55
790.5 D18:0-22:6 58.18 + 1.87 58.66 + 8.62
      D18:1-22:5
792.6 D18:1-22:4 3.62 + 0.29 4.90 + 0.38
      D18:0-22:5
794.6 D20:0-20:4 6.53 + 0.46 15.63 + 2.58
      D18:1-22:3
      D18:0-22:4
796.6 D20:0-20:3 6.85 + 1.34 9.14 + 0.48
      D18:0-22:3
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Non-synaptic Synaptic
Table 9  Mass content of ethanolamine glycerophospholipid 
molecular species in C57BL/6J brain mitochondria
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[M+Li]+ Major Species
712.5 D14:0-16:0 0.35 + 0.11 1.96 + 2.37
722.6 P16:0-16:1 0.04 + 0.07 0.09 + 0.15
     P16:1-16:0
     P18:1-14:0
724.6 A16:0-16:1 0.09 + 0.02 0.14 + 0.13
726.6 A16:0-16:0 0.11 + 0.10 0.27 + 0.06
736.5 D14:1-18:1 0.31 + 0.15 0.42 + 0.19
738.6 D16:1-16:0 2.39 + 0.44 3.10 + 0.31
      D14:1-18:0
740.6 D16:0-16:0 10.00 + 1.27 13.58 + 1.32
748.6 A16:0-18:3 0.12 + 0.03
750.6 P18:1-16:0 0.05 + 0.08 0.14 + 0.07
752.6 P16:0-18:0 0.22 + 0.06 0.25 + 0.08
      P18:0-16:0
      A18:1-16:0
760.5 D14:1-20:3 0.13 + 0.06 0.14 + 0.06
      D16:2-18:2
      D14:0-20:4
762.6 D16:1-18:2 0.15 + 0.10 0.20 + 0.13
764.6 D16:0-18:2 1.71 + 0.26 1.42 + 0.22
766.6 D16:0-18:1 33.31 + 1.31 37.34 + 3.07
768.6 D16:0-18:0 2.47 + 0.26 3.36 + 0.93
772.6 P18:2-18:2 0.03 + 0.05 0.05 + 0.05
      P16:0-20:4
      P20:4-16:0
774.6 A16:0-20:4 0.05 + 0.04 0.02 + 0.03
776.6 P18:1-18:1 0.00 0.09 + 0.08
778.6 P18:1-18:0 0.10 + 0.05 0.20 + 0.17
780.6 A18:0-18:1 0.59 + 0.05 0.95 + 0.50
      P18:0-18:0
782.7 A16:0-20:0 7.42 + 2.81 13.18 + 7.40
786.6 D18:2-18:3 0.53 + 0.12 0.56 + 0.21
      D16:1-20:4
788.6 D18:2-18:2 23.37 + 1.28 23.13 + 2.55
      D16:0-20:4
790.6 D18:1-18:2 1.07 + 0.14 1.49 + 0.23
      D16:0-20:3
792.6 D18:0-18:2 4.15 + 0.42 3.89 + 0.28
      D18:1-18:1
794.6 D18:0-18:1 4.39 + 0.46 6.43 + 0.99
796.6 D18:0-18:0 0.08 + 0.07 0.69 + 0.52
798.6 P18:1-20:4 0.07 + 0.01 0.33 + 0.31
800.6 P18:0-20:4 0.07 + 0.01 0.08 + 0.06
802.6 P18:2-20:1 0.27 + 0.10 0.29 + 0.10
      P20:1-18:2
      A18:0-20:4
810.7 A18:0-20:0 0.91 + 0.23 2.02 + 0.92
812.6 D16:0-22:6 13.94 + 0.79 14.08 + 1.45
      D18:2-20:4
814.6 D18:1-20:4 5.66 + 0.72 5.51 + 1.07
      D16:0-22:5
816.6 D18:2-20:2 11.36 + 0.90 12.21 + 2.03
      D18:0-20:4
818.6 D18:0-20:3 0.36 + 0.17 0.44 + 0.26
820.6 D18:0-20:2 0.16 + 0.03 0.39 + 0.18
      P18:2-22:6
822.7 P18:1-22:6 0.10 + 0.09 0.15 + 0.07
824.6 P18:0-22:6 0.02 + 0.02 0.11 + 0.09
      P18:1-22:5
826.6 A18:0-22:6 0.05 + 0.05 0.16 + 0.12
      P18:0-22:5
836.6 D18:2-22:6 0.12 + 0.11 0.23 + 0.07
838.6 D18:1-22:6 1.29 + 1.15 2.07 + 0.58
      D18:2-22:5
840.6 D18:0-22:6 2.07 + 1.96 4.14 + 1.02
      D20:2-20:4
842.6 D18:0-22:5 0.20 + 0.18 0.50 + 0.24
      D20:2-20:3
844.6 D18:0-22:4 0.14 + 0.14 0.33 + 0.20
      D20:0-20:4
      D20:2-20:2
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Non-synaptic Synaptic
Table 10  Mass content of choline glycerophospholipid 
molecular species in C57BL/6J brain mitochondria
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[M-2H]- Major Species
700.0 18:1-18:1-16:1-16:1 0.30 + 0.03 0.25 + 0.05
701.0 18:1-18:1-16:0-16:1       0.31 + 0.05 0.32 + 0.06
     18:2-18:1-16:0-16:0
     18:2-18:0-16:1-16:0
702.0 18:1-18:1-16:0-16:0     0.24 + 0.04 0.28 + 0.03
     18:2-18:0-16:0-16:0
     18:1-18:0-16:0-16:1
710.0 20:4-18:2-16:1-16:1 0.09 + 0.01 0.08 + 0.01
711.0 20:4-18:1-16:1-16:1     0.41 + 0.06 0.29 + 0.01
     20:4-18:2-16:1-16:0
712.0 20:4-18:1-16:1-16:0     0.45 + 0.06 0.34 + 0.07
     18:2-18:2-18:1-16:1
713.0 18:2-18:1-18:1-16:1     0.71 + 0.02 0.53 + 0.04
     18:1-18:1-18:1-16:2
     18:2-18:1-18:0-16:2 
     18:2-18:2-18:0-16:1
714.0 18:1-18:1-18:1-16:1     1.47 + 0.23 1.03 + 0.12
     18:2-18:1-18:1-16:0
715.0 18:1-18:1-18:1-16:0     0.68 + 0.04 0.61 + 0.08
     18:0-18:1-18:1-16:1
716.0 18:0-18:1-18:1-16:0    0.09 + 0.02 0.07 + 0.04
     18:0-18:0-18:1-16:1
722.0 20:4-20:4-16:1-16:1 0.23 + 0.03 0.17 + 0.05
723.0 20:4-20:4-16:1-16:0     0.36 + 0.03 0.28 + 0.06
     20:4-18:2-18:2-16:1
724.0 20:4-18:2-18:1-16:1 0.95 + 0.08 0.66 + 0.08
725.0 20:4-18:2-18:1-16:0     2.22 + 0.17 1.56 + 0.22
     20:4-18:1-18:1-16:1
726.0 20:4-18:1-18:1-16:0     1.74 + 0.13 1.31 + 0.09
     20:3-18:1-18:1-16:1  
     20:3-18:1-18:1-16:1
727.0 18:2-18:1-18:1-18:1 2.48 + 0.33 1.59 + 0.18
728.0 18:1-18:1-18:1-18:1 3.72 + 0.72 2.21 + 0.15
729.0 18:1-18:1-18:1-18:0 0.30 + 0.03 0.16 + 0.04
734.0 22:6-20:4-16:1-16:1 0.14 + 0.02 0.09 + 0.01
735.0 20:4-20:4-18:2-16:1 0.56 + 0.06 0.39 + 0.02
736.0 20:4-20:4-18:1-16:1 1.41 + 0.16 1.10 + 0.12
737.0 20:4-20:4-18:1-16:0     2.11 + 0.07 1.54 + 0.17
     22:6-18:1-18:1-16:1 
     22:6-18:2-18:1-16:0
738.0 20:4-18:2-18:1-18:1     2.68 + 0.37 2.02 + 0.12
     22:6-18:1-18:1-16:0
739.0 20:4-18:1-18:1-18:1 3.30 + 0.45 2.48 + 0.23
740.0 20:4-18:1-18:1-18:0     1.07 + 0.14 0.75 + 0.03
     20:3-18:1-18:1-18:1
741.0 20:4-18:1-18:0-18:0     0.25 + 0.08 0.15 + 0.03
     20:3-18:1-18:1-18:0
747.0 22:6-18:3-18:2-18:2 0.40 + 0.04 0.27 + 0.05
748.0 20:4-20:4-18:2-18:2     1.38 + 0.09 1.11 + 0.17
     20:4-20:4-20:4-16:0 
     22:6-20:4-18:1-16:1 
     22:6-22:6-16:0-16:0 
     22:6-18:2-18:2-18:2
749.0 20:4-20:4-18:2-18:1 1.99 + 0.19 1.46 + 0.20
750.0 20:4-20:4-18:1-18:1 3.24 + 0.24 2.31 + 0.28
751.0 22:6-18:1-18:1-18:1     2.74 + 0.10 2.36 + 0.26
     20:4-20:3-18:1-18:1
752.0 22:6-18:1-18:1-18:0 0.54 + 0.17 0.46 + 0.07
753.0 20:4-20:2-18:1-18:0     0.15 + 0.04 0.16 + 0.03
     20:4-20:1-18:1-18:1
754.0 20:4-20:1-18:1-18:0 0.09 + 0.02 0.08 + 0.01
759.0 22:6-20:4-20:4-16:1     0.32 + 0.04 0.27 + 0.03
     22:6-22:6-18:2-16:1
760.0 22:6-20:4-18:2-18:2     0.76 + 0.05 0.58 + 0.09
     22:6-20:4-20:4-16:0  
     22:6-22:6-18:1-16:1
761.0 22:6-20:4-18:2-18:1 1.72 + 0.08 1.27 + 0.05
762.0 22:6-20:4-18:1-18:1 2.94 + 0.23 2.36 + 0.13
763.0 22:6-20:4-18:1-18:0     1.03 + 0.05 0.78 + 0.07
     22:6-20:3-18:1-18:1
764.0 22:4-20:4-18:1-18:1     0.24 + 0.02 0.22 + 0.02
     22:6-20:3-18:1-18:0
771.0 22:6-20:4-20:4-18:3 0.18 + 0.05 0.16 + 0.02
772.0 22:6-22:6-20:4-16:0     0.42 + 0.05 0.32 + 0.05
     20:4-20:4-20:4-20:4 
     22:6-20:4-20:4-18:2 
     22:6-22:6-18:2-18:2
773.0 22:6-20:4-20:4-18:1 1.42 + 0.12 1.10 + 0.10
774.0 22:6-22:6-18:1-18:1     1.81 + 0.09 1.56 + 0.17
     22:6-20:4-20:3-18:1
775.0 16:0-20:3-22:5-22:5     0.28 + 0.10 0.29 + 0.01
     18:2-20:3-20:3-22:5 
     18:0-18:1-22:6-22:6  
     18:0-20:3-20:4-22:6
776.0 18:0-18:0-22:6-22:6 0.16 + 0.05 0.17 + 0.03
784.0 22:6-22:6-20:4-18:2 0.33 + 0.05 0.26 + 0.04
786.0 22:6-22:6-20:4-18:1     1.33 + 0.08 1.11 + 0.16
     22:6-20:4-20:4-20:3
796.0 20:4-20:4-22:6-22:6 0.25 + 0.09 0.26 + 0.10
797.0 22:6-22:6-22:6-18:1     0.50 + 0.04 0.50 + 0.05
     22:6-22:6-20:4-20:3
798.0 20:4-20:3-22:6-22:5   0.16 + 0.07 0.16 + 0.04
         22:6-22:6-22:6-18:0   
      22:6-22:6-22:5-18:1
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Non-synaptic Synaptic
Table 11  Mass content of cardiolipin molecular species in 
C57BL/6J brain mitochondria
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[M-H]- Major Species
809.5 16:0-16:0 0.07 + 0.02 0.07 + 0.04
833.5 16:0-18:2 0.02 + 0.01 0.03 + 0.01
835.5 16:0-18:1 0.18 + 0.08 0.15 + 0.05
837.5 16:0-18:0 0.05 + 0.02 0.06 + 0.03
857.5 16:0-20:4 1.12 + 0.09 1.17 + 0.11
859.5 18:1-18:2 0.03 + 0.02 0.17 + 0.20
861.5 18:0-18:2 0.03 + 0.01 0.07 + 0.02
863.6 18:0-18:1 0.06 + 0.03 0.10 + 0.01
865.6 18:0-18:0 0.03 + 0.01 0.02 + 0.01
881.5 18:2-20:4 0.23 + 0.01 0.26 + 0.06
      16:0-22:6
885.5 18:0-20:4 6.68 + 0.41 7.04 + 0.69
887.6 18:0-20:3 0.17 + 0.15 0.18 + 0.06
889.6 18:0-20:2 0.03 + 0.01 0.03 + 0.03
893.6 18:0-20:0 0.09 + 0.02 0.06 + 0.04
907.5 18:1-22:6 0.05 + 0.03 0.09 + 0.06
909.5 18:0-22:6 0.37 + 0.02 0.48 + 0.03
953.5 22:6-22:6 0.08 + 0.03 0.09 + 0.05
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
SynapticNon-synaptic
Table 12  Mass content of phosphatidylinositol molecular 
species in C57BL/6J brain mitochondria
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[M-H]- Major Species
719.5 16:0-16:1 0.29 + 0.02 0.31 + 0.02
721.5 16:0-16:0 0.49 + 0.04 0.49 + 0.03
743.5 16:1-18:2 0.22 + 0.04 0.19 + 0.04
745.5 16:0-18:2 0.54 + 0.10 0.48 + 0.05
747.5 16:0-18:1 3.41 + 0.13 3.07 + 0.43
769.5 18:2-18:2 0.82 + 0.04 0.64 + 0.10
771.5 18:1-18:2 0.29 + 0.03 0.26 + 0.02
773.5 18:1-18:1 0.47 + 0.12 0.38 + 0.02
775.5 18:0-18:1 0.55 + 0.10 0.60 + 0.14
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
SynapticNon-synaptic
Table 13  Mass content of phosphatidylglycerol molecular 
species in C57BL/6J brain mitochondria
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
[M+Li]+ Major Species
709.6 N16:0 0.27 + 0.32 0.27 + 0.13
735.6 N18:1 0.26 + 0.02 0.29 + 0.08
737.6 N18:0 1.99 + 0.38 2.76 + 0.17
761.6 N20:2 0.03 + 0.04 0.09 + 0.15
763.6 N20:1 0.07 + 0.00 0.11 + 0.13
765.6 N20:0 2.33 + 0.41 2.61 + 0.32
793.7 N22:0 0.16 + 0.27 0.32 + 0.13
821.7 N24:0 0.20 + 0.14 0.08 + 0.02
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
SynapticNon-synaptic
Table 14  Mass content of sphingomyelin molecular 
species in C57BL/6J brain mitochondria
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[M-H]- Major Species
706.5 14:0-16:0 0.01 + 0.01 0.04 + 0.00
760.5 16:0-18:1 0.07 + 0.02 0.20 + 0.09
784.5 18:1-18:2 0.02 + 0.01 0.01 + 0.01
786.5 18:0-18:2 0.29 + 0.07 0.47 + 0.11
788.5 18:0-18:1 0.24 + 0.21 1.61 + 0.77
790.6 18:0-18:0 0.01 + 0.01 0.18 + 0.13
806.5 18:2-20:4 0.05 + 0.03 0.06 + 0.05
808.5 18:1-20:4 0.04 + 0.04 0.04 + 0.03
810.5 18:0-20:4 0.10 + 0.08 0.35 + 0.15
832.5 18:1-22:6 0.05 + 0.01 0.17 + 0.05
834.5 18:0-22:6 3.13 + 1.22 9.59 + 1.60
836.5 18:0-22:5 0.22 + 0.27 0.31 + 0.20
838.6 20:0-20:4 0.28 + 0.07 0.79 + 0.04
      18:0-22:4
878.5 22:6-22:6 0.07 + 0.01 0.12 + 0.03
882.5 22:6-22:4 0.06 + 0.07 0.19 + 0.05
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Synaptic
Table 15  Mass content of phosphatidylserine molecular 
species in C57BL/6J brain mitochondria
Non-synaptic
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[M+Na]+ Major Species
490.3 14:0 0.06 + 0.01 0.04 + 0.02
504.3  A16:0    0.06 + 0.03 0.04 + 0.01
516.3 16:1 0.09 + 0.04 0.13 + 0.07
518.3 16:0 0.89 + 0.21 1.22 + 0.14
542.3 18:2 0.06 + 0.02 0.03 + 0.02
544.3 18:1 0.41 + 0.13 0.54 + 0.12
546.4 18:0 0.32 + 0.08 0.44 + 0.08
566.3 20:4 0.16 + 0.09 0.16 + 0.03
568.3 20:3 0.02 + 0.00 0.06 + 0.04
570.4 20:2 0.03 + 0.01 0.02 + 0.02
572.4 20:1 0.04 + 0.02 0.05 + 0.01
574.4 20:0 0.04 + 0.02 0.07 + 0.09
590.3 22:6 0.24 + 0.12 0.27 + 0.03
592.3 22:5 0.08 + 0.03 0.09 + 0.03
594.4 22:4 0.04 + 0.02 0.05 + 0.02
596.4 22:3 0.03 + 0.03 0.06 + 0.01
598.4 22:2 0.01 + 0.01 0.02 + 0.01
600.4 22:1 0.04 + 0.03 0.04 + 0.01
602.4 22:0 0.02 + 0.02 0.02 + 0.02
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Non-synaptic Synaptic
Table 16  Mass content of lysophosphatidylcholine 
molecular species in C57BL/6J brain mitochondria
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[M-H]- Major Species
536.5 N16:0 0.01 + 0.01 0.02 + 0.01
564.5 N18:0 0.66 + 0.15 1.54 + 0.19
592.6 N20:0 0.04 + 0.02 0.03 + 0.00
646.6 N24:1 0.02 + 0.02 0.04 + 0.02
648.6 N24:0 0.02 + 0.00 0.01 + 0.01
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
SynapticNon-synaptic
Table 17  Mass content of ceramide molecular species 
in C57BL/6J brain mitochondria
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Figure 5.  Procedure used for the isolation and purification of NS and Syn 
mitochondria from mouse cerebral cortex. 
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Figure 6.  Distribution of protein markers on Western blots (A) and of 
gangliosides on thin-layer chromatography (B) in subcellular fractions from 
mouse cerebral cortex.  Subcellular fractions included total homogenate (TH), 
crude myelin (My), Ficoll gradient purified NS mitochondria (FM), Ficoll and 
sucrose gradient purified non-synaptic mitochondria (NS), and Ficoll and sucrose 
gradient purified synaptic mitochondria (Syn).  Western blots were performed to 
determine the distribution of specific protein markers for the inner mitochondria 
membrane (complex IV, subunit IV), outer mitochondrial membrane (monoamine 
oxidase A), myelin (proteolipid protein), synaptosomal membrane (SNAP25), 
cytoskeleton (β-actin), nuclear membrane (proliferating cell nuclear antigen), 
Golgi membrane (Tuberin), and microsomal membrane (calnexin).  GM1a was 
visualized on TLC plates with cholera toxin b immunostaining as described in 
Methods.  Std, is GM1a. 
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 Figure 7. Distribution of fatty acid molecular species in NS (black bar) and Syn 
(white bar) mitochondrial phospholipids.  Phospholipids included (A) 
Phosphatidylinositol (PtdIns), (B) Sphingomyelin (CerPCho), (C) 
Phosphatidylserine (PtdSer), (D) Phosphatidylglycerol (PtdGro), (E) 
Lysophosphatidylcholine (LysoPtdCho), (F) Choline glycerophospholipids 
(ChoGpl), and (G) Ethanolamine glycerophospholipids (EtnGpl).  Molar 
percentages less than 2% of the total lipid are not shown.  Glycerolipid 
subclasses include D (phosphatidyl), P (plasmenyl), and A (plasmanyl).  The total 
molecular species content of each lipid class is presented in Tables 9-17.  All 
values are expressed as the mean of three independent samples (n = 3), where 
6 cortexes were pooled for each sample. 
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 Figure 8. Distribution of Ptd2Gro molecular species in NS (black bar) and Syn 
(white bar) mitochondria.  Ptd2Gro molecular species were arranged according to 
the mass to charge ratio based on percentage distribution.  Ptd2Gro molecular 
species were subdivided into 7 groups, which contained a predominance of oleic, 
arachidonic, and/or docosahexanoic fatty acids in varying concentrations.   
Corresponding mass content of molecular species in NS and Syn mitochondria 
can be found in Table 11.  All values are expressed as the mean of three 
independent samples (n = 3), where 6 cortexes were pooled for each sample. 
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 Figure 9.  Mathematical prediction of the distribution of brain cardiolipin 
molecular species.  (A) Distribution of molecular species of NS brain Ptd2Gro as 
determined by shotgun lipidomics.  (B) Distribution of molecular species of 
Ptd2Gro as determined by mathematical modeling as described in methods.  
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 Figure 10. Coenzyme Q9 and Q10 content in NS (black bar) and Syn (white bar) 
mitochondria.  Coenzyme Q content was measured by HPLC/ECD as described 
in Methods.  The content of Q9 and Q10 were significantly lower in Syn 
mitochondria compared to NS mitochondria.  Values are expressed as the mean 
pmol/mg protein + S.D. (N = 3), where 6 cortexes were pooled for each sample.  
Asterisks indicate that the Q9 and Q10 values were lower in the Syn 
mitochondria than in the NS mitochondria at *: P < 0.02 and **: P < 0.001. 
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Figure 11.  Expression of ETC protein markers in NS and Syn mitochondria. 
 
Representative protein markers for each of the five ETC complexes were 
evaluated by Western blot as described in Methods.  This pattern is 
representative of expression found from three separate isolations, where 6 
cortexes were pooled for each sample.  ETC protein expression was evaluated at 
least three times to confirm accuracy of data.  Voltage dependent anion channel 
(VDAC) was used as a loading control for mitochondrial protein.   
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CHAPTER FOUR 
Brain Mitochondrial Lipid Abnormalities in Mice Susceptible to 
Spontaneous Gliomas 
 
INTRODUCTION 
 
Mitochondrial Membrane Lipids 
Mitochondria are necessary for the maintenance of brain metabolism 
supporting neurological function.  Alterations in brain mitochondria can impair 
bioenergetic efficiency resulting in disease pathology or neurological impairment.  
Although such alterations can exist at the DNA or protein level, little attention has 
focused on the role of mitochondrial lipids in neurological function.  Mitochondrial 
membrane lipids can regulate numerous functions to include ETC activities, 
membrane fluidity, mitochondrial protein import, and ATP synthesis (Daum 1985; 
Hoch 1992; Petrushka et al. 1959; Shinzawa-Itoh et al. 2007; Jiang et al. 2000).  
NS brain mitochondria are derived from the cell bodies of neurons and glia and 
represent the predominant mitochondrial population in brain (Davey and Clark 
1996).  Alterations in the NS mitochondrial lipid composition could influence ETC 
activities resulting in a change in neural cell metabolism.   
Shotgun Lipidomics and Brain Cardiolipin 
 Shotgun lipidomics, using ESI/MS, can now determine the total content 
and composition of mitochondrial lipids (the lipidome).  Using this approach, we 
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recently characterized the lipid composition of mouse brain mitochondria (Kiebish 
et al. 2008).  The mitochondrial specific lipid cardiolipin (1,3-diphosphatidyl-sn-
glycerol, Ptd2Gro), contains nearly 100 different molecular species in the B6 
mouse brain (Kiebish et al. 2008).  Moreover, these molecular species are 
symmetrically distributed in 7 major groups when arranged according to mass to 
charge ratios (Kiebish et al. 2008).  This distribution in B6 mice is similar to that 
in several other mammalian species and reflects a conserved Ptd2Gro 
remodeling process for brain (Cheng et al., unpublished observation). 
 Our objective was to compare and contrast the lipidome of NS 
mitochondria and ETC activities in mice of the B6 and the VM/Dk (VM) strains.  
B6 mice are often used as a control strain for many existing neurological 
mutations that alter CNS function (Bedell et al. 1997a; Bedell et al. 1997b). VM 
mice are unique in expressing a relatively high incidence (1.5%) of spontaneous 
brain tumors.  Most of these brain tumors were characterized as gliomas 
(astrocytomas and microgliomas) (Huysentruyt et al. 2008; Fraser 1971; Fraser 
1986).  Indeed, the incidence in VM mice is about 210-fold greater than the 
incidence in B6 mice.  Although altered mitochondrial energy metabolism has 
long been connected to tumorigenesis (Warburg hypothesis) (Warburg 1931; 
Warburg 1956; Cavalli and Liang 1998; Augenlicht and Heerdt 2001), the role of 
mitochondrial lipids in this connection remains unclear.  Ours is the first 
comparative analysis of the NS brain mitochondria lipidome in two mouse strains 
that differ in susceptibility to spontaneous gliomas. 
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MATERIALS AND METHODS 
Mice 
The VM mice were obtained from Professor H. Fraser, University of Edinburgh.  
The B6 mice were obtained from the Jackson Laboratory (Bar Harbor, ME).  Mice 
of both strains were propagated at the Boston College Animal Facility and were 
maintained by brother-sister inbreeding.  All mice were housed in plastic cages 
with filter tops containing Sani-Chip bedding (P.J. Murphy Forest Products Corp., 
Montville, NJ).  The room was maintained at 22 ºC on a 12 hr light/dark cycle.  
Food (Prolab RMH 3000; PMI LabDiet, Richmond, IN) and water were provided 
ad libitum.  This study was conducted with the National Institutes of Health Guide 
for the Care and Use of Laboratory Animals and was approved by the 
Institutional Animal Care Committee.   
 
Non-synaptic Brain Mitochondrial Isolation 
We recently described an improved procedure for isolation and purification of NS 
mitochondria from mouse brain for the purpose of lipid analysis and biochemical 
analysis of ETC activities (Kiebish et al. 2008).  Briefly, aged matched B6 and 
VM mice (4 months) were sacrificed by cervical dislocation and the cerebral 
cortex was dissected.  Mitochondria were isolated in a cold room (4 ºC) and all 
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reagents were kept on ice.  The isolation procedure employed a combination of 
gradients and strategies as previously described (Lai and Clark 1976; Lai et al. 
1977; Mena et al. 1980; Dagani et al. 1983; Rendon and Masmoudi 1985; Battino 
et al. 1991; Brown et al. 2006) (Fig. 12). The cerebral cortexes (a pool of 
6/sample) were diced on an ice cold metal plate and then placed in 12 mL of 
mitochondria isolation buffer (MIB; 0.32 M sucrose, 10 mM Tris-HCl, and 1 mM 
EDTA-K (pH 7.4)).  The pooled cerebral cortexes were homogenized using a 
Potter Elvehjem homogenizer with a Teflon coated pestle attached to a hand-
held drill.  Samples were homogenized using 15 up and down strokes at 500 
rpm.  The homogenate was centrifuged at 1,000 x g for 5 min.  The supernatant 
was collected and the pellet was washed twice by centrifugation, collecting the 
supernatants each time.  The supernatants were pooled and centrifuged at 1,000 
x g for 5 min.  The collected supernatant was then spun at 14,000 x g for 15 min.  
The supernatant was discarded and the pellet, which contained primarily NS 
mitochondria, synaptosomes and myelin, was resuspended in 12 mL MIB and 
was layered on a 7.5%/12% discontinuous Ficoll gradient.  Each Ficoll gradient 
layer contained 12 mL for a total volume of 36 mL.  The Ficoll gradients were 
made from a 20% Ficoll stock with MIB.  The gradient was centrifuged at 73,000 
x g for 36 min (4 ºC) in a Sorvall SW 28 rotor with slow acceleration and 
deceleration (Optima L-90K Ultracentrifuge).  The centrifugation time used 
permitted sufficient acceleration and deceleration to achieve maximum g force 
and to prevent synaptosomal contamination of the mitochondrial fraction below 
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the 12% Ficoll layer (Battino et al. 1991).  Crude myelin collected at the 
MIB/7.5% Ficoll interface was discarded.  The Ficoll gradient purified NS 
mitochondria (FM) were collected as a pellet below the 12% Ficoll.  
 The FM pellet, containing NS mitochondria, was resuspended in MIB 
containing 0.5 mg/mL bovine serum albumin (BSA) and was centrifuged at 
12,000 x g for 15 min.  The resulting pellet was collected and resuspended in 6 
mL of MIB.  The resuspended FM pellet was layered on a discontinuous sucrose 
gradient containing 0.8 M/ 1.0 M/ 1.3 M/ 1.6 M sucrose.  The volumes for the 
sucrose gradient were 6 mL/ 6 mL/ 10 mL/ 8 mL, respectively.  The gradients 
were made from a 1.6 M sucrose stock containing 1 mM EDTA-K and 10 mM 
Tris-HCl (pH 7.4).  The discontinuous sucrose gradient was centrifuged at 50,000 
x g for 2 hr (4 ºC) in a Sorvall SW 28 rotor using slow acceleration and 
deceleration to prevent disruption of the gradient.  Purified NS mitochondria were 
collected at the interface of 1.3 M and 1.6 M sucrose.  NS Mitochondria were 
collected and resuspended in (1:3, v/v) TE buffer  (1 mM EDTA-K and 10 mM 
Tris-HCl, pH 7.4) containing 0.5 mg/mL BSA and centrifuged at 18,000 x g for 15 
min.  The pellet was then resuspended in MIB and centrifuged at 12,000 x g for 
10 min.  The pellet was again resuspended in MIB and centrifuged at 8,200 x g 
for 10 min. 
 
Materials for Mass Spectrometry 
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Synthetic phospholipids including 1,2-dimyristoleoyl-sn-glycero-3-phosphocholine 
(14:1-14:1 PtdCho), 1,2-dipalmitoleoyl-sn-glycero-3phosphoethanolamine (16:1-
16:1 PtdEtn), 1,2-dipentadecanoyl-sn-glycero-3-phosphoglycerol (15:0-15:0 
PtdGro), 1,2-dimyristoyl-sn-glycero-3-phosphoserine (14:0-14:0 PtdSer), N-
lauroryl sphingomyelin (N12:0 CerPCho), 1,1’,2,2’-tetramyristoyl cardiolipin 
(T14:0 Ptd2Gro), heptadecanoyl ceramide (N17:0 Cer), 1-heptadecanoyl-2-
hydroxy-sn-Glycero-3-phosphocholine (17:0 LysoPtdCho) were purchased from 
Avanti Polar Lipids, Inc. (Alabaster, AL, USA).  It should be noted that the prefix 
“N” denotes the amide-linked acyl chain.  All the solvents were obtained from 
Burdick and Jackson (Honeywell International Inc., Burdick and Jackson, 
Muskegon, MI, USA).  All other chemicals were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).   
 
Sample Preparation for Mass Spectrometric Analysis 
Samples were prepared as described in methods in Chapter 3. 
 
Instrumentation and Mass Spectrometry 
Instrumentation and Mass spectrometry was performed as described in methods 
in Chapter 3. 
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Electron Transport Chain Enzyme Activities 
ETC enzyme analysis for Complex I (NADH-ubiquinone oxidoreductase), 
Complex II (succinate decylubiquinone DCIP oxidoreductase), Complex III 
(ubiquinol cytochrome c reductase), Complex IV (cytochrome c oxidase), 
Complex I/III (NADH cytochrome c reductase), and Complex II/III (succinate 
cytochrome c reductase) was performed as described in methods in Chapter 3.  
 
RESULTS 
 
Lipid Composition of B6 and VM NS Brain Mitochondria 
The differences between the B6 and VM mice for the content NS 
mitochondrial lipids are shown in Table 18.  The lipid classes are listed according 
to their relative abundance.  The mass content of PtdIns, PtdSer, and Cer was 
higher, whereas the content of total ChoGpl, in particular PtdCho, was lower in 
VM mice than in B6 mice.  PlsEtn was significantly higher in VM mice than in B6 
mice.  PakEtn was detected only in the NS mitochondria of VM mice.  No 
differences were found between the strains for the mass content of PtdEtn, 
Ptd2Gro, CerPCho, PlsCho, or PakCho.  Previously, it was reported that the 
ratios of ChoGpl/EtnGpl and CerPCho/EtnGpl were accurate indicators of a 
change in mitochondrial membrane fluidity.  Bangur et al. 1995 showed that 
differences in these ratios correlated to changes in membrane fluidity as 
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determined by fluorescence polarization (Bangur et al. 1995).  The ratio of 
ChoGpl to EtnGpl in the B6 and VM mice was 0.693 and 0.333, respectively, 
whereas the ratio of CerPCho to EtnGpl in these strains was 0.028 and 0.010, 
respectively.  Myelin-enriched lipids, sulfatides and cerebrosides, were not 
detected in B6 or VM NS mitochondria (data not shown).  Our previous findings 
also showed that gangliosides are not present in NS mitochondria from B6 mice 
(Kiebish et al 2008).  Corresponding lipid molecular species mass content can be 
found in Tables 21-29. 
 
Cardiolipin Molecular Species Distribution in B6 and VM NS Brain Mitochondria 
B6 mice contained 95 molecular species of Ptd2Gro, whereas VM mice contained 
only 45 molecular species (Table 23).  In addition, some Ptd2Gro molecular 
species found in the VM mice (18:1-16:1-16:1-16:1, 18:1-16:1-16:1-16:0, 18:1-
16:1-16:0-16:0, 18:2-18:1-16:1-16:1) were not found in the B6 mice.  These 
species may represent newly synthesized forms of Ptd2Gro based on their 
shorter chain lengths and degree of unsaturation.  These fatty acids are also 
similar to those found in PtdGro, the precursor of Ptd2Gro (Table 25).  When 
presented as mole percentage relative to the distribution of molecular species 
based on mass to charge ratios, B6 Ptd2Gro forms a unique pattern consisting of 
seven major molecular species groups (Fig 13).  Group I has the shortest fatty 
acid chain lengths and the least degree unsaturation, whereas group VII has the 
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longest chains and the greatest unsaturation (Kiebish et al. 2008).  The Ptd2Gro 
pattern found for VM mice differed markedly from that of B6 mice (Fig 13 and 
Table 23).  The Ptd2Gro in VM mice had elevated amounts of short chain fatty 
acids and lacked the molecular species found in groups IV, V, and VII.  These 
groups are generally enriched in 20:4 and 22:6 fatty acids, which are reduced in 
VM Ptd2Gro (Table 19).  Cardiolipin molecular species in VM NS mitochondria 
also contained a higher 16:0, 16:1, 16:2, and 18:1 content compared to B6 NS 
mitochondria (Table 19).  EtnGpl fatty acids varied in VM NS compared to B6 NS 
mitochondria and only 22:6 fatty acids were lower in VM NS ChoGpl compared to 
B6 NS ChoGpl. 
 
ETC activities in NS mitochondria of B6 and VM mice 
The activities of the unlinked ETC complexes (Complex I, II, III, and IV) as well 
as those of the linked enzyme complexes (Complex I/III and II/III) are shown in 
(Table 20).  The activities of Complex I, I/III, and II/III were 22%, 51%, and 25% 
lower and Complex IV was 22% higher in VM mitochondria than in B6 
mitochondria (Table 20). 
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DISCUSSION 
 
We found that the NS mitochondrial lipidome differed markedly between 
the B6 and VM mice.  Mitochondrial membrane lipids are known to influence 
membrane fluidity/permeability, ETC activities, membrane fusion, calcium 
homeostasis, and ATP synthesis (Daum 1985; Brand et al. 2003b; Petrushka et 
al. 1959; Fleischer et al. 1962).  EtnGpl and ChoGpl were the most abundant 
phospholipids in the NS mitochondria of both mouse strains.  Previous studies 
showed that changes in the ChoGpl/EtnGpl ratio and the CerPCho/EtnGpl ratio 
could significantly influence mitochondrial membrane fluidity (Bangur et al. 1995).  
We found that these lipid ratios were markedly lower in the VM NS mitochondria 
than in the B6 mitochondria indicating that mitochondrial membrane fluidity is 
greater in VM mice than in B6 mice.   
The most remarkable difference in NS mitochondrial lipid composition 
found between the strains was for the distribution of Ptd2Gro molecular species.  
While B6 mice expressed 95 molecular species that were symmetrically 
distributed over seven major groups, the VM mice expressed only 45 molecular 
species that were asymmetrically distributed and contained species not found in 
the B6 mice.  The distribution of brain Ptd2Gro molecular species in B6 NS 
mitochondria is similar to that in the brains of other mammalian species indicating 
that the distribution in B6 mitochondria is a conserved pattern (Cheng et al. 
unpublished observation).  It is also important to mention that the distribution of 
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Ptd2Gro molecular species in brain differs significantly from the distribution in 
non-neural tissues, which contain predominantly tetralinoleic Ptd2Gro (18:2-18:2-
18:2-18:2).  The unusual Ptd2Gro distribution in VM brain mitochondria could 
result from a strain difference in the activities or specificities of phospholipases 
and/or acyltransferases, which regulate Ptd2Gro remodeling.  Also, the observed 
Ptd2Gro distribution for VM NS mitochondria could not be explained by the 
random incorporation of fatty acids during Ptd2Gro remodeling as previously 
shown for B6 NS Ptd2Gro (Kiebish et al. 2008).  Nevertheless, the NS 
mitochondrial lipid differences found between the strains would indicate 
differences in mitochondrial function.  
Consistent with this notion, we found significant differences in the ETC 
enzyme activities between the strains.  Changes in Ptd2Gro molecular speciation 
can influence the activity of complex I and may affect the mitochondrial 
membrane environment influencing linked enzyme activities (I/III and II/III) or 
supercomplex formation (Hoch 1992; Chicco and Sparagna 2007; Fry and Green 
1981; Pfeiffer et al. 2003b; Zhang et al. 2002).  Increased docosahexaenoic 
(DHA) containing Ptd2Gro results in decreased complex IV activity (Kraffe et al. 
2002; Yamaoka et al. 1988; Fry et al. 1980).  A loss of DHA containing Ptd2Gro 
might therefore produce increased Complex IV activity as we found in the VM 
strain.  As mitochondrial membrane lipids can influence ETC activities (Fry and 
Green 1981; Hoch 1992; Gohil et al. 2004; Daum 1985), it is likely that the 
differences in lipid composition underlie the differences in ETC activities. 
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Alterations in brain mitochondrial lipid composition should affect 
mitochondrial energy production and neurological function.  Additionally, 
disturbances in the brain mitochondrial lipidome could produce a bioenergetic 
state conducive to brain tumorigenesis.  Further studies will be needed to 
determine if the differences in brain mitochondrial lipid composition between the 
B6 and VM mouse strains are related to the differences between these strains for 
the incidence of spontaneous brain tumors.   
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Lipid
Ethanolamine glycerophospholipids 187.4 + 12.1 264.0 + 4.8*
164.9 + 10.0 186.1 + 5.9
22.5 + 2.2 72.2 + 3.7*
5.7 + 0.9*
Choline glycerophospholipids 129.9 + 7.7 87.9 + 12.9*
119.6 + 5.3 74.9 + 13.2*
1.2 + 0.1 4.2 + 4.2
9.1 + 3.2 8.8 + 4.1
Cardiolipin 52.7 + 4.5 50.0 + 2.4
Phosphatidylinositol 9.3 + 0.8 12.5 + 0.8*
Phosphatidylglycerol 7.1 + 0.5 8.2 + 0.5
Sphingomyelin 5.3 + 1.2 2.7 + 0.2
Phosphatidylserine 4.6 + 1.5 18.6 + 2.0**
Lysophosphatidylcholine 2.7 + 0.6 4.7 + 0.9
Ceramide 0.7 + 0.2 2.0 + 0.1*
Total 399.7 + 29.1 450.6 + 24.6
Values are expressed as nmol/mg protein + S.D.M. of three independent samples
Astericks indicate that the value in VM mice differ from B6 mice at *: P < 0.02; **: P < 0.001 as determined from the two-tailed t-test
N.D. - Not detected
Plasmanylcholine
   N.D.
B6 VM
Table 18 Lipid composition of non-synaptic brain mitochondria in B6 and VM mice
Phosphatidylethanolamine
Plasmenylethanolamine
Plasmanylethanolamine
Phosphatidylcholine
Plasmenylcholine
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Fatty Acid
14:0 0.2 + 0.1 0.7 + 0.3 2.6 + 3.8
14:1 0.6 + 0.1 0.1 + 0.0 0.7 + 0.5
16:0 12.3 + 0.3 34.3 + 1.7 3.9 + 0.0 13.7 + 0.1** 32.8 + 2.4 7.1 + 0.5**
16:1 0.7 + 0.1 5.4 + 0.0 1.7 + 0.1** 2.1 + 2.5 11.5 + 1.1*
16:2 0.2 + 0.0 0.1 + 0.0 0.4 + 0.0***
18:0 20.8 + 0.2 7.6 + 0.2 2.0 + 0.0 17.3 + 0.2*** 10.7 + 2.2 1.9 + 0.3
18:1 17.0 + 0.1 18.0 + 0.7 44.7 + 1.0 19.2 + 0.3** 15.9 + 1.9 51.3 + 0.9***
18:2 1.3 + 0.1 16.1 + 0.4 8.2 + 0.2 4.3 + 0.2*** 13.3 + 2.2 7.9 + 0.1
18:3 0.1 + 0.0 0.3 + 0.0 0.1 + 0.0
20:0 2.6 + 0.1 3.2 + 1.1 3.0 + 0.4 3.5 + 1.4
20:1 0.1 + 0.0 0.1 + 0.0 3.0 + 0.3** 0.2 + 0.1
20:2 1.5 + 0.2 2.7 + 0.5 1.1 + 0.2 1.4 + 1.0
20:3 1.9 + 0.3 0.4 + 0.1 2.7 + 0.1 3.7 + 0.1** 0.5 + 0.6 1.9 + 0.0***
20:4 7.8 + 0.2 11.1 + 0.3 21.0 + 0.3 7.7 + 0.4 6.9 + 2.5 12.9 + 1.5*
22:2 0.6 + 0.3
22:3 2.7 + 0.3 0.9 + 0.2**
22:4 7.2 + 0.1 0.1 + 0.0 3.9 + 0.1***
22:5 11.3 + 0.2 1.4 + 0.3 0.2 + 0.1 7.9 + 0.8* 2.1 + 0.9
22:6 13.6 + 0.3 3.5 + 0.5 11.4 + 0.4 11.1 + 0.8* 7.2 + 1.0* 5.1 + 0.5***
Values represented as the mean mole percentage distribution of fatty acids + S.D.M. from 3 independent analyses as determined by electrospray MS
Significantly different values from B6 NS mitochondria at *: P < 0.05; **: P< 0.01; ***: P < 0.001 as determined by the two-tailed t -test
N.D. - not detected
Ptd2Gro
VM
EtnGpl ChoGpl Ptd2Gro
B6
EtnGpl ChoGpl
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D. N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
Table 19  Fatty acid percent distribution in phospholipids involved in cardiolipin remodeling
N.D.
N.D.
N.D.
N.D.
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Complex I 975 + 64 761 + 48**
NADH ubiquinone oxidoreductase
Complex II 292 + 18 316 + 42
succinate decylubiquinone DCIP oxidoreductase
Complex III 437 + 71 308 + 46
ubiquinol cytochrome c oxidoreductase
Complex IV 179 + 25 230 + 19*
cytochrome c oxidase
Complex I/III 269 + 59 133 + 26*
NADH cytochrome c oxidoreductase
Complex II/III 309 + 30 230 +   8*
succinate cytochrome c reductase
a - Enzyme activities are expressed as (nmol/min/mg protein) + S.D.M. (N=3-4)
Signficantly different values from B6 NS mitochondria at*: P < 0.05; **: P < 0.01 as  determined from
the two-tailed t-test
B6 VM
Table 20  Electron transport chain activities of non-synaptic 
brain mitochondriaa
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[M-H]- Major Species
698.5 P16:0-18:2 1.53 + 0.23
700.5 P18:1-16:0 2.83 + 0.21
P16:0-18:1
702.5 P18:0-16:0 1.75 + 0.67
P16:0-18:0
712.5 D16:1-18:2 1.41 + 0.28
714.5 D16:0-18:2 3.43 + 0.70
D16:1-18:1
716.5 D16:0-18:1 5.11 + 1.14 4.31 + 0.56
718.5 P14:0-22:6 2.81 + 1.43
720.5 P16:1-20:4 1.57 + 0.33
P14:0-22:5
722.5 P16:0-20:4 3.91 + 0.40
724.5 P16:0-20:3 2.05 + 0.18
P18:1-18:2
726.5 P18:1-18:1 3.34 + 0.33
P18:0-18:2
P16:0-20:2
728.6 P18:0-18:1 3.18 + 0.63
P16:0-20:1
730.6 A18:0-18:1 4.61 + 0.67
732.5 D14:1-22:6 1.74 + 0.34
734.5 D16:2-20:4 1.46 + 0.28
D14:1-22:5
736.5 D16:1-20:4 2.22 + 0.11
738.5 D16:0-20:4 5.77 + 0.27
D18:2-18:2
740.5 D18:1-18:2 1.91 + 0.29
D16:0-20:3
742.5 D18:0-18:2 5.07 + 0.62 7.30 + 0.62
D18:1-18:1
D16:0-20:2
744.6 D18:0-18:1 18.48 + 2.59
D16:0-20:1
746.5 P16:0-22:6 9.03 + 1.39 8.44 + 1.67
D18:0-18:0
P18:2-20:4
748.5 P18:1-20:4 7.92 + 1.07
P16:0-22:5
750.5 P18:0-20:4 6.53 + 0.46
P16:0-22:4
P18:1-20:3
752.6 P18:0-20:3 1.81 + 0.28
754.6 P20:1-18:1 1.68 + 0.35
P18:1-20:1
756.6 P18:1-20:0 1.52 + 0.42
758.5 P20:0-18:0 2.13 + 0.50
P18:0-20:0
760.5 D16:1-22:6 2.59 + 0.10
762.5 D16:0-22:6 9.39 + 0.81 9.26 + 1.19
764.5 D16:0-22:5 8.78 + 0.52 11.02 + 2.33
D18:1-20:4
766.5 D18:0-20:4 37.49 + 2.42 32.34 + 2.61
D16:0-22:4
768.6 D18:1-20:2 11.49 + 2.19 3.00 + 0.44
D16:0-22:3
D18:0-20:3
770.5 P18:2-22:6 2.03 + 0.42
D18:1-20:1
772.5 P18:1-22:6 4.87 + 1.08
D18:0-20:1
774.5 P18:0-22:6 10.37 + 1.44 12.66 + 1.32
P18:1-22:5
D18:0-20:0
776.6 P18:0-22:5 7.29 + 2.19 4.03 + 0.21
P18:1-22:4
778.6 P18:0-22:4 2.23 + 0.52 3.08 + 0.34
P20:0-20:4
P18:1-22:3
780.6 A20:0-20:4 2.16 + 0.52
P18:0-22:3
782.6 P18:0-22:2 1.95 + 0.65
786.5 D18:2-22:6 2.76 + 0.26
788.5 D18:1-22:6 5.95 + 0.44 6.36 + 1.25
790.5 D18:0-22:6 58.18 + 1.87 44.97 + 5.56
D18:1-22:5
792.6 D18:1-22:4 3.62 + 0.29 3.96 + 0.17
D18:0-22:5
794.6 D20:0-20:4 6.53 + 0.46 5.57 + 0.71
D18:1-22:3
D18:0-22:4
796.6 D20:0-20:3 6.85 + 1.34 3.40 + 0.70
D18:0-22:3
798.6 D20:0-20:2 2.31 + 1.28
D18:0-22:2
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
B6 VM
Table 21  Mass content of ethanolamine glycerolphospholipid 
molecular species in non-synaptic brain mitochondria
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[M+Li]+ Major Species
698.6 A14:0-16:0 0.46 + 0.60
710.5 D14:0-16:1 1.63 + 1.91
712.5 D14:0-16:0 0.35 + 0.11 2.36 + 2.87
722.6 P16:0-16:1 0.04 + 0.07 0.24 + 0.26
P16:1-16:0
P18:1-14:0
724.6 A16:0-16:1 0.09 + 0.02 0.38 + 0.43
726.6 A16:0-16:0 0.11 + 0.10 0.79 + 0.74
736.5 D14:1-18:1 0.31 + 0.15 0.46 + 0.50
738.6 D16:1-16:0 2.39 + 0.44 1.80 + 0.62
D14:1-18:0
740.6 D16:0-16:0 10.00 + 1.27 6.85 + 1.87
748.6 A16:0-18:3 0.15 + 0.14
750.6 P18:1-16:0 0.05 + 0.08 0.26 + 0.29
752.6 P16:0-18:0 0.22 + 0.06 0.50 + 0.50
P18:0-16:0
A18:1-16:0
760.5 D14:1-20:3 0.13 + 0.06 0.20 + 0.23
D16:2-18:2
D14:0-20:4
762.6 D16:1-18:2 0.15 + 0.10 0.28 + 0.28
764.6 D16:0-18:2 1.71 + 0.26 4.24 + 5.27
766.6 D16:0-18:1 33.31 + 1.31 16.29 + 8.07
768.6 D16:0-18:0 2.47 + 0.26 1.53 + 0.06
772.6 P18:2-18:2 0.03 + 0.05 0.18 + 0.23
P16:0-20:4
P20:4-16:0
774.6 A16:0-20:4 0.05 + 0.04 0.14 + 0.13
776.6 P18:1-18:1 0.10 + 0.11
778.6 P18:1-18:0 0.10 + 0.05 0.55 + 0.77
780.6 A18:0-18:1 0.59 + 0.05 1.21 + 0.78
P18:0-18:0
782.7 A16:0-20:0 7.42 + 2.81 5.35 + 4.75
786.6 D18:2-18:3 0.53 + 0.12 0.28 + 0.15
D16:1-20:4
788.6 D18:2-18:2 23.37 + 1.28 6.64 + 4.04
D16:0-20:4
790.6 D18:1-18:2 1.07 + 0.14 1.37 + 1.16
D16:0-20:3
792.6 D18:0-18:2 4.15 + 0.42 2.83 + 0.82
D18:1-18:1
794.6 D18:0-18:1 4.38 + 0.46 2.45 + 0.98
796.6 D18:0-18:0 0.08 + 0.07 0.31 + 0.11
798.6 P18:1-20:4 0.07 + 0.01 0.32 + 0.38
800.6 P18:0-20:4 0.07 + 0.01 0.12 + 0.10
802.6 P18:2-20:1 0.27 + 0.10 0.30 + 0.09
P20:1-18:2
A18:0-20:4
810.7 A18:0-20:0 0.91 + 0.23 0.75 + 1.12
812.6 D16:0-22:6 13.94 + 0.79 7.85 + 3.79
D18:2-20:4
814.6 D18:1-20:4 5.66 + 0.72 2.91 + 2.02
D16:0-22:5
816.6 D18:2-20:2 11.36 + 0.90 4.61 + 3.77
D18:0-20:4
818.6 D18:0-20:3 0.36 + 0.17 0.07 + 0.12
820.6 D18:0-20:2 0.16 + 0.03 0.10 + 0.13
P18:2-22:6
822.7 P18:1-22:6 0.10 + 0.09 0.05 + 0.06
824.6 P18:0-22:6 0.02 + 0.02 0.75 + 1.16
P18:1-22:5
826.6 A18:0-22:6 0.05 + 0.05 0.23 + 0.21
P18:0-22:5
836.6 D18:2-22:6 0.12 + 0.11 1.44 + 1.41
838.6 D18:1-22:6 1.29 + 1.15 3.43 + 1.35
D18:2-22:5
840.6 D18:0-22:6 2.07 + 1.96 4.43 + 3.54
D20:2-20:4
842.6 D18:0-22:5 0.20 + 0.18 0.37 + 0.38
D20:2-20:3
844.6 D18:0-22:4 0.14 + 0.14 0.18 + 0.25
D20:0-20:4
D20:2-20:2
850.6 P20:1-22:6 0.12 + 0.09
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
B6 VM
Table 22  Mass content of choline glycerophospholipid 
molecular species in non-synaptic brain mitochondria
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[M-2H]- Major Species
685.0 18:1-16:1-16:1-16:1 0.94 + 0.31
686.0 18:1-16:1-16:1-16:0 1.24 + 0.48
687.0 18:1-16:1-16:0-16:0 0.88 + 0.19
699.0 18:2-18:1-16:1-16:1 0.77 + 0.29
700.0 18:1-18:1-16:1-16:1 0.30 + 0.03 0.95 + 0.14
701.0 18:1-18:1-16:0-16:1    0.30 + 0.05 0.97 + 0.35
18:2-18:1-16:0-16:0    
18:2-18:0-16:1-16:0
702.0 18:1-18:1-16:0-16:0         0.22 + 0.04 0.65 + 0.29
18:2-18:0-16:0-16:0 
18:1-18:0-16:0-16:1
710.0 20:4-18:2-16:1-16:1 0.08 + 0.01
711.0 20:4-18:1-16:1-16:1          0.37 + 0.06
20:4-18:2-16:1-16:0
712.0 20:4-18:1-16:1-16:0         0.43 + 0.06 0.95 + 0.28
18:2-18:2-18:1-16:1
713.0 18:2-18:1-18:1-16:1          0.71 + 0.02 1.62 + 0.05
18:1-18:1-18:1-16:2 
18:2-18:1-18:0-16:2 
18:2-18:2-18:0-16:1
714.0 18:1-18:1-18:1-16:1          1.36 + 0.23 3.34 + 0.73
18:2-18:1-18:1-16:0
715.0 18:1-18:1-18:1-16:0     0.66 + 0.04 1.30 + 0.09
18:0-18:1-18:1-16:1
716.0 18:0-18:1-18:1-16:0    0.08 + 0.02
18:0-18:0-18:1-16:1
722.0 20:4-20:4-16:1-16:1 0.24 + 0.03
723.0 20:4-20:4-16:1-16:0      0.35 + 0.03
20:4-18:2-18:2-16:1
724.0 20:4-18:2-18:1-16:1 0.93 + 0.08 2.01 + 0.13
725.0 20:4-18:2-18:1-16:0      2.13 + 0.17 3.08 + 0.34
20:4-18:1-18:1-16:1
726.0 20:4-18:1-18:1-16:0          1.69 + 0.13 2.46 + 0.26
20:3-18:1-18:1-16:1 
20:3-18:1-18:1-16:1
727.0 18:2-18:1-18:1-18:1 2.31 + 0.33 3.73 + 0.18
728.0 18:1-18:1-18:1-18:1 3.31 + 0.72 5.13 + 0.95
729.0 18:1-18:1-18:1-18:0 0.30 + 0.03 0.75 + 0.26
734.0 22:6-20:4-16:1-16:1 0.14 + 0.02
735.0 20:4-20:4-18:2-16:1 0.53 + 0.06
736.0 20:4-20:4-18:1-16:1 1.31 + 0.16 2.29 + 0.67
737.0 20:4-20:4-18:1-16:0           2.10 + 0.07 2.78 + 0.42
22:6-18:1-18:1-16:1  
22:6-18:2-18:1-16:0
738.0 20:4-18:2-18:1-18:1           2.51 + 0.37 3.52 + 0.65
22:6-18:1-18:1-16:0
739.0 20:4-18:1-18:1-18:1 3.04 + 0.45 3.71 + 0.45
740.0 20:4-18:1-18:1-18:0      1.00 + 0.14 1.62 + 0.30
20:3-18:1-18:1-18:1
741.0 20:4-18:1-18:0-18:0      0.20 + 0.08
20:3-18:1-18:1-18:0
747.0 22:6-18:3-18:2-18:2 0.41 + 0.04
748.0 20:4-20:4-18:2-18:2     1.36 + 0.09
20:4-20:4-20:4-16:0  
22:6-20:4-18:1-16:1  
22:6-22:6-16:0-16:0 
22:6-18:2-18:2-18:2
749.0 20:4-20:4-18:2-18:1 1.93 + 0.19
750.0 20:4-20:4-18:1-18:1 3.11 + 0.24
751.0 22:6-18:1-18:1-18:1          2.77 + 0.10
20:4-20:3-18:1-18:1
752.0 22:6-18:1-18:1-18:0 0.44 + 0.17
753.0 20:4-20:2-18:1-18:0          0.15 + 0.04
20:4-20:1-18:1-18:1
754.0 20:4-20:1-18:1-18:0 0.09 + 0.02
759.0 22:6-20:4-20:4-16:1        0.31 + 0.04
22:6-22:6-18:2-16:1
760.0 22:6-20:4-18:2-18:2         0.77 + 0.05
22:6-20:4-20:4-16:0  
22:6-22:6-18:1-16:1
761.0 22:6-20:4-18:2-18:1 1.68 + 0.08
762.0 22:6-20:4-18:1-18:1 2.90 + 0.23
763.0 22:6-20:4-18:1-18:0         1.04 + 0.05
22:6-20:3-18:1-18:1
764.0 22:4-20:4-18:1-18:1         0.24 + 0.02
22:6-20:3-18:1-18:0
771.0 22:6-20:4-20:4-18:3 0.16 + 0.05
772.0 22:6-22:6-20:4-16:0         0.43 + 0.05
20:4-20:4-20:4-20:4
22:6-20:4-20:4-18:2  
22:6-22:6-18:2-18:2
773.0 22:6-20:4-20:4-18:1 1.36 + 0.12 2.65 + 0.12
774.0 22:6-22:6-18:1-18:1      1.76 + 0.09 2.68 + 0.10
22:6-20:4-20:3-18:1
775.0 16:0-20:3-22:5-22:5      0.27 + 0.10
18:2-20:3-20:3-22:5  
18:0-18:1-22:6-22:6 
18:0-20:3-20:4-22:6
776.0 18:0-18:0-22:6-22:6 0.16 + 0.05
784.0 22:6-22:6-20:4-18:2 0.31 + 0.05
786.0 22:6-22:6-20:4-18:1      1.34 + 0.04
22:6-20:4-20:4-20:3
796.0 20:4-20:4-22:6-22:6 0.25 + 0.09
797.0 22:6-22:6-22:6-18:1          0.49 + 0.04
22:6-22:6-20:4-20:3
798.0 20:4-20:3-22:6-22:5   0.14 + 0.07
22:6-22:6-22:6-18:0  
22:6-22:6-22:5-18:1
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Table 23  Mass content of cardiolipin molecular species in non-
synaptic brain mitochondria
B6 VM
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[M-H]- Major Species
807.5 16:0-16:1 0.02 + 0.01
809.5 16:0-16:0 0.07 + 0.02 0.03 + 0.01
821.6 A16:0-18:1 0.03 + 0.02
831.5 16:1-18:2 0.05 + 0.02
16:0-18:3
833.5 16:0-18:2 0.02 + 0.01 0.06 + 0.02
835.5 16:0-18:1 0.18 + 0.08 0.13 + 0.06
837.5 16:0-18:0 0.05 + 0.02 0.06 + 0.03
843.5 P18:1-18:2 0.03 + 0.00
845.6 P18:1-18:1 0.08 + 0.05
847.6 P18:0-18:1 0.07 + 0.01
849.6 A18:0-18:1 0.02 + 0.01
857.5 16:0-20:4 1.12 + 0.09 0.90 + 0.05
859.5 18:1-18:2 0.03 + 0.02 0.06 + 0.03
861.5 18:0-18:2 0.03 + 0.01 0.08 + 0.06
863.6 18:0-18:1 0.06 + 0.03 0.09 + 0.04
865.6 18:0-18:0 0.03 + 0.01 0.08 + 0.02
869.6 P18:0-20:4 0.08 + 0.01
873.6 A18:0-20:3 0.04 + 0.01
P18:0-20:2
875.6 A18:0-20:2 0.02 + 0.01
P18:0-20:1
877.6 A18:0-20:1 0.04 + 0.02
P18:0-20:0
881.5 18:2-20:4 0.23 + 0.01 0.24 + 0.08
16:0-22:6
883.5 18:1-20:4 1.23 + 0.22
885.5 18:0-20:4 6.68 + 0.41 5.40 + 0.45
887.6 18:0-20:3 0.17 + 0.15 0.15 + 0.05
889.6 18:0-20:2 0.03 + 0.01 0.14 + 0.03
893.6 18:0-20:0 0.09 + 0.02 0.15 + 0.09
897.6 A18:0-22:5 0.10 + 0.08
897.6 P18:0-22:4 0.10 + 0.08
899.6 A18:0-22:4 0.30 + 0.12
901.6 A18:0-22:3 0.10 + 0.08
905.5 18:2-22:6 0.11 + 0.05
907.5 18:1-22:6 0.05 + 0.03 0.14 + 0.04
909.5 18:0-22:6 0.37 + 0.02 0.25 + 0.04
911.6 18:0-22:5 0.10 + 0.03
913.6 18:0-22:4 0.21 + 0.05
915.6 18:0-22:3 0.12 + 0.07
937.6 20:0-22:6 0.10 + 0.04
937.5 P22:6-22:6 0.11 + 0.05
953.5 22:6-22:6 0.08 + 0.03 1.47 + 0.50
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
B6 VM
Table 24  Mass content of phosphatidylinositol molecular 
species in non-synaptic brain mitochondria
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[M-H]- Major Species
719.5 16:0-16:1 0.29 + 0.02 0.67 + 0.14
721.5 16:0-16:0 0.49 + 0.04 0.41 + 0.04
743.5 16:1-18:2 0.22 + 0.04 0.42 + 0.12
745.5 16:0-18:2 0.54 + 0.10 0.83 + 0.15
747.5 16:0-18:1 3.41 + 0.13 3.14 + 0.18
769.5 18:2-18:2 0.82 + 0.04 0.85 + 0.03
771.5 18:1-18:2 0.29 + 0.03 0.39 + 0.08
773.5 18:1-18:1 0.47 + 0.12 1.10 + 0.08
775.5 18:0-18:1 0.55 + 0.10 0.49 + 0.06
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Table 25  Mass content of phosphatidylglycerol molecular 
species in non-synaptic brain mitochondria
B6 VM
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[M+Li]+ Major Species
707.6 N16:1 0.10 + 0.04
709.6 N16:0 0.27 + 0.32 0.07 + 0.05
735.6 N18:1 0.26 + 0.02 0.10 + 0.06
737.6 N18:0 1.99 + 0.38 0.84 + 0.07
761.6 N20:2 0.03 + 0.04 0.05 + 0.03
763.6 N20:1 0.07 + 0.00 0.08 + 0.02
765.6 N20:0 2.33 + 0.41 1.43 + 0.20
793.7 N22:0 0.16 + 0.27
821.7 N24:0 0.20 + 0.14
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Table 26  Mass content of sphingomyelin molecular 
species in non-synaptic brain mitochondria
B6 VM
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[M-H]- Major Species
706.5 14:0-16:0 0.01 + 0.01
734.5 16:0-16:0 0.01 + 0.00
744.5 P16:0-18:1 0.01 + 0.01
746.5 P16:0-18:0 0.01 + 0.01
758.5 16:0-18:2 0.02 + 0.11
760.5 16:0-18:1 0.07 + 0.02 0.25 + 0.03
762.5 16:0-18:0 0.05 + 0.01
772.5 P18:0-18:1 0.01 + 0.03
774.6 P18:0-18:0 0.03 + 0.02
782.5 18:2-18:2 0.02 + 0.01
784.5 18:1-18:2 0.02 + 0.01 0.04 + 0.42
786.5 18:0-18:2 0.29 + 0.07 1.38 + 0.48
788.5 18:0-18:1 0.24 + 0.21 1.55 + 0.03
790.6 18:0-18:0 0.01 + 0.01 0.02 + 0.01
794.5 P18:0-20:4 0.01 + 0.01
800.6 P18:0-20:1 0.05 + 0.02
802.6 P18:0-20:0 0.04 + 0.03
806.5 18:2-20:4 0.05 + 0.03 0.11 + 0.03
808.5 18:1-20:4 0.04 + 0.04 0.15 + 0.10
810.5 18:0-20:4 0.10 + 0.08 0.53 + 0.09
812.5 18:0-20:3 0.12 + 0.03
814.6 18:0-20:2 0.09 + 0.10
816.6 18:0-20:1 0.16 + 0.02
818.6 18:0-20:0 0.03 + 0.02
820.5 P18:0-22:5 0.02 + 0.01
822.6 P20:0-20:4 0.01 + 0.01
P18:0-22:4
824.6 P20:0-20:3 0.01 + 0.02
P18:0-22:3
826.6 P20:0-20:2 0.05 + 0.01 0.03 + 0.01
P18:0-22:2
832.5 18:1-22:6 0.26 + 0.06
834.5 18:0-22:6 3.13 + 1.22 12.02 + 1.55
836.5 18:0-22:5 0.22 + 0.27 0.41 + 0.39
838.6 20:0-20:4 0.28 + 0.07 0.71 + 0.14
18:0-22:4
840.6 20:0-20:3 0.05 + 0.06
18:0-22:3
842.6 20:0-20:2 0.06 + 0.02
18:0-22:2
844.6 20:0-20:1 0.07 + 0.01
18:0-22:1
860.5 20:1-22:6 0.06 + 0.06
862.6 20:0-22:6 0.08 + 0.05
864.6 20:0-22:5 0.09 + 0.01
870.6 20:0-22:2 0.02 + 0.02
872.6 20:0-22:1 0.03 + 0.03
878.5 22:6-22:6 0.07 + 0.01
882.5 22:6-22:4 0.06 + 0.07
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Table 27  Mass content of phosphatidylserine molecular 
species in non-synaptic brain mitochondria
B6 VM
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[M+Na]+ Major Species
490.3 14:0 0.06 + 0.01 0.04 + 0.04
504.3 A16:0 0.06 + 0.03 0.10 + 0.09
516.3 16:1 0.09 + 0.04
518.3 16:0 0.89 + 0.21 2.04 + 0.27
542.3 18:2 0.06 + 0.02 0.07 + 0.03
544.3 18:1 0.41 + 0.13 0.97 + 0.31
546.4 18:0 0.32 + 0.08 0.82 + 0.07
566.3 20:4 0.16 + 0.09 0.22 + 0.07
568.3 20:3 0.02 + 0.00 0.03 + 0.01
570.4 20:2 0.03 + 0.01 0.05 + 0.03
572.4 20:1 0.04 + 0.02 0.09 + 0.06
574.4 20:0 0.04 + 0.02 0.23 + 0.06
590.3 22:6 0.24 + 0.12 0.02 + 0.02
592.3 22:5 0.08 + 0.03
594.4 22:4 0.04 + 0.02
596.4 22:3 0.03 + 0.03
598.4 22:2 0.01 + 0.01
600.4 22:1 0.04 + 0.03
602.4 22:0 0.02 + 0.02
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Table 28  Mass content of lysophosphatidylcholine 
molecular species in non-synaptic brain mitochondria
B6 VM
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 [M-H]- Major Species B6 VM
536.5 N16:0 0.01 + 0.01 0.03 + 0.01
562.5 N18:1 0.02 + 0.01
564.5 N18:0 0.66 + 0.15 1.50 + 0.07
592.6 N20:0 0.04 + 0.02 0.05 + 0.01
606.6 N21:0 0.01 + 0.00
616.6 N22:2 0.01 + 0.01
618.6 N22:1 0.01 + 0.00
620.6 N22:0 0.01 + 0.01
632.6 N23:1 0.01 + 0.01
634.6 N23:0 0.01 + 0.00
636.6 OH_N22:0 0.01 + 0.00
644.6 N24:2 0.01 + 0.01
646.6 N24:1 0.02 + 0.02 0.11 + 0.02
648.6 N24:0 0.02 + 0.00 0.03 + 0.02
660.6 OH_N24:2 0.01 + 0.01
662.6 OH_N24:1 0.02 + 0.01
664.6 OH_N24:0 0.01 + 0.01
674.6 N26:1 0.01 + 0.01
678.6 OH_N25:0 0.01 + 0.01
700.7 N28:2 0.04 + 0.01
702.7 N28:1 0.03 + 0.01
704.7 N28:0 0.01 + 0.01
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
Table 29  Mass content of ceramide molecular species in 
non-synaptic brain mitochondria
 
 
 
 
 
 
 
 
 
120 
 
Figure 12.  Procedure used for the isolation and purification of NS mitochondria 
from mouse cerebral cortex. 
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Figure 13.   Distribution of brain cardiolipin molecular species in B6 NS (black 
bar) and VM NS (grey bar) mitochondria.  Cardiolipin molecular species were 
arranged according to mass charge.  Corresponding molecular species mass 
content can be found in Table 23.  Molecular species can be arranged into seven 
groups (I - VII) based on chain length and degree of unsaturation.   
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CHAPTER FIVE 
Mitochondrial Lipidome and Electron Transport Chain Alterations in Spontaneous 
Brain Tumors in the VM Mouse Strain 
 
INTRODUCTION 
 
Mitochondria and Cancer 
Defects in mitochondrial respiration have long been considered a hallmark 
of cancer (Warburg 1931; Warburg 1956; Cori and Cori 1925).  Little attention 
has focused on the role of mitochondrial lipids on mitochondrial dysfunction.  
Mitochondrial membrane lipids regulate membrane fluidity, proton leak, ETC 
activities, and apoptosis (Daum 1985; McMillin and Dowhan 2002; Kagan et al. 
2006).  Alterations in lipid molecular species or content would likely result in 
severe pathological consequences resulting in a decrease of efficiency of the 
proton gradient (Daum 1985). 
Brain Mitochondrial Lipids 
 Brain mitochondria are primarily composed of phospholipids consisting of 
EtnGpl, ChoGpl, and Ptd2Gro with lesser amounts of PtdIns, PtdGro, CerPCho, 
PtdSer, LysoPtdCho, and Cer in order of abundance (Chapter 2).  Ptd2Gro and 
PtdGro are unique since they are synthesized in the mitochondria (Daum and 
Vance 1997).  Ptd2Gro is synthesized by the condensation of PtdGro and CDP-
DAG to form immature Ptd2Gro (Hoch 1992).  Ptd2Gro is then remodeled using 
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donor fatty acids from ChoGpl and EtnGpl via acyltransferases to form mature 
Ptd2Gro (Hatch 1998; Schlame 2007; Xu et al. 2003).  This process is termed 
Ptd2Gro remodeling.  Alterations in the content or distribution molecular species 
of these phospholipids will likely result in decreased ability of mitochondria to 
produce ATP. 
VM Mouse Strain 
 The VM mouse strain is unique since it expresses a relatively high 
incidence (1.5%) of spontaneous brain tumors (Fraser 1971; Fraser 1986).  
Recently, it was found that the VM mouse strain contained altered brain 
mitochondria lipid composition compared to C57BL/6J (B6) mice (Chapter 4).  
Alterations in the mitochondrial lipidome in VM mice compared to B6 mice likely 
results in a decrease in the efficiency of VM mouse brain mitochondria to 
produce energy through oxidative phosphorylation.  This most likely contributes 
to the increased incidence of spontaneous brain tumors as found in VM mice 
compared to B6 mice (Chapter 4). 
 The objective of this study was to analyze the mitochondrial lipid 
composition and ETC activities in three spontaneous brain tumors derived from 
the VM mouse strain.  These tumors have recently been characterized as non-
invasive tumor (VM-NM1) as well as two metastatic tumors expressing 
characteristics of macrophage/microglia (VM-M2 and VM-M3) (Huysentruyt et al. 
2008).  Tumors were grown in vivo as well as in vitro to determine if differences 
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in lipid composition or ETC activities differed depending on growth environment.  
Analysis of the mitochondrial lipidome provides new evidence for the role of 
mitochondrial lipid alterations contributing to mitochondrial dysfunction in 
spontaneous brain tumors. 
 
MATERIALS AND METHODS 
 
Mice and brain tumors 
The inbred VM mouse strain was obtained from H. Fraser (University of 
Edinburgh, Scotland).  VM mice were propagated at the Boston College Animal 
Facility  and were housed in plastic cages with filter tops containing Sani-Chip 
bedding (P.J. Murphy Forest Products Corp., Montville, NJ, USA).  The room was 
maintained at 22 ºC on a 12 hour light/dark cycle.  Food (Prolab RMH 3000; PMI 
LabDiet, Richmond, IN, USA) and water were provided ad libitum.  This study 
was conducted with the National Institutes of Health Guide for the Care and Use 
of Laboratory Animals and was approved by the Institutional Animal Care 
Committee. 
The VM-NM1, VM-M2, and VM-M3 tumors arose spontaneously in the cerebrum 
of 3 adult VM mice, as previously described (El-Abbadi et al. 2001; Huysentruyt 
et al. 2008).  VM-NM1 is a non-metastatic tumor with characteristics of neural 
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stem cells and VM-M2 and VM-M3 are metastatic tumors with characteristics of 
macrophage/microglia (Huysentruyt et al. 2008). 
Male VM mice (8-12 weeks of age) were used as tumor recipients.  Tumor pieces 
from donor mice were diced and resuspended in cold phosphate buffered saline 
(PBS) at pH 7.4.  Mice were anesthetized with isoflurane (Halocarbon, NJ) and 
0.1 mL of diced tumor tissue suspended in 0.2 mL PBS, was implanted 
subcutaneously in the right flank by injection using a 1 cc tuberculin syringe and 
an 18-gauge needle. 
Cell Culture 
Cultured cell lines were prepared from each tumor as we previously described 
(Bai and Seyfried 1997; el-Abbadi and Seyfried 1994).  VM-NM1, VM-M2, and 
VM-M3, and transformed microglia (BV 2 cell line) were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) (Sigma, St. Louis, MO, USA) supplemented 
with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA, USA) and 
0.5% penicillin/streptomycin (Sigma) in a humidified atmosphere containing 95% 
air and 5% CO2 at 37 ºC.  Cells were grown to 90% confluency and removed 
using a BD Falcon cell scraper (Becton Dickinson, NJ, USA). 
Mitochondrial Isolation 
Mitochondria were isolated in a cold room (4 ºC) and all reagents were kept on 
ice.  NS mouse brain mitochondria and brain tumor mitochondria were isolated 
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as previously described utilizing a series of discontinuous Ficoll and sucrose 
gradients (Kiebish et al. 2008).  Briefly, the cerebral cortexes (a pool of 
6/samples) or (a pool of 4 tumors/sample) were homogenized and differentially 
centrifuged to remove membrane contamination.  A crude mitochondrial pellet 
was layered on a 7.5%/12% Ficoll discontinuous gradient and centrifuged at 
73,000 x g for 36 min in a Sorval SW 28 rotor.  An enriched mitochondrial pellet 
was collected below the 12% Ficoll layer.  The enriched mitochondrial pellet was 
then layered on a 0.8M/ 1.0M/ 1.3M/ 1.6M discontinuous sucrose gradient and 
centrifuged at 50,000 x g for 2 hr in a Sorvall SW 28 rotor.  Purified NS brain or 
brain tumor mitochondria were collected at the interface between 1.3M and 1.6M 
sucrose. 
Mitochondria were isolated from the VM-NM1, VM-M2, VM-M3, and transformed 
microglia cell lines as a single enriched mitochondrial fraction as previously 
described (Yang et al. 1997; Pon and Schon 2001).  Cells grown to 90% 
confluency on 6 T150s were pelleted and resuspended in mitochondrial isolation 
buffer (MIB; 0.32 M sucrose, 10 mM Tris-HCl, and 1 mM EDTA-K (pH 7.4)) and 
homogenized using a teflon coated homogenizer attached to a hand-held drill.  
Samples were homogenized using 10 up and down strokes at 500 rpm.  The 
homogenate was then centrifuged at 800 x g for 5 min.  The supernatant was 
collected and centrifuged at 1,000 x g for 5 min.  The pellet was discarded and 
the supernatant was collected and centrifuged at 14,000 g for 10 min.  The pellet 
was collected and resuspended in MIB and recentrifuged at 8,600 x g for 10 min.   
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The supernatant was discarded and the pellet was resuspended in MIB and 
layered on a 0.8M/ 1.0M/ and 1.7M discontinuous sucrose gradient and 
centrifuged at 80,000 x g for 2 hr in a Sorvall SW 55 Ti rotor.  Purified 
mitochondria were collected at the 1.0M/1.7M sucrose interface.  The collected 
band was suspended in MIB and centrifuged at 19,000 x g for 15 min.  The pellet 
was resuspended in MIB and centrifuged at 10,200 x g for 10 min.  The pellet 
was resuspended twice more in MIB and recentrifuged at 8,200 x g for 10 min.  
The collected pellet contained purified mitochondria. 
 
Materials for Mass Spectrometry 
Materials are described in methods in Chapter 3. 
 
Sample Preparation for Mass Spectrometric Analysis 
Samples were prepared for Mass spectrometry as described in methods in 
Chapter 3. 
 
Instrumentation and Mass Spectrometry 
Mass spectrometry was performed as described in methods in Chapter 3. 
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Electron Transport Chain Enzyme Activities 
ETC enzyme analysis for Complex I (NADH-ubiquinone oxidoreductase), 
Complex II (succinate decylubiquinone DCIP oxidoreductase), Complex III 
(ubiquinol cytochrome c reductase), Complex IV (cytochrome c oxidase), 
Complex I/III (NADH cytochrome c reductase), and Complex II/III (succinate 
cytochrome c reductase) was performed as described in methods in Chapter 3.  
 
 
RESULTS 
 
Lipid Composition of VM Brain Tumors and Controls 
We used shotgun lipidomics for the analysis of lipid content and molecular 
species.  The lipid classes and subclasses are arranged according to their 
relative abundance in VM brain mitochondria (Table 30).  Mass content of 
molecular species can be found in Tables 31-39. 
 
Analysis of Mitochondria from Solid Tumors Grown In Vivo 
EtnGpl comprised more than 50% of the total phospholipid content in the 
mitochondrial membrane in brain and tumor mitochondria.  Total EtnGpl varied 
among tumors, however PtdEtn was 40 to 50% lower in the mitochondria from 
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VM-NM1, VM-M2, and VM-M3 tumors than VM brain mitochondria.  No 
differences were detected among the tumors for the content of PlsEtn or PakEtn 
for tumor mitochondria.  Total ChoGpl content was higher in VM-M3 compared to 
VM brain mitochondria.  No differences in PakCho were detected, however, 
PlsCho was around 4 ½ fold higher in VM-M2 and VM-M3 mitochondria 
compared to brain mitochondria.  The Ptd2Gro content of VM-NM1 and VM-M2 
mitochondria was 45% and 28% lower, respectively, compared to VM brain 
mitochondria.  However, no differences in Ptd2Gro content were detected in VM 
M3 mitochondria compared to VM brain mitochondria.  PtdSer was 70% higher in 
VM-NM1 mitochondria compared to VM brain mitochondria.  No differences were 
detected in PtdIns.  PtdGro was lower in VM-NM1 and higher in VM-M3 
mitochondria compared to VM brain mitochondria.  LysoPtdCho was higher in 
VM-M2 and CerPCho was higher in VM-M2 and VM-M3 compared to VM brain 
mitochondria.  Also, Cer was 2 ½ fold and 1 ½ fold higher in VM-NM1 and VM-
M2 mitochondria, respectively, compared to brain mitochondria. 
 
Analysis of Mitochondria from Cells Grown In Vitro 
Total EtnGpl were similar in tumor mitochondria grown in vitro, however, VM-
NM1 was 45% lower compared to control microglia.  PtdEtn was lower in VM-
NM1 and VM-M3 mitochondria and PlsEtn was higher in VM-M2 and VM-M3 
compared to control microglia.  PakEtn was lower in all tumors compared to 
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control microglia.  No differences were detected among the tumor cell lines 
grown in vitro for ChoGpl or subclasses.  Ptd2Gro was 3, 1 ½, and 7 fold lower in 
VM-NM1, VM-M2, and VM-M3 mitochondria, respectively, compared to control 
microglia.  PtdSer was higher in all tumor mitochondria grown in vitro compared 
to microglia control.  PtdGro was lower in VM-NM1 mitochondria compared to 
microglia control.  No differences were detected for LysoPtdCho or Cer in tumor 
mitochondria compared to control microglia.  CerPCho was 2 ½ and 3 fold higher 
in VM-M2 and VM-M3 mitochondria compared to control microglia. 
 
Analysis of Cardiolipin Molecular Species  
We showed that VM brain mitochondrial Ptd2Gro distribution differed from the 
conserved pattern found in the B6 mouse as well as other mammals (Chpater 4).  
The VM brain as well as all VM brain tumors examined also had this unique brain 
Ptd2Gro distribution (Fig. 14).  VM brain and brain tumors contain lower amounts 
of arachidonic and docosahexaenoic fatty acids in Ptd2Gro molecular species 
compared to other mammalian and B6 mouse brain cardiolipin (Chapter 4).  The 
percent distribution of Ptd2Gro molecular species in VM-NM1 grown in vivo 
appears to resemble newly synthesized Ptd2Gro, which is primarily composed of 
16:0, 16:1, 18:0, 18:1, and 18:2 fatty acids.  Ptd2Gro molecular species 
containing these fatty acids will resemble molecular species with lower mass to 
charge ratios, which will be located closer to the left of the overall distribution (Fig 
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14).  The distribution of VM-NM1 Ptd2Gro was arranged into 4 groups.  The 
predominant molecular species of VM-NM1 mitochondria was 20:4-18:1-18:1-
16:0/20:3-18:1-18:1-16:1.  The distribution of Ptd2Gro in VM-M2 mitochondria 
grown in vivo, contained 6 major groups, with no predominance of any particular 
molecular species.  VM-M3 grown in vivo contained a distribution of Ptd2Gro with 
5 major groups, in which 20:4-18:2-18:1-16:1 was the predominant molecular 
species.  The distribution of Ptd2Gro molecular species found in VM tumor 
mitochondria grown in vivo resemble partial Ptd2Gro remodeling in which the rate 
as well as the selection of donor fatty acids influenced the overall Ptd2Gro 
molecular species. 
 The number of Ptd2Gro molecular species was increased in mitochondria 
isolated from cells grown in vitro compared to mitochondria isolated from tumors 
grown in vivo (Fig. 15).  Subtle differences lipid molecular species existed 
between control microglia, VM-NM1, and VM-M2 mitochondria isolated from cells 
grown in vitro.  Ptd2Gro from mitochondria isolated from VM-M3 grown in vitro 
contained a broad distribution of species, likely due to equalization of donor fatty 
acids for remodeling.  However, VM-M3 Ptd2Gro in vitro did contain one 
predominant species consisting of a 22:6-22:6-18:1-18:1/22:6-20:4-20:3-18:1 
molecular species. 
 
ETC Activities of VM brain Tumor Mitochondria and Controls 
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ETC activities were measured in mitochondria isolated from brain, brain 
tumors, and cells (Fig. 16).  Complex I was 70%, 58%, and 48% lower in VM-
NM1, VM-M2, and VM-M3 mitochondria grown in vivo, respectively, compared to 
VM brain mitochondria.  The activity of Complex I was also 70%, 79%, and 96% 
lower in VM-NM1, VM-M2, and VM-M3 mitochondria, respectively, isolated from 
cells grown in vitro compared to control microglia cells.  Complex II activities 
were 63% and 29% (P < 0.037) lower in VM-NM1 and VM-M2 mitochondria, 
respectively, compared to VM brain mitochondria.   Isolated mitochondria from 
cells grown in vitro demonstrated activities that were 71%, 84%, and 91% lower 
in VM-NM1, VM-M2, and VM-M3 mitochondria, respectively, isolated from cells 
grown in vitro compared to control microglia mitochondria.  The activity of 
Complex III in isolated mitochondria from tumors grown in vivo was 23% (P < 
0.042) and 39% lower in VM-NM1 and VM-M2 mitochondria, respectively, 
compared to VM brain mitochondria.  Complex III activities from isolated 
mitochondria from cell grown in vitro were 36%, 69%, and 81% lower in VM-
NM1, VM-M2, and VM-3 mitochondria, respectively, compared to control 
microglia mitochondria.  Complex IV activities were 63% and 40% lower for VM-
NM1 and VM-M2 mitochondria, respectively, compared to VM brain 
mitochondria, however, no differences were detected in Complex IV for 
mitochondria isolated from cells grown in vitro.  The linked ETC activities, 
including Complex I/III and II/III were both lower in tumor mitochondria compared 
to microglia or brain mitochondria.  Complex I/III activities were 4 ½, 6, and 1 ½ 
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fold lower in VM-NM1, VM-M2, and VM-M3 grown in vivo and 3 ½, 2, and 3 fold 
lower in VM-NM1, VM-M2, and VM-3 grown in vitro compared to control 
mitochondria.  Complex II/III activities were 62%, 42%, and 40% lower in VM-
NM1, VM-M2, and VM-M3, respectively, grown in vivo and 53%, 82%, and 84% 
lower in VM-NM1, VM-M2, and VM-M3, respectively, grown in vitro compared to 
controls. 
 
 
 
 
DISCUSSION 
 
Our findings show that alterations in the mitochondrial lipidome as well as 
lower ETC activities exist in spontaneous brain tumors discovered in the VM 
mouse strain.  Alterations in mitochondrial lipid content or molecular species will 
alter mitochondrial membrane physiology changing the membrane fluidity as well 
as proton impermeability that is critical for energy transducing membranes 
(Mileykovskaya et al. 2005; Daum 1985).  Interestingly, the ETC complex 
activities are intricately regulated by the mitochondrial membrane lipid content 
and molecular species, which contribute to the efficiency of the complexes in the 
proton gradient (Shinzawa-Itoh et al. 2007).  Thus, altered mitochondrial 
membrane lipids will result in changes to ETC activities. 
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Alterations in the mitochondrial lipidome of spontaneous brain tumors can 
exist in content as well as molecular species.  Hence, the analysis of the 
mitochondrial lipidome using shotgun lipidomics provides a comprehensive 
analysis of all aspects of lipids (Han and Gross 2005a).  Interestingly, Ptd2Gro, 
which is synthesized by the mitochondria and remodeled in the mitochondrial 
membrane is significantly affected by any fatty acid lipid changes in ChoGpl, 
EtnGpl, or PtdGro.  Since, Ptd2Gro is extensively remodeled using ChoGpl and 
EtnGpl fatty acids, the decreased polyunsaturated fatty acids content, as found in 
tumors compared to normal brain, will result in shorter chain less unsaturated 
Ptd2Gro molecular species.  Also, since tumors are constantly dividing, the rate 
at which Ptd2Gro is remodeled will be decreased thus an abnormal or altered 
distribution as well as arrangement of molecular species will appear due to the 
proliferative state of tumors.  If the remodeling enzymes are unable to maintain 
consistent molecular speciation of Ptd2Gro, the resulting Ptd2Gro will contain 
species reminiscent of immature Ptd2Gro as found in other tumors (Canuto et al. 
1989). 
Altered mitochondrial lipids will affect the efficiency of the proton gradient.  
Ptd2Gro content as well as molecular species can affect the activity of multiple 
enzyme complexes of the ETC (Chicco and Sparagna 2007).  Also, Ptd2Gro can 
affect the efficiency of electron transport regarding supercomplex formation 
(Zhang et al. 2002; Pfeiffer et al. 2003b; McKenzie et al. 2006).  Therefore, any 
change to Ptd2Gro will severely impact oxidative phosphorylation.  Unfortunately, 
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the VM strain is already predisposed to altered Ptd2Gro remodeling, therefore the 
distribution of molecular species in VM tumors appears to be relatively similar to 
VM brain, however, the content of Ptd2Gro is generally lower in tumors compared 
to brain.  The VM tumors also harbor this altered neural Ptd2Gro remodeling 
pattern, thus reflecting on this genetic predisposition.  The alterations in the VM 
brain mitochondrial lipidome contribute to lower ETC activities in multiple 
complexes compared to B6 brain mitochondria (Kiebish et al. unpublished 
observation).  Other lipids, such as ChoGpl, EtnGpl, Cer, as well as LysoPtdCho 
are also likely to affect membrane physiology as well as have been shown to be 
located in or inhibit some of the ETC complexes (Di Paola et al. 2000; Shinzawa-
Itoh et al. 2007; Daum 1985).  The lower linked activities in tumor mitochondria 
compared to brain or microglia mitochondria (Complex I/III and II/III) also 
demonstrate the contribution of the dysfunctional mitochondrial lipid membrane 
to the decrease in efficiency of the proton gradient. 
Our findings, taken together, support the Warburg theory of defective 
respiration in cancer.   Each tumor examined contained at least one, if not 
multiple, defects in the individual complexes, and all measurements of the linked 
ETC complexes were lower compared to controls.  Alterations in the 
mitochondria lipidome of spontaneous brain tumors provides new support for the 
Warburg theory and can help explain the existence of altered ETC activities 
found in cancer. 
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[M-H]- Molecular Species
698.5 P16:0-18:2 1.53 + 0.23 1.74 + 0.44 2.34 + 0.40 2.90 + 0.34 3.31 + 0.92 2.88 + 0.44 3.78 + 0.26 5.56 + 0.41
700.5 P18:1-16:0 2.83 + 0.21 2.45 + 0.29 4.32 + 0.81 3.88 + 0.11 11.75 + 0.89 3.69 + 0.39 9.93 + 0.67 28.15 + 0.98
P16:0-18:1
702.5 P18:0-16:0 1.75 + 0.67 1.23 + 0.32 5.74 + 0.63 2.58 + 0.12 2.14 + 0.74 2.21 + 0.55 2.17 + 0.21 2.78 + 0.38
P16:0-18:0
712.5 D16:1-18:2 1.41 + 0.28 1.96 + 0.87 1.68 + 0.45 1.18 + 0.23 3.21 + 0.87 1.13 + 0.14 1.73 + 0.13 1.01 + 0.21
714.5 D16:0-18:2 3.43 + 0.70 3.32 + 1.43 5.43 + 0.83 4.69 + 0.14 7.41 + 0.49 2.57 + 0.24 2.96 + 0.16 3.46 + 0.38
D16:1-18:1
716.5 D16:0-18:1 4.31 + 0.56 2.90 + 0.58 4.07 + 0.65 3.72 + 0.23 17.04 + 1.10 2.67 + 0.18 4.84 + 0.26 4.81 + 0.47
718.5 P14:0-22:6 2.81 + 1.43 1.83 + 0.52 14.61 + 1.33 3.61 + 0.30 1.70 + 0.83 1.07 + 0.12 1.40 + 0.15 0.72 + 0.12
720.5 P16:1-20:4 1.57 + 0.33 1.99 + 0.19 2.56 + 0.61 1.32 + 0.43 1.69 + 1.17 1.88 + 0.16 3.09 + 0.34 1.92 + 0.22
P14:0-22:5
722.5 P16:0-20:4 3.91 + 0.40 8.08 + 0.14 3.20 + 0.84 7.97 + 0.81 3.16 + 0.73 5.65 + 0.73 17.03 + 0.98 16.62 + 2.63
724.5 P16:0-20:3 2.05 + 0.18 3.33 + 0.51 2.39 + 0.61 5.55 + 0.44 2.39 + 0.47 2.32 + 0.27 4.97 + 0.16 6.17 + 0.47
P18:1-18:2
726.5 P18:1-18:1 3.34 + 0.33 1.94 + 0.25 2.02 + 0.51 3.34 + 0.51 8.02 + 0.59 2.21 + 0.30 3.19 + 0.12 6.34 + 0.74
P18:0-18:2
P16:0-20:2
728.6 P18:0-18:1 3.18 + 0.63 1.73 + 0.15 3.43 + 0.69 2.67 + 0.21 7.67 + 0.47 3.00 + 0.39 4.33 + 0.47 7.54 + 0.58
P16:0-20:1
730.6 A18:0-18:1 4.61 + 0.67 5.01 + 0.47 9.92 + 2.49 7.52 + 2.02 6.99 + 0.61 3.44 + 0.18 3.09 + 0.19 3.54 + 0.26
732.5 D14:1-22:6 1.74 + 0.34 1.84 + 0.60 3.50 + 0.50 1.67 + 0.15 2.03 + 0.91 0.71 + 0.07 1.08 + 0.03 0.99 + 0.27
734.5 D16:2-20:4 1.46 + 0.28 1.49 + 0.50 3.45 + 0.62 1.15 + 0.33 1.02 + 0.58 0.87 + 0.22 0.79 + 0.14 0.81 + 0.13
D14:1-22:5
736.5 D16:1-20:4 2.22 + 0.11 3.14 + 0.96 2.60 + 0.57 1.81 + 0.45 1.98 + 1.04 1.35 + 0.17 2.19 + 0.23 1.42 + 0.18
738.5 D16:0-20:4 5.77 + 0.27 3.94 + 0.34 2.01 + 0.46 3.58 + 0.50 3.68 + 0.41 2.14 + 0.16 5.24 + 0.66 2.50 + 0.17
D18:2-18:2
740.5 D18:1-18:2 1.91 + 0.29 3.24 + 0.19 2.77 + 0.60 5.48 + 0.52 2.86 + 0.41 1.22 + 0.11 1.76 + 0.12 1.58 + 0.34
D16:0-20:3
742.5 D18:0-18:2 7.30 + 0.62 5.12 + 0.34 6.14 + 0.80 12.76 + 1.74 19.25 + 2.33 3.27 + 0.14 3.95 + 0.15 5.19 + 0.79
D18:1-18:1
D16:0-20:2
744.6 D18:0-18:1 18.48 + 2.59 13.56 + 3.05 16.15 + 1.14 13.15 + 0.40 31.01 + 2.47 8.58 + 1.66 9.18 + 0.29 7.43 + 2.22
D16:0-20:1
746.5 P16:0-22:6 8.44 + 1.67 4.44 + 0.53 3.99 + 0.38 6.70 + 0.90 3.19 + 0.36 6.35 + 1.17 10.19 + 0.51 9.53 + 0.85
D18:0-18:0
P18:2-20:4
748.5 P18:1-20:4 7.92 + 1.07 9.68 + 0.17 6.63 + 2.10 8.42 + 1.25 6.16 + 1.19 12.26 + 1.40 19.16 + 0.54 17.82 + 0.57
P16:0-22:5
750.5 P18:0-20:4 6.53 + 0.46 7.68 + 0.33 4.64 + 0.56 6.43 + 0.13 2.92 + 0.52 4.89 + 0.84 13.19 + 1.12 8.35 + 1.02
P16:0-22:4
P18:1-20:3
752.6 P18:0-20:3 1.81 + 0.28 2.56 + 0.35 2.10 + 0.59 2.79 + 0.24 1.67 + 0.28 2.40 + 0.30 3.29 + 0.15 2.98 + 0.08
754.6 P20:1-18:1 1.68 + 0.35 1.59 + 0.62 2.19 + 0.46 2.27 + 0.04 1.73 + 0.28 1.51 + 0.16 1.16 + 0.08 2.16 + 0.26
P18:1-20:1
756.6 P18:1-20:0 1.52 + 0.42 1.09 + 0.32 2.72 + 0.61 2.06 + 0.06 2.17 + 0.30 1.21 + 0.13 1.38 + 0.17 2.04 + 0.38
758.5 P20:0-18:0 2.13 + 0.50 1.77 + 0.43 3.89 + 0.38 2.78 + 0.10 3.08 + 0.79 1.22 + 0.15 1.10 + 0.10 2.22 + 0.74
P18:0-20:0
760.5 D16:1-22:6 2.59 + 0.10 1.99 + 0.46 3.24 + 0.53 1.93 + 0.12 3.37 + 0.94 1.10 + 0.06 1.14 + 0.17 2.09 + 0.40
762.5 D16:0-22:6 9.26 + 1.19 3.47 + 0.21 3.54 + 0.26 3.34 + 0.38 3.75 + 0.54 1.17 + 0.09 3.18 + 0.22 1.14 + 0.01
764.5 D18:1-20:4 11.02 + 2.33 9.18 + 0.39 2.79 + 0.73 4.30 + 0.57 7.73 + 1.03 3.58 + 0.22 4.86 + 0.33 2.06 + 0.12
D16:0-22:5
766.5 D18:1-20:3 32.34 + 2.61 17.84 + 0.74 3.20 + 0.80 11.85 + 2.12 11.92 + 1.42 10.29 + 1.27 27.94 + 2.50 6.24 + 0.19
D18:0-20:4
D16:0-22:4
768.6 D18:0-20:3 3.00 + 0.44 3.94 + 0.23 3.79 + 0.96 4.12 + 0.38 3.25 + 0.38 7.94 + 0.69 8.62 + 0.18 6.81 + 0.66
D18:1-20:2
D16:0-22:3
770.5 P18:2-22:6 2.03 + 0.42 1.50 + 0.38 2.95 + 0.60 2.68 + 0.11 2.39 + 0.37 1.00 + 0.05 1.02 + 0.01 1.40 + 0.16
D18:1-20:1
772.5 P18:1-22:6 4.87 + 1.08 3.07 + 0.40 4.02 + 0.87 4.36 + 0.31 3.06 + 0.53 2.40 + 0.36 2.00 + 0.07 3.05 + 0.26
D18:0-20:1
774.5 P18:0-22:6 12.66 + 1.32 3.98 + 0.48 5.87 + 0.97 5.78 + 0.26 6.45 + 1.17 4.26 + 0.73 5.20 + 0.17 6.09 + 0.24
P18:1-22:5
D18:0-20:0
776.6 P18:0-22:5 4.03 + 0.21 4.08 + 0.25 4.84 + 0.98 3.20 + 0.41 3.39 + 0.76 3.76 + 0.50 6.33 + 0.33 4.05 + 0.19
P18:1-22:4
778.6 P18:0-22:4 3.08 + 0.34 2.82 + 0.51 2.51 + 0.56 2.98 + 0.29 1.54 + 0.50 2.32 + 0.42 5.13 + 0.37 3.21 + 0.11
P20:0-20:4
P18:1-22:3
780.6 A20:0-20:4 2.16 + 0.52 2.67 + 0.49 2.61 + 0.71 2.96 + 0.32 1.64 + 0.53 2.49 + 0.49 3.24 + 0.29 3.49 + 0.50
P18:0-22:3
782.6 P18:0-22:2 1.95 + 0.65 1.80 + 0.29 2.53 + 0.50 2.51 + 0.02 1.45 + 0.33 1.73 + 0.32 2.17 + 0.21 3.57 + 0.54
786.5 D18:2-22:6 2.76 + 0.26 2.07 + 0.46 4.03 + 0.61 4.04 + 0.32 2.98 + 0.56 0.97 + 0.02 0.92 + 0.20 1.48 + 0.32
788.5 D18:1-22:6 6.36 + 1.25 4.35 + 0.59 3.99 + 0.74 4.39 + 0.34 6.66 + 0.83 2.24 + 0.14 2.02 + 0.17 3.19 + 0.38
790.5 D18:0-22:6 44.97 + 5.56 6.47 + 0.38 3.20 + 0.56 9.78 + 2.33 10.92 + 1.35 3.25 + 0.39 11.34 + 0.57 2.49 + 0.10
D18:1-22:5
792.6 D18:0-22:5 3.96 + 0.17 4.89 + 0.60 3.21 + 0.67 5.60 + 0.90 7.63 + 1.32 3.21 + 0.29 9.92 + 0.49 3.95 + 0.10
D18:1-22:4
794.6 D20:0-20:4 5.57 + 0.71 4.35 + 0.45 3.35 + 0.79 4.89 + 0.59 4.61 + 1.86 5.13 + 0.43 9.21 + 0.64 7.39 + 0.39
D18:0-22:4
796.6 D20:0-20:3 3.40 + 0.70 2.55 + 0.48 2.95 + 0.69 2.87 + 0.15 1.76 + 0.74 1.95 + 0.16 2.38 + 0.24 1.99 + 0.16
D18:0-22:3
798.6 D20:0-20:2 2.31 + 1.28 1.73 + 0.55 3.00 + 0.69 3.26 + 0.14 1.35 + 0.49
D18:0-22:2
Values are expressed as nmol/mg protein + S.D.M. of three independent samples
VM NM1 VM M2 VM M3
In vivo In vitro
Table 31   Mass content of ethanolamine glycerophospholipid molecular species of mitochondria isolated from VM brain, brain tumor, and cells
Brain VM NM1 VM M2 VM M3 Microglia
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[M+Li]+ Molecular Species
698.6 A14:0-16:0 0.46 + 0.60 0.15 + 0.08 1.12 + 0.15 0.25 + 0.06 0.38 + 0.20 0.18 + 0.05 0.31 + 0.08 0.21 + 0.02
710.5 D14:0-16:1 1.63 + 1.91 0.71 + 0.19 2.86 + 0.10 1.13 + 0.01 2.91 + 1.23 4.48 + 0.44 15.48 + 3.82 8.28 + 0.65
712.5 D14:0-16:0 2.36 + 2.87 1.04 + 0.27 5.30 + 0.62 1.24 + 0.15 3.04 + 0.86 2.92 + 0.29 4.39 + 1.14 3.20 + 0.40
722.6 P16:0-16:1 0.24 + 0.26 0.10 + 0.05 0.50 + 0.07 0.21 + 0.03 0.14 + 0.09 0.10 + 0.02 0.16 + 0.04 0.07 + 0.03
P16:1-16:0
P18:1-14:0
724.6 P16:0-16:0 0.38 + 0.43 0.24 + 0.02 0.93 + 0.04 0.40 + 0.06 0.84 + 0.26 0.80 + 0.11 1.32 + 0.37 0.68 + 0.05
A16:0-16:1
726.6 A16:0-16:0 0.79 + 0.74 0.46 + 0.12 1.54 + 0.10 0.68 + 0.05 1.49 + 0.32 1.18 + 0.15 3.05 + 0.59 1.80 + 0.20
736.5 D16:1-16:1 0.46 + 0.50 1.04 + 0.09 0.62 + 0.04 0.82 + 0.04 1.49 + 0.23 1.24 + 0.60 0.17 + 0.15 0.90 + 0.12
D14:1-18:1
738.6 D16:1-16:0 1.80 + 0.62 5.15 + 0.67 2.49 + 0.64 2.44 + 0.15 11.54 + 1.65 12.45 + 1.24 8.79 + 0.82 11.36 + 0.63
D14:1-18:0
740.6 D16:0-16:0 6.85 + 1.87 4.07 + 0.25 5.03 + 0.22 2.76 + 0.13 2.64 + 0.65 6.65 + 1.13 14.99 + 4.32 8.48 + 1.54
748.6 P16:0-18:2 0.15 + 0.14 0.09 + 0.06 0.23 + 0.02 0.19 + 0.06 0.12 + 0.07 0.07 + 0.03 0.03 + 0.02 0.04 + 0.02
A16:0-18:3
750.6 P16:0-18:1 0.26 + 0.29 0.35 + 0.07 0.70 + 0.05 0.75 + 0.09 0.73 + 0.19 0.58 + 0.10 0.34 + 0.05 0.32 + 0.06
P18:1-16:0
752.6 P16:0-18:0 0.50 + 0.50 1.02 + 0.10 1.31 + 0.19 1.02 + 0.11 3.32 + 0.64 2.04 + 0.21 2.13 + 0.10 1.80 + 0.11
P18:0-16:0
A18:1-16:0
A16:0-18:1
760.5 D14:1-20:3 0.20 + 0.23 0.34 + 0.05 0.11 + 0.02 0.26 + 0.02 0.48 + 0.04 0.17 + 0.17 0.00 + 0.00 0.14 + 0.01
D16:2-18:2
D14:0-20:4
762.6 D16:1-18:2 0.28 + 0.28 1.29 + 0.12 0.29 + 0.05 1.20 + 0.08 0.59 + 0.13 0.61 + 0.54 0.00 + 0.00 0.34 + 0.06
764.6 D16:0-18:2 4.24 + 5.27 9.39 + 0.45 7.37 + 0.96 12.68 + 1.08 10.48 + 1.15 7.27 + 2.64 2.46 + 0.86 5.33 + 0.31
766.6 D16:0-18:1 16.29 + 8.07 12.20 + 0.51 8.63 + 1.03 6.61 + 0.73 30.42 + 6.55 26.13 + 2.51 24.73 + 1.47 16.59 + 1.56
768.6 D16:0-18:0 1.53 + 0.06 1.21 + 0.13 2.47 + 0.23 1.08 + 0.10 2.71 + 0.65 1.75 + 0.15 3.52 + 0.57 1.44 + 0.58
772.6 P16:0-20:4 0.18 + 0.23 0.15 + 0.04 0.14 + 0.02 0.38 + 0.02 0.37 + 0.17 0.32 + 0.29 0.36 + 0.07 0.48 + 0.09
P20:4-16:0
P18:2-18:2
774.6 A16:0-20:4 0.14 + 0.13 0.33 + 0.03 0.12 + 0.03 0.99 + 0.01 0.26 + 0.10 0.34 + 0.31 0.38 + 0.10 0.23 + 0.05
776.6 P18:1-18:1 0.10 + 0.11 0.33 + 0.03 0.36 + 0.02 0.78 + 0.12 0.46 + 0.10 0.47 + 0.04 0.39 + 0.06 0.16 + 0.02
778.6 P18:0-18:1 0.55 + 0.77 1.10 + 0.18 5.68 + 0.35 2.00 + 0.22 2.72 + 0.67 1.65 + 0.33 1.21 + 0.14 0.80 + 0.13
P18:1-18:0
780.6 A18:0-18:1 1.21 + 0.78 4.48 + 0.64 7.91 + 0.79 7.46 + 1.10 6.84 + 1.38 2.76 + 0.56 2.91 + 0.25 1.41 + 0.24
P18:0-18:0
782.7 A16:0-20:0 5.35 + 4.75 6.26 + 0.73 7.28 + 1.08 4.42 + 0.80 17.41 + 5.13 4.04 + 0.91 4.73 + 0.30 2.57 + 0.13
786.6 D18:2-18:3 0.28 + 0.15 0.90 + 0.08 0.08 + 0.02 0.65 + 0.01 0.70 + 0.36 0.57 + 0.53 0.45 + 0.01 0.49 + 0.17
D16:1-20:4
788.6 D18:2-18:2 6.64 + 4.04 8.97 + 0.19 0.63 + 0.32 8.30 + 1.05 2.93 + 0.57 3.24 + 2.99 9.52 + 1.52 2.14 + 0.20
D16:0-20:4
790.6 D18:1-18:2 1.37 + 1.16 5.47 + 0.33 1.99 + 0.52 9.81 + 0.96 2.42 + 0.38 3.87 + 1.71 3.62 + 0.47 1.72 + 0.32
D16:0-20:3
792.6 D18:0-18:2 2.83 + 0.82 8.13 + 0.56 5.82 + 0.62 9.54 + 0.59 29.76 + 5.12 16.46 + 1.78 8.51 + 0.63 7.86 + 0.64
D18:1-18:1
794.6 D18:0-18:1 2.45 + 0.98 2.73 + 0.49 5.96 + 0.10 2.42 + 0.32 10.34 + 2.93 14.90 + 2.71 15.19 + 1.43 4.87 + 1.05
796.6 D18:0-18:0 0.31 + 0.11 0.53 + 0.28 9.31 + 0.64 2.23 + 0.34 1.43 + 0.50 0.28 + 0.08 0.66 + 0.19 0.22 + 0.06
798.6 P18:1-20:4 0.32 + 0.38 0.17 + 0.02 0.24 + 0.03 1.46 + 0.10 0.70 + 0.26 0.62 + 0.48 0.72 + 0.46 0.58 + 0.07
800.6 P18:0-20:4 0.12 + 0.10 0.60 + 0.01 0.26 + 0.04 2.19 + 0.30 0.60 + 0.30 2.62 + 1.03 2.61 + 2.13 3.48 + 1.24
802.6 P18:2-20:1 0.30 + 0.09 0.68 + 0.03 0.34 + 0.11 1.39 + 0.13 0.45 + 0.20 0.68 + 0.17 1.20 + 0.81 0.21 + 0.11
P20:1-18:2
A18:0-20:4
810.7 A18:0-20:0 0.75 + 1.12 1.93 + 0.25 3.83 + 0.18 1.76 + 0.62 5.38 + 2.23 2.74 + 0.79 1.08 + 0.22 0.93 + 0.24
812.6 D16:0-22:6 7.85 + 3.79 1.86 + 0.05 0.24 + 0.22 6.74 + 0.53 1.41 + 1.32 1.61 + 1.43 12.19 + 5.44 1.48 + 0.10
D18:2-20:4
814.6 D18:1-20:4 2.91 + 2.02 3.75 + 0.08 0.23 + 0.05 4.43 + 0.31 3.27 + 0.50 3.40 + 2.71 11.09 + 5.89 1.79 + 0.19
D16:0-22:5
816.6 D18:2-20:2 4.61 + 3.77 7.87 + 0.15 0.74 + 0.39 6.80 + 0.23 1.50 + 0.53 6.95 + 2.33 15.00 + 8.30 2.05 + 0.26
D18:0-20:4
818.6 D18:0-20:3 0.07 + 0.12 0.45 + 0.27 0.85 + 0.20 1.50 + 0.20 0.55 + 0.12 2.96 + 0.19 1.43 + 1.53 2.10 + 0.23
820.6 D18:0-20:2 0.10 + 0.13 0.23 + 0.19 2.25 + 0.26 2.05 + 0.18 1.97 + 0.55 1.30 + 0.65 0.76 + 0.80 0.96 + 0.45
P18:2-22:6
822.7 D18:0-20:1 0.05 + 0.06 0.26 + 0.09 4.63 + 0.18 2.31 + 0.29 0.48 + 0.21 0.08 + 0.07 0.00 + 0.00 0.00 + 0.00
P18:1-22:6
824.6 P18:0-22:6 0.75 + 1.16 0.12 + 0.01 0.82 + 0.24 3.39 + 0.47 0.40 + 0.32 0.47 + 0.20 0.19 + 0.10 0.14 + 0.12
826.6 A18:0-22:6 0.23 + 0.21 0.20 + 0.04 0.36 + 0.08 1.88 + 0.37 0.78 + 0.40 1.83 + 0.68 0.68 + 0.19 1.02 + 0.21
P18:0-22:5
836.6 D18:2-22:6 1.44 + 1.41 0.00 + 0.00 0.00 + 0.00 3.24 + 0.35 0.62 + 0.82 0.72 + 0.09
838.6 D18:1-22:6 3.43 + 1.35 0.28 + 0.07 0.09 + 0.15 3.27 + 0.22 1.12 + 1.17 1.22 + 1.01 2.30 + 0.43 0.97 + 0.18
D18:2-22:5
840.6 D18:0-22:6 4.43 + 3.54 0.91 + 0.09 0.38 + 0.14 4.59 + 0.39 0.96 + 0.51 2.40 + 0.99 6.64 + 1.90 1.12 + 0.17
842.6 D18:0-22:5 0.37 + 0.38 0.60 + 0.07 0.28 + 0.07 2.03 + 0.22 0.69 + 0.26 1.69 + 0.15 4.49 + 1.26 0.84 + 0.23
844.6 D18:0-22:4 0.18 + 0.25 0.57 + 0.08 0.44 + 0.15 1.59 + 0.22 0.20 + 0.08 0.86 + 0.21 2.16 + 0.69 0.33 + 0.11
D20:0-20:4
D20:2-20:2
846.7 D18:0-22:3 0.23 + 0.13 0.61 + 0.18 1.09 + 0.15 0.19 + 0.10 0.29 + 0.15 0.06 + 0.03 0.14 + 0.03
D20:0-20:3
D18:2-22:1
848.7 D18:0-22:2 0.19 + 0.09 1.13 + 0.12 2.35 + 0.20 0.25 + 0.06 0.46 + 0.11 0.27 + 0.07 0.20 + 0.09
D20:0-20:2
850.6 P20:1-22:6 0.12 + 0.09 0.01 + 0.01 0.16 + 0.14 0.94 + 0.42 0.03 + 0.05 0.37 + 0.05 0.18 + 0.06 0.14 + 0.12
854.7 P20:1-22:4 0.27 + 0.05 0.42 + 0.11 1.07 + 0.35 0.62 + 0.29 0.31 + 0.15 0.49 + 0.09 0.30 + 0.09
860.7 P20:0-22:2 0.72 + 0.09 0.95 + 0.49 0.95 + 0.40 0.14 + 0.07 0.50 + 0.10
862.7 P20:0-22:1 0.46 + 0.17 1.87 + 0.62 0.82 + 0.32 0.24 + 0.19 0.37 + 0.12
864.6 P21:1-22:6 0.03 + 0.03 0.26 + 0.17 0.69 + 0.15 0.09 + 0.09 0.13 + 0.08 0.45 + 0.11 0.11 + 0.07
866.7 P21:1-22:5 0.07 + 0.03 0.28 + 0.13 0.51 + 0.16 0.17 + 0.15 0.18 + 0.05 0.70 + 0.19 0.11 + 0.08
868.7 P21:1-22:4 0.10 + 0.03 0.38 + 0.14 0.52 + 0.20 0.11 + 0.07 0.19 + 0.02 0.85 + 0.32 0.12 + 0.06
870.7 D20:0-22:5 0.09 + 0.02 0.22 + 0.03 0.62 + 0.30 0.06 + 0.02 0.69 + 0.23
D20:1-22:4
872.7 D20:0-22:4 0.10 + 0.07 0.30 + 0.13 0.86 + 0.45 0.04 + 0.02 0.40 + 0.09
D20:2-22:2
874.7 D20:0-22:3 0.08 + 0.03 0.32 + 0.15 0.91 + 0.51 0.08 + 0.04 0.16 + 0.04
D20:2-22:1
876.7 D20:0-22:2 0.23 + 0.11 0.84 + 0.36 0.81 + 0.40 0.13 + 0.05 0.21 + 0.04 0.22 + 0.06 0.09 + 0.04
D20:2-22:0
878.7 D20:0-22:1 0.17 + 0.05 0.92 + 0.38 0.51 + 0.18 0.10 + 0.05 0.16 + 0.03 0.14 + 0.01 0.08 + 0.04
880.7 D20:0-22:0 0.18 + 0.03 1.07 + 0.37 0.35 + 0.09 0.05 + 0.03 0.09 + 0.04
Values are expressed as nmol/mg protein + S.D.M. of three independent samples
Table 32    Mass content of choline glycerophospholipid molecular species of mitochondria isolated from VM brain, brain tumor, and cells
Brain VM NM1 VM M2 VM M3 Microglia VM NM1 VM M2 VM M3
In vivo In vitro
 
141 
 
[M-2H]- Molecular Species
685.0 18:1-16:1-16:1-16:1 0.94 + 0.31 1.85 + 0.55 0.88 + 0.09 1.63 + 0.44 0.39 + 0.25
686.0 18:1-16:1-16:1-16:0 1.24 + 0.48 1.59 + 0.75 0.32 + 0.01 0.47 + 0.09 0.20 + 0.01
687.0 18:1-16:1-16:0-16:0 0.88 + 0.19 1.05 + 0.30 1.52 + 0.58 0.45 + 0.01 0.40 + 0.07 0.18 + 0.08
699.0 18:2-18:1-16:1-16:1 0.77 + 0.29 0.88 + 0.02 0.92 + 0.11 0.59 + 0.14 1.57 + 0.28 0.48 + 0.07 0.69 + 0.07 0.26 + 0.01
700.0 18:1-18:1-16:1-16:1 0.95 + 0.14 0.63 + 0.05 1.29 + 0.08 0.58 + 0.12 5.52 + 0.69 1.22 + 0.14 0.78 + 0.14 0.48 + 0.01
701.0 18:1-18:1-16:0-16:1     0.97 + 0.35 0.51 + 0.09 0.97 + 0.17 0.59 + 0.21 4.08 + 0.95 1.00 + 0.07 0.60 + 0.10 0.25 + 0.02
18:2-18:1-16:0-16:0
18:2-18:0-16:1-16:0
702.0 18:1-18:1-16:0-16:0          0.65 + 0.29 0.47 + 0.03 1.14 + 0.17 0.67 + 0.25 3.19 + 0.65 0.75 + 0.17 0.77 + 0.16 0.15 + 0.03
18:2-18:0-16:0-16:0
18:1-18:0-16:0-16:1
710.0 20:4-18:2-16:1-16:1 1.03 + 0.39 0.82 + 0.36 0.09 + 0.01 0.19 + 0.02 0.06 + 0.04
711.0 20:4-18:1-16:1-16:1          2.02 + 0.12 0.51 + 0.06 0.29 + 0.05 0.35 + 0.04 0.08 + 0.02
20:4-18:2-16:1-16:0
712.0 20:4-18:1-16:1-16:0         0.95 + 0.28 1.91 + 0.02 2.35 + 0.16 1.51 + 0.23 1.27 + 0.20 0.53 + 0.10 0.94 + 0.11 0.17 + 0.03
18:2-18:2-18:1-16:1
713.0 18:2-18:1-18:1-16:1            1.62 + 0.05 1.92 + 0.11 1.04 + 0.15 1.00 + 0.19 5.69 + 0.78 1.38 + 0.26 1.90 + 0.16 0.42 + 0.08
18:1-18:1-18:1-16:2
18:2-18:1-18:0-16:2
18:2-18:2-18:0-16:1
714.0 18:1-18:1-18:1-16:1          3.34 + 0.73 1.35 + 0.08 1.99 + 0.31 1.33 + 0.20 8.46 + 1.52 1.90 + 0.28 1.52 + 0.13 0.36 + 0.02
18:2-18:1-18:1-16:0
715.0 18:1-18:1-18:1-16:0     1.30 + 0.09 0.59 + 0.08 1.34 + 0.08 0.76 + 0.15 4.19 + 0.98 0.76 + 0.06 0.55 + 0.04 0.12 + 0.03
18:0-18:1-18:1-16:1
716.0 18:0-18:1-18:1-16:0    0.76 + 0.43 1.14 + 0.23 0.20 + 0.04 0.24 + 0.05 0.06 + 0.00
18:0-18:0-18:1-16:1
720.0 O-20:4-18:1-16:1-16:0         1.16 + 0.35 0.23 + 0.04 0.46 + 0.04 0.10 + 0.02
O-18:2-18:2-18:1-16:1
721.0 O-18:2-18:1-18:1-16:1            1.08 + 0.26 0.29 + 0.00 0.43 + 0.06 0.13 + 0.04
O-18:1-18:1-18:1-16:2
O-18:2-18:1-18:0-16:2
O-18:2-18:2-18:0-16:1
722.0 20:4-20:4-16:1-16:1 1.03 + 0.27 0.19 + 0.01 0.42 + 0.11 0.23 + 0.12
723.0 20:4-20:4-16:1-16:0               0.60 + 0.10 0.81 + 0.26 0.20 + 0.01 0.36 + 0.04 0.14 + 0.06
20:4-18:2-18:2-16:1
724.0 20:4-18:2-18:1-16:1 2.01 + 0.13 2.24 + 0.19 1.42 + 0.32 7.42 + 1.09 0.72 + 0.10 0.36 + 0.07 0.69 + 0.09 0.10 + 0.03
725.0 20:4-18:2-18:1-16:0                3.08 + 0.34 3.38 + 0.14 1.35 + 0.11 6.07 + 0.44 1.16 + 0.09 0.61 + 0.11 1.59 + 0.19 0.17 + 0.03
20:4-18:1-18:1-16:1
726.0 20:4-18:1-18:1-16:0           2.46 + 0.26 3.93 + 0.29 1.58 + 0.05 3.83 + 0.65 2.73 + 0.42 0.92 + 0.24 2.99 + 0.41 0.22 + 0.01
20:3-18:1-18:1-16:1
727.0 18:2-18:1-18:1-18:1 3.73 + 0.18 1.52 + 0.13 1.35 + 0.40 1.90 + 0.22 4.17 + 0.62 1.06 + 0.20 1.82 + 0.26 0.19 + 0.01
728.0 18:1-18:1-18:1-18:1 5.13 + 0.95 0.65 + 0.09 1.33 + 0.33 0.97 + 0.17 3.13 + 0.48 0.71 + 0.21 0.56 + 0.09 0.12 + 0.01
729.0 18:1-18:1-18:1-18:0 0.75 + 0.26 0.33 + 0.06 0.76 + 0.08 0.20 + 0.01 0.25 + 0.03 0.11 + 0.04
731.0 O-20:4-20:4-16:1-16:0              0.72 + 0.22 0.19 + 0.00 0.35 + 0.04 0.17 + 0.08
O-20:4-18:2-18:2-16:1
732.0 O-20:4-18:2-18:1-16:1 0.61 + 0.17 0.11 + 0.01 0.21 + 0.04 0.06 + 0.02
734.0 22:6-20:4-16:1-16:1 0.46 + 0.13 0.10 + 0.02 0.25 + 0.02 0.08 + 0.03
735.0 20:4-20:4-18:2-16:1 0.42 + 0.09 0.15 + 0.03 0.27 + 0.01 0.13 + 0.07
736.0 20:4-20:4-18:1-16:1 2.29 + 0.67 0.63 + 0.11 0.60 + 0.20 0.16 + 0.01 0.44 + 0.06 0.08 + 0.02
737.0 20:4-20:4-18:1-16:0           2.78 + 0.42 1.18 + 0.10 2.38 + 0.62 1.23 + 0.26 0.70 + 0.11 0.36 + 0.07 1.34 + 0.17 0.17 + 0.07
22:6-18:1-18:1-16:1 
22:6-18:2-18:1-16:0
738.0 20:4-18:2-18:1-18:1           3.52 + 0.65 1.21 + 0.25 2.32 + 0.54 1.67 + 0.26 0.99 + 0.32 0.38 + 0.07 1.26 + 0.22 0.35 + 0.25
22:6-18:1-18:1-16:0
739.0 20:4-18:1-18:1-18:1 3.71 + 0.45 0.81 + 0.08 1.27 + 0.15 1.61 + 0.25 0.82 + 0.16 0.39 + 0.04 1.00 + 0.18 0.10 + 0.04
740.0 20:4-18:1-18:1-18:0               1.62 + 0.30 0.94 + 0.38 2.08 + 0.85 3.35 + 0.62 0.65 + 0.16 0.30 + 0.03 0.38 + 0.04 0.08 + 0.05
20:3-18:1-18:1-18:1
741.0 20:4-18:1-18:0-18:0               2.34 + 0.30 0.38 + 0.09 0.10 + 0.04 0.18 + 0.04 0.05 + 0.02
20:3-18:1-18:1-18:0
747.0 22:6-18:3-18:2-18:2 3.23 + 0.33 1.96 + 0.95 0.23 + 0.00 0.35 + 0.09 0.19 + 0.03
748.0 20:4-20:4-18:2-18:2               2.81 + 0.47 2.73 + 0.69 0.63 + 0.08 0.99 + 0.25 0.58 + 0.13
20:4-20:4-20:4-16:0 
22:6-20:4-18:1-16:1 
22:6-22:6-16:0-16:0  
22:6-18:2-18:2-18:2
749.0 20:4-20:4-18:2-18:1 0.72 + 0.31 0.11 + 0.01 0.46 + 0.08 0.13 + 0.03
750.0 20:4-20:4-18:1-18:1 0.86 + 0.36 0.27 + 0.08 0.74 + 0.09 0.18 + 0.00
751.0 22:6-18:1-18:1-18:1          1.06 + 0.62 0.20 + 0.02 0.92 + 0.11 0.10 + 0.04
20:4-20:3-18:1-18:1
752.0 22:6-18:1-18:1-18:0 0.98 + 0.51 0.50 + 0.04
753.0 20:4-20:2-18:1-18:0          0.58 + 0.19 0.21 + 0.02
20:4-20:1-18:1-18:1
754.0 20:4-20:1-18:1-18:0 0.50 + 0.23 0.13 + 0.03
755.0 20:4-20:1-18:0-18:0 0.31 + 0.13 0.12 + 0.00
759.0 22:6-20:4-20:4-16:1        0.89 + 0.19 0.71 + 0.29 0.16 + 0.01 0.25 + 0.02 0.44 + 0.40
22:6-22:6-18:2-16:1
760.0 22:6-20:4-18:2-18:2                 0.66 + 0.18 0.15 + 0.02
22:6-20:4-20:4-16:0 
22:6-22:6-18:1-16:1
761.0 22:6-20:4-18:2-18:1 1.31 + 0.32 0.45 + 0.15 0.18 + 0.01 0.29 + 0.01 0.31 + 0.12
762.0 22:6-20:4-18:1-18:1 1.35 + 0.15 0.97 + 0.16 0.77 + 0.28 0.25 + 0.03
763.0 22:6-20:4-18:1-18:0         1.16 + 0.26 1.45 + 0.22 0.34 + 0.17 0.26 + 0.03
22:6-20:3-18:1-18:1
764.0 22:4-20:4-18:1-18:1         1.48 + 0.33 1.47 + 0.24 0.60 + 0.23 0.19 + 0.04
22:6-20:3-18:1-18:0
765.0 22:4-20:4-18:1-18:0 0.78 + 0.38 0.21 + 0.03
771.0 22:6-20:4-20:4-18:3 0.54 + 0.13 0.07 + 0.00 0.10 + 0.01 0.10 + 0.04
772.0 22:6-22:6-20:4-16:0           2.04 + 0.23 0.79 + 0.31 0.13 + 0.01 0.23 + 0.05 0.19 + 0.06
20:4-20:4-20:4-20:4 
22:6-20:4-20:4-18:2 
22:6-22:6-18:2-18:2
773.0 22:6-20:4-20:4-18:1 2.65 + 0.12 2.25 + 0.45 2.32 + 0.31 3.28 + 1.59 0.20 + 0.00 0.12 + 0.01 0.43 + 0.10
774.0 22:6-22:6-18:1-18:1           2.68 + 0.10 2.30 + 0.99 2.22 + 0.42 4.43 + 0.85 0.56 + 0.00 0.42 + 0.09 1.34 + 0.28
22:6-20:4-20:3-18:1
783.0 O-22:6-22:6-18:0-18:1   0.15 + 0.01 0.14 + 0.01 0.25 + 0.18
O-22:6-20:3-20:4-18:0
796.0 20:4-20:4-22:6-22:6 0.24 + 0.05 0.41 + 0.12 0.20 + 0.11
797.0 22:6-22:6-22:6-18:1          0.16 + 0.03 0.26 + 0.03 0.13 + 0.06
22:6-22:6-20:4-20:3
798.0 20:4-20:3-22:6-22:5    0.16 + 0.01 0.27 + 0.04 0.22 + 0.08
22:6-22:6-22:6-18:0  
22:6-22:6-22:5-18:1
808.0 20:4-22:6-22:6-22:6 0.23 + 0.01 0.28 + 0.05 0.36 + 0.25
813.0 22:6-22:6-22:6-22:5 0.18 + 0.01 0.19 + 0.03 0.26 + 0.03
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
In vitro
Table 33    Mass content of cardiolipin molecular species of mitochondria isolated from VM brain, brain tumor, and cells
Brain VM-NM1 VM-M2 VM-M3 Microglia VM-NM1 VM-M2 VM-M3
In vivo
 
142 
 
[M-H]- Molecular Species
732.5 16:0-16:1 0.01 + 0.02 0.02 + 0.00 0.06 + 0.04 0.04 + 0.03 0.03 + 0.01 0.12 + 0.03 0.04 + 0.01 1.37 + 0.22
734.5 16:0-16:0 0.01 + 0.01 0.07 + 0.04 0.07 + 0.01 0.02 + 0.01 0.01 + 0.01 0.02 + 0.01 0.02 + 0.00 0.12 + 0.06
744.5 P16:0-18:1   0.01 + 0.00 0.03 + 0.01 0.05 + 0.08 0.03 + 0.02 0.01 + 0.01 0.02 + 0.00 0.02 + 0.01 0.09 + 0.03
746.5 P16:0-18:0   0.01 + 0.01 0.05 + 0.03 0.11 + 0.05 0.08 + 0.01 0.04 + 0.01 0.07 + 0.02 0.03 + 0.01 0.31 + 0.05
758.5 16:0-18:2 0.02 + 0.01 0.14 + 0.03 0.13 + 0.05 0.14 + 0.04 0.04 + 0.02 0.20 + 0.09 0.07 + 0.02 0.98 + 0.16
760.5 16:0-18:1 0.25 + 0.11 0.50 + 0.16 0.53 + 0.17 0.32 + 0.08 0.53 + 0.16 2.40 + 0.14 1.19 + 0.34 9.69 + 0.53
762.5 16:0-18:0 0.05 + 0.03 0.17 + 0.06 0.26 + 0.12 0.09 + 0.01 0.03 + 0.05 0.07 + 0.05 0.10 + 0.03 0.18 + 0.07
772.5 P18:0-18:1   0.01 + 0.01 0.03 + 0.03 0.10 + 0.06 0.13 + 0.08 0.05 + 0.03 0.09 + 0.01 0.05 + 0.02 0.19 + 0.05
774.6 P18:0-18:0   0.03 + 0.03 0.10 + 0.03 0.05 + 0.03 0.16 + 0.06 0.17 + 0.06 0.35 + 0.02 0.39 + 0.03 1.06 + 0.13
782.5 18:2-18:2 0.02 + 0.02 0.17 + 0.03 0.09 + 0.04 0.09 + 0.03 0.01 + 0.01 0.06 + 0.04 0.06 + 0.01 0.16 + 0.03
784.5 18:1-18:2 0.04 + 0.01 0.24 + 0.04 0.14 + 0.06 0.22 + 0.10 0.05 + 0.01 0.20 + 0.09 0.14 + 0.03 0.53 + 0.06
786.5 18:0-18:2 1.38 + 0.42 2.50 + 0.61 2.96 + 0.33 4.25 + 0.74 0.65 + 0.26 2.00 + 0.44 2.16 + 0.41 5.05 + 0.62
788.5 18:0-18:1 1.55 + 0.48 3.94 + 0.16 3.10 + 0.50 3.54 + 0.23 4.27 + 0.61 8.77 + 0.44 8.71 + 1.10 17.77 + 0.99
790.6 18:0-18:0 0.02 + 0.03 0.12 + 0.21 0.09 + 0.10 0.04 + 0.04 0.02 + 0.02 0.16 + 0.09 0.17 + 0.02 0.24 + 0.04
794.5 P18:0-20:4  0.01 + 0.01 0.12 + 0.11 0.10 + 0.13 0.08 + 0.03 0.01 + 0.01 0.03 + 0.01 0.03 + 0.02 0.06 + 0.02
800.6 P18:0-20:1  0.05 + 0.01 0.04 + 0.04 0.44 + 0.09 0.15 + 0.06 0.03 + 0.02 0.07 + 0.03 0.04 + 0.01 0.16 + 0.01
802.6 P18:0-20:0  0.04 + 0.02 0.09 + 0.05 0.68 + 0.31 0.17 + 0.02 0.13 + 0.07 0.11 + 0.03 0.11 + 0.04 0.24 + 0.02
806.5 18:2-20:4 0.11 + 0.03 0.21 + 0.06 0.09 + 0.02 0.14 + 0.05 0.06 + 0.02 0.04 + 0.02 0.12 + 0.08 0.34 + 0.05
808.5 18:1-20:4 0.15 + 0.03 0.59 + 0.30 0.01 + 0.01 0.10 + 0.04 0.12 + 0.04 0.19 + 0.09 0.23 + 0.04 0.36 + 0.00
810.5 18:0-20:4 0.53 + 0.10 5.64 + 1.40 0.66 + 0.27 1.25 + 0.11 0.11 + 0.07 1.24 + 0.29 2.04 + 0.28 1.58 + 0.23
812.5 18:0-20:3 0.12 + 0.09 3.41 + 0.95 0.27 + 0.12 0.81 + 0.31 0.18 + 0.04 1.56 + 0.28 1.69 + 0.23 1.93 + 0.15
814.6 18:0-20:2 0.09 + 0.03 0.47 + 0.20 0.26 + 0.05 0.21 + 0.02 0.09 + 0.03 0.37 + 0.11 0.20 + 0.01 0.69 + 0.13
816.6 18:0-20:1 0.16 + 0.10 0.13 + 0.14 0.41 + 0.14 0.15 + 0.01 0.18 + 0.09 0.22 + 0.04 0.27 + 0.05 0.38 + 0.04
818.6 18:0-20:0 0.03 + 0.02 0.06 + 0.04 0.48 + 0.29 0.12 + 0.09 0.00 + 0.00 0.03 + 0.01 0.01 + 0.01 0.07 + 0.06
820.5 P18:0-22:5  0.02 + 0.02 0.05 + 0.04 0.31 + 0.29 0.05 + 0.01 0.02 + 0.01 0.07 + 0.03 0.07 + 0.02 0.14 + 0.08
822.6 P20:0-20:4  0.01 + 0.01 0.18 + 0.09 0.05 + 0.07 0.07 + 0.02 0.04 + 0.03 0.06 + 0.03 0.08 + 0.04 0.08 + 0.00
P18:0-22:4
824.6 P20:0-20:3  0.01 + 0.01 0.16 + 0.12 0.11 + 0.08 0.11 + 0.02 0.04 + 0.04 0.07 + 0.03 0.06 + 0.02 0.06 + 0.03
P18:0-22:3
826.6 P20:0-20:2  0.03 + 0.02 0.14 + 0.06 0.14 + 0.08 0.10 + 0.05 0.03 + 0.02 0.07 + 0.02 0.09 + 0.04 0.12 + 0.02
P18:0-22:2
828.6 P20:0-20:1  0.01 + 0.01 0.07 + 0.04 0.28 + 0.21 0.07 + 0.03 0.04 + 0.02 0.05 + 0.02 0.05 + 0.04 0.06 + 0.04
P18:0-22:1
832.5 18:1-22:6 0.26 + 0.06 0.29 + 0.12 0.31 + 0.26 0.15 + 0.04 0.09 + 0.10 0.10 + 0.07 0.05 + 0.03 0.26 + 0.06
834.5 18:0-22:6 12.02 + 1.55 4.54 + 0.31 0.51 + 0.29 1.81 + 0.58 0.44 + 0.07 2.04 + 0.46 5.45 + 0.08 4.82 + 0.23
836.5 18:0-22:5 0.41 + 0.39 2.50 + 0.31 0.29 + 0.24 0.83 + 0.32 0.49 + 0.13 2.20 + 0.49 5.31 + 0.39 3.37 + 0.23
838.6 20:0-20:4 0.71 + 0.14 3.35 + 0.93 0.24 + 0.09 0.74 + 0.31 0.14 + 0.09 0.66 + 0.13 2.82 + 0.27 1.41 + 0.23
18:0-22:4
840.6 20:0-20:3 0.05 + 0.06 0.34 + 0.33 0.11 + 0.05 0.06 + 0.05 0.02 + 0.01 0.26 + 0.02 0.23 + 0.05 0.16 + 0.01
18:0-22:3
842.6 20:0-20:2 0.06 + 0.02 0.27 + 0.22 0.21 + 0.17 0.10 + 0.04 0.07 + 0.02 0.23 + 0.04 0.04 + 0.01 0.10 + 0.03
18:0-22:2
844.6 20:0-20:1 0.07 + 0.01 0.16 + 0.08 0.06 + 0.05 0.02 + 0.02 0.06 + 0.04 0.28 + 0.02 0.09 + 0.03 0.12 + 0.04
18:0-22:1
860.5 20:1-22:6 0.06 + 0.06 0.13 + 0.13 0.15 + 0.20 0.06 + 0.08 0.01 + 0.01 0.02 + 0.03 0.04 + 0.05 0.07 + 0.04
862.6 20:0-22:6 0.08 + 0.05 0.15 + 0.07 0.07 + 0.10 0.09 + 0.10 0.01 + 0.01 0.12 + 0.04 0.23 + 0.04 0.21 + 0.04
864.6 20:0-22:5 0.09 + 0.01 0.16 + 0.12 0.19 + 0.06 0.14 + 0.03 0.01 + 0.01 0.04 + 0.03 0.15 + 0.03 0.10 + 0.04
870.6 20:0-22:2 0.02 + 0.02 0.17 + 0.08 0.11 + 0.10 0.04 + 0.03 0.07 + 0.04 0.10 + 0.01 0.02 + 0.03 0.04 + 0.02
872.6 20:0-22:1 0.03 + 0.03 0.08 + 0.10 0.29 + 0.21 0.06 + 0.04 0.10 + 0.03 0.22 + 0.05 0.02 + 0.00 0.03 + 0.01
Values are expressed as nmol/mg protein + S.D.M. of three independent samples
VM NM1 VM M2 VM M3
In vivo In vitro
Table 34   Mass content of phosphatidylserine molecular species of mitochondria isolated from VM brain, brain tumor, and cells
Brain VM NM1 VM M2 VM M3 Microglia
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[M-H]- Molecular Species
807.5 16:0-16:1 0.02 + 0.01 0.01 + 0.01 0.07 + 0.08 0.05 + 0.01 0.05 + 0.00 0.13 + 0.08 0.09 + 0.03 0.13 + 0.02
809.5 16:0-16:0 0.03 + 0.01 0.03 + 0.00 0.06 + 0.03 0.03 + 0.01 0.03 + 0.02 0.04 + 0.01 0.07 + 0.03 0.08 + 0.04
821.6 A16:0-18:1   0.03 + 0.02 0.02 + 0.02 0.06 + 0.01 0.04 + 0.00 0.05 + 0.01 0.04 + 0.02 0.05 + 0.04 0.15 + 0.01
831.5 16:1-18:2 0.05 + 0.02 0.05 + 0.03 0.08 + 0.06 0.05 + 0.03 0.07 + 0.01 0.14 + 0.16 0.04 + 0.01 0.03 + 0.02
16:0-18:3
833.5 16:0-18:2 0.06 + 0.02 0.09 + 0.02 0.15 + 0.06 0.23 + 0.03 0.30 + 0.06 0.50 + 0.27 0.16 + 0.03 0.43 + 0.24
835.5 16:0-18:1 0.13 + 0.06 0.06 + 0.00 0.21 + 0.09 0.19 + 0.02 0.52 + 0.03 0.73 + 0.06 0.60 + 0.34 1.67 + 0.56
837.5 16:0-18:0 0.06 + 0.03 0.05 + 0.02 0.11 + 0.10 0.03 + 0.02 0.04 + 0.03 0.05 + 0.03 0.06 + 0.01 0.06 + 0.06
843.5 P18:1-18:2   0.03 + 0.00 0.02 + 0.01 0.10 + 0.02 0.16 + 0.02 0.02 + 0.01 0.08 + 0.05 0.06 + 0.04 0.04 + 0.02
845.6 P18:1-18:1   0.08 + 0.05 0.03 + 0.01 0.12 + 0.01 0.10 + 0.04 0.03 + 0.02 0.07 + 0.03 0.03 + 0.02 0.05 + 0.02
847.6 P18:0-18:1   0.07 + 0.01 0.05 + 0.01 0.12 + 0.03 0.13 + 0.03 0.19 + 0.05 0.20 + 0.10 0.07 + 0.02 0.17 + 0.06
849.6 A18:0-18:1   0.02 + 0.01 0.05 + 0.03 0.22 + 0.08 0.06 + 0.04 0.17 + 0.08 0.10 + 0.03 0.06 + 0.01 0.15 + 0.06
857.5 16:0-20:4 0.90 + 0.05 0.29 + 0.16 0.33 + 0.32 0.51 + 0.14 0.09 + 0.04 0.59 + 0.19 2.04 + 0.54 0.69 + 0.06
859.5 18:1-18:2 0.06 + 0.03 0.20 + 0.04 0.21 + 0.08 0.48 + 0.08 0.27 + 0.03 0.93 + 0.34 0.33 + 0.10 0.40 + 0.19
861.5 18:0-18:2 0.08 + 0.06 0.27 + 0.05 0.83 + 0.31 1.03 + 0.12 3.55 + 0.41 2.65 + 0.55 0.54 + 0.34 2.24 + 0.39
863.6 18:0-18:1 0.09 + 0.04 0.06 + 0.00 0.30 + 0.07 0.29 + 0.08 1.24 + 0.05 1.21 + 0.25 0.47 + 0.30 1.21 + 0.28
865.6 18:0-18:0 0.08 + 0.02 0.03 + 0.01 0.21 + 0.12 0.12 + 0.03 0.11 + 0.03 0.04 + 0.04 0.15 + 0.02 0.06 + 0.05
869.6 P18:0-20:4   0.08 + 0.01 0.09 + 0.00 0.08 + 0.06 0.23 + 0.04 0.09 + 0.02 0.15 + 0.06 0.08 + 0.02 0.10 + 0.01
873.6 A18:0-20:3   0.04 + 0.01 0.04 + 0.02 0.11 + 0.09 0.06 + 0.02 0.05 + 0.02 0.23 + 0.03 0.08 + 0.03 0.11 + 0.03
P18:0-20:2
875.6 A18:0-20:2   0.02 + 0.01 0.03 + 0.02 0.11 + 0.02 0.06 + 0.01 0.11 + 0.03 0.15 + 0.03 0.04 + 0.01 0.11 + 0.02
P18:0-20:1
877.6 A18:0-20:1   0.04 + 0.02 0.02 + 0.00 0.16 + 0.03 0.07 + 0.03 0.05 + 0.02 0.05 + 0.03 0.04 + 0.05 0.05 + 0.01
P18:0-20:0
881.5 18:2-20:4 0.24 + 0.08 0.09 + 0.04 0.04 + 0.02 0.11 + 0.03 0.07 + 0.05 0.11 + 0.04 0.24 + 0.06 0.06 + 0.01
16:0-22:6
883.5 18:1-20:4 1.23 + 0.22 1.17 + 0.38 0.19 + 0.01 0.57 + 0.05 0.57 + 0.14 1.45 + 0.55 1.31 + 0.25 0.89 + 0.04
885.5 18:0-20:4 5.40 + 0.45 4.52 + 1.60 1.16 + 0.28 3.96 + 0.57 1.04 + 0.10 5.60 + 1.01 7.99 + 0.40 2.54 + 0.44
887.6 18:0-20:3 0.15 + 0.05 0.64 + 0.19 0.44 + 0.24 0.61 + 0.15 0.33 + 0.08 2.74 + 0.46 0.72 + 0.09 1.00 + 0.13
889.6 18:0-20:2 0.14 + 0.03 0.08 + 0.06 0.26 + 0.14 0.20 + 0.03 0.24 + 0.08 0.53 + 0.09 0.11 + 0.06 0.28 + 0.05
893.6 18:0-20:0 0.15 + 0.09 0.22 + 0.11 0.50 + 0.23 0.21 + 0.10 0.08 + 0.04 0.05 + 0.01 0.06 + 0.04 0.06 + 0.02
897.6 A18:0-22:5  0.10 + 0.08 0.08 + 0.06 0.23 + 0.01 0.09 + 0.02 0.08 + 0.05 0.04 + 0.03 0.12 + 0.02 0.04 + 0.02
897.6 P18:0-22:4  0.10 + 0.08 0.08 + 0.06 0.23 + 0.01 0.09 + 0.02 0.08 + 0.05 0.03 + 0.03 0.12 + 0.02 0.04 + 0.02
899.6 A18:0-22:4  0.30 + 0.12 0.35 + 0.20 0.27 + 0.12 0.30 + 0.08 0.17 + 0.05 0.05 + 0.04 0.09 + 0.02 0.07 + 0.02
901.6 A18:0-22:3  0.10 + 0.08 0.04 + 0.03 0.18 + 0.05 0.14 + 0.07 0.02 + 0.01 0.06 + 0.05 0.07 + 0.03 0.05 + 0.03
905.5 18:2-22:6 0.11 + 0.05 0.04 + 0.02 0.15 + 0.06 0.06 + 0.03 0.03 + 0.01 0.03 + 0.03 0.05 + 0.01 0.02 + 0.01
907.5 18:1-22:6 0.14 + 0.04 0.09 + 0.02 0.15 + 0.03 0.12 + 0.01 0.05 + 0.06 0.04 + 0.03 0.04 + 0.01 0.04 + 0.01
909.5 18:0-22:6 0.25 + 0.04 0.13 + 0.01 0.15 + 0.02 0.34 + 0.09 0.13 + 0.05 0.16 + 0.11 0.45 + 0.09 0.16 + 0.05
911.6 18:0-22:5 0.10 + 0.03 0.15 + 0.05 0.17 + 0.09 0.23 + 0.04 0.11 + 0.07 0.18 + 0.11 0.66 + 0.15 0.24 + 0.11
913.6 18:0-22:4 0.21 + 0.05 0.33 + 0.19 0.19 + 0.03 0.31 + 0.05 0.14 + 0.06 0.08 + 0.08 0.42 + 0.11 0.17 + 0.05
915.6 18:0-22:3 0.12 + 0.07 0.06 + 0.01 0.31 + 0.21 0.13 + 0.08 0.03 + 0.01 0.07 + 0.06 0.05 + 0.02 0.04 + 0.01
937.6 20:0-22:6 0.10 + 0.04 0.03 + 0.02 0.25 + 0.28 0.07 + 0.05 0.01 + 0.00 0.00 + 0.00 0.02 + 0.01 0.01 + 0.02
937.5 P22:6-22:6   0.11 + 0.05 0.03 + 0.02 0.28 + 0.33 0.08 + 0.06 0.01 + 0.01 0.00 + 0.00 0.02 + 0.01 0.01 + 0.01
953.5 22:6-22:6 1.47 + 0.50 1.29 + 0.90 1.38 + 0.58 0.99 + 0.53 0.21 + 0.25 0.02 + 0.03 0.23 + 0.07 0.19 + 0.16
Values are expressed as nmol/mg protein + S.D.M. of three independent samples
VM NM1 VM M2 VM M3
In vivo In vitro
Table 35   Mass content of phosphatidylinositol molecular species of mitochondria isolated from VM brain, brain tumor, and cells
Brain VM NM1 VM M2 VM M3 Microglia
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[M-H]- Molecular Species
707.5 A16:0-16:0  2.15 + 0.41 0.38 + 0.03 0.40 + 0.24
719.5 16:0-16:1 0.67 + 0.14 0.42 + 0.04 1.05 + 0.25 0.52 + 0.14 0.57 + 0.07 0.35 + 0.03 0.44 + 0.05 0.55 + 0.13
721.5 16:0-16:0 0.41 + 0.04 0.17 + 0.03 0.38 + 0.08 0.29 + 0.07 0.24 + 0.06 0.26 + 0.05 1.46 + 0.42 0.51 + 0.12
743.5 16:1-18:2 0.42 + 0.12 0.30 + 0.03 0.56 + 0.08 0.48 + 0.15 0.26 + 0.07 0.11 + 0.00 0.16 + 0.05 0.17 + 0.04
745.5 16:0-18:2 0.83 + 0.15 0.80 + 0.12 0.96 + 0.24 1.13 + 0.06 1.37 + 0.12 0.73 + 0.06 0.46 + 0.03 1.45 + 0.32
747.5 16:0-18:1 3.14 + 0.18 1.79 + 0.02 2.02 + 0.55 4.09 + 0.42 3.27 + 0.13 2.48 + 0.31 4.02 + 0.54 2.53 + 0.13
769.5 18:2-18:2 0.85 + 0.03 0.33 + 0.06 0.40 + 0.11 0.95 + 0.08 0.17 + 0.05 0.20 + 0.02 0.41 + 0.08 0.24 + 0.05
771.5 18:1-18:2 0.39 + 0.08 0.51 + 0.01 0.82 + 0.21 2.13 + 0.11 0.49 + 0.05 0.36 + 0.01 0.55 + 0.06 0.63 + 0.11
773.5 18:1-18:1 1.10 + 0.08 0.83 + 0.02 1.72 + 0.36 2.74 + 0.09 5.07 + 0.24 1.63 + 0.05 1.19 + 0.14 4.81 + 0.54
775.5 18:0-18:1 0.49 + 0.06 0.52 + 0.04 0.56 + 0.10 0.53 + 0.02 1.53 + 0.08 0.77 + 0.06 1.53 + 0.10 1.06 + 0.17
Values are expressed as nmol/mg protein + S.D.M. of three independent samples
VM NM1 VM M2 VM M3
In vivo In vitro
Table 36  Mass content of phosphatidylglycerol molecular species of mitochondria isolated from VM brain, brain tumor, and cells
Brain VM NM1 VM M2 VM M3 Microglia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
145 
 
[M+Na]+ Molecular Species
490.3 14:0 0.04 + 0.04 0.10 + 0.03 0.14 + 0.06 0.15 + 0.04 0.13 + 0.03 0.05 + 0.02 0.10 + 0.04 0.10 + 0.02
504.3 A16:0   0.10 + 0.09 0.26 + 0.04 1.34 + 0.35 1.33 + 0.13 0.13 + 0.02 0.25 + 0.03 0.34 + 0.05 1.45 + 0.64
518.3 16:0 2.04 + 0.27 2.32 + 0.26 4.01 + 0.67 2.22 + 0.23 0.41 + 0.14 0.59 + 0.15 2.29 + 0.75 2.20 + 0.53
542.3 18:2 0.07 + 0.03 0.35 + 0.06 0.33 + 0.14 0.67 + 0.06 0.02 + 0.01 0.02 + 0.00 0.02 + 0.01 0.02 + 0.00
544.3 18:1 0.97 + 0.31 1.01 + 0.15 1.24 + 0.12 1.05 + 0.12 0.52 + 0.11 0.15 + 0.01 0.16 + 0.03 0.29 + 0.09
546.4 18:0 0.82 + 0.07 1.45 + 0.14 2.22 + 0.52 1.10 + 0.16 0.17 + 0.04 0.51 + 0.09 1.40 + 0.15 0.97 + 0.18
566.3 20:4 0.22 + 0.07 0.29 + 0.04 0.03 + 0.02 0.11 + 0.02 0.01 + 0.01
568.3 20:3 0.03 + 0.01 0.09 + 0.03 0.01 + 0.01 0.04 + 0.01 0.01 + 0.00
570.4 20:2 0.05 + 0.03 0.07 + 0.02 0.06 + 0.02 0.10 + 0.02 0.02 + 0.01 0.01 + 0.01 0.01 + 0.00 0.01 + 0.00
572.4 20:1 0.09 + 0.06 0.06 + 0.00 0.10 + 0.03 0.08 + 0.04 0.10 + 0.02 0.03 + 0.01 0.03 + 0.00 0.05 + 0.02
574.4 20:0 0.23 + 0.06 0.11 + 0.02 0.03 + 0.01 0.09 + 0.01 0.03 + 0.01
590.3 22:6 0.02 + 0.02 0.04 + 0.01 0.02 + 0.00 0.04 + 0.01 0.01 + 0.00 0.01 + 0.00 0.02 + 0.01
Values are expressed as nmol/mg protein + S.D.M. of three independent samples
VM NM1 VM M2 VM M3
In vivo In vitro
Table 37   Mass content of lysophosphatidylcholine molecular species of mitochondria isolated from VM brain, brain tumor, and cells
Brain VM NM1 VM M2 VM M3 Microglia
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[M+Li]+ Molecular Species
691.5 N15:2 0.01 + 0.00 0.02 + 0.01 0.02 + 0.01
693.6 N15:1 0.01 + 0.00 0.01 + 0.01 0.01 + 0.00
695.6 N15:0 0.49 + 0.17 0.61 + 0.05 0.84 + 0.04
707.6 N16:1 0.10 + 0.04 0.15 + 0.05 0.27 + 0.06 0.24 + 0.07 0.10 + 0.01 1.22 + 0.30 0.48 + 0.02 0.80 + 0.04
709.6 N16:0 0.07 + 0.05 0.89 + 0.14 2.51 + 0.15 3.78 + 0.38 5.55 + 0.47 8.35 + 2.23 20.67 + 0.79 22.31 + 0.29
721.6 N17:1 0.02 + 0.00 0.02 + 0.00 0.02 + 0.00
723.6 N17:0 0.27 + 0.07 0.28 + 0.01 0.24 + 0.04
733.6 N18:2 0.02 + 0.01 0.02 + 0.00 0.01 + 0.00
735.6 N18:1 0.10 + 0.06 0.08 + 0.02 0.03 + 0.02 0.04 + 0.00 0.07 + 0.01 0.17 + 0.02 0.09 + 0.03 0.13 + 0.04
737.6 N18:0 0.84 + 0.07 0.29 + 0.08 0.18 + 0.03 0.10 + 0.09 0.32 + 0.02 0.77 + 0.09 1.38 + 0.10 0.88 + 0.03
749.6 N19:1 0.01 + 0.00 0.02 + 0.01 0.01 + 0.01
751.6 N19:0 0.08 + 0.04 0.15 + 0.02 0.07 + 0.02
761.6 N20:2 0.05 + 0.03 0.02 + 0.03 0.05 + 0.04 0.04 + 0.03 0.01 + 0.02 0.01 + 0.01
763.6 N20:1 0.08 + 0.02 0.53 + 0.24 0.44 + 0.09 0.63 + 0.12 0.28 + 0.07 0.37 + 0.05 0.29 + 0.03 0.21 + 0.02
765.6 N20:0 1.43 + 0.20 0.11 + 0.09 0.50 + 0.09 0.73 + 0.09 1.34 + 0.16 0.67 + 0.08
775.6 N21:2 0.01 + 0.01
777.6 N21:1 0.02 + 0.01 0.01 + 0.02 0.03 + 0.01
779.7 N21:0 0.03 + 0.04 0.15 + 0.02 0.03 + 0.02
789.6 N22:2 0.05 + 0.04 0.09 + 0.13 0.01 + 0.02 0.04 + 0.04 0.05 + 0.03
791.7 N22:1 0.12 + 0.07 0.85 + 0.09 0.62 + 0.15 0.22 + 0.15 0.77 + 0.07
793.7 N22:0 0.32 + 0.30 3.93 + 0.79 1.79 + 0.16
805.7 N23:1 0.16 + 0.09 0.22 + 0.02 0.51 + 0.03
807.7 N23:0 0.10 + 0.00 0.53 + 0.07 0.35 + 0.03
817.7 N24:2 0.51 + 0.01 0.48 + 0.40 0.71 + 0.25 0.07 + 0.07 0.72 + 0.08
819.7 N24:1 0.90 + 0.08 0.72 + 0.10 1.50 + 0.23 1.93 + 0.50 2.68 + 0.04 5.95 + 0.41
821.7 N24:0 0.16 + 0.10 0.04 + 0.06 0.72 + 0.05 0.42 + 0.18 3.13 + 0.27 2.16 + 0.20
833.7 N25:1 0.19 + 0.05 0.19 + 0.04 0.17 + 0.02
835.7 N25:0 0.25 + 0.04 0.30 + 0.01 0.68 + 0.04
Values are expressed as nmol/mg protein + S.D.M. of three independent samples
VM NM1 VM M2 VM M3
In vivo In vitro
Table 38    Mass content of sphingomyelin molecular species of mitochondria from VM brain, brain tumor, and cells
Brain VM NM1 VM M2 VM M3 Microglia
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[M-H]- Molecular Species
536.5 N16:0 0.03 + 0.01 3.21 + 0.25 1.36 + 0.11 1.53 + 0.49 0.40 + 0.17 0.40 + 0.11 0.88 + 0.27 0.14 + 0.03
562.5 N18:1 0.02 + 0.01 0.02 + 0.01 0.04 + 0.02 0.03 + 0.01 0.01 + 0.00
564.5 N18:0 1.50 + 0.07 0.13 + 0.02 0.07 + 0.00 0.05 + 0.02 0.02 + 0.02 0.02 + 0.01 0.04 + 0.00 0.01 + 0.00
592.6 N20:0 0.05 + 0.01 0.05 + 0.02 0.03 + 0.00 0.02 + 0.01 0.01 + 0.00 0.01 + 0.01 0.03 + 0.01
606.6 N21:0 0.01 + 0.00 0.01 + 0.00 0.02 + 0.00 0.01 + 0.00 0.01 + 0.01
616.6 N22:2 0.01 + 0.01 0.01 + 0.00 0.02 + 0.00 0.02 + 0.01 0.01 + 0.00
618.6 N22:1 0.01 + 0.00 0.04 + 0.01 0.06 + 0.03 0.03 + 0.01 0.02 + 0.02 0.01 + 0.00 0.02 + 0.01 0.01 + 0.01
620.6 N22:0 0.01 + 0.01 0.24 + 0.05 0.23 + 0.05 0.10 + 0.04 0.06 + 0.02 0.08 + 0.04 0.43 + 0.12 0.04 + 0.00
632.6 N23:1 0.01 + 0.01 0.02 + 0.01 0.03 + 0.01 0.01 + 0.01 0.02 + 0.01 0.01 + 0.00 0.02 + 0.01 0.01 + 0.00
634.6 N23:0 0.01 + 0.00 0.07 + 0.02 0.09 + 0.03 0.04 + 0.01 0.02 + 0.01 0.03 + 0.00 0.09 + 0.03 0.02 + 0.00
636.6 OH_N22:0 0.01 + 0.00 0.01 + 0.01 0.01 + 0.01 0.01 + 0.01
644.6 N24:2 0.01 + 0.01 0.40 + 0.02 0.53 + 0.13 0.64 + 0.23 0.02 + 0.01 0.02 + 0.01 0.03 + 0.01 0.01 + 0.01
646.6 N24:1 0.11 + 0.02 2.25 + 0.06 1.47 + 0.24 1.41 + 0.37 0.51 + 0.21 0.40 + 0.07 0.38 + 0.10 0.15 + 0.03
648.6 N24:0 0.03 + 0.02 0.66 + 0.09 0.45 + 0.03 0.35 + 0.08 0.52 + 0.14 0.36 + 0.10 1.01 + 0.15 0.19 + 0.02
660.6 OH_N24:2 0.01 + 0.01 0.03 + 0.01 0.02 + 0.01 0.03 + 0.01 0.01 + 0.01 0.01 + 0.00 0.01 + 0.00
662.6 OH_N24:1 0.02 + 0.01 0.02 + 0.01 0.04 + 0.00 0.03 + 0.02 0.01 + 0.01 0.01 + 0.00 0.02 + 0.00
664.6 OH_N24:0 0.01 + 0.01 0.01 + 0.00 0.03 + 0.01 0.01 + 0.00 0.01 + 0.00
674.6 N26:1 0.01 + 0.01 0.02 + 0.01 0.04 + 0.01 0.06 + 0.04 0.02 + 0.01 0.01 + 0.00 0.03 + 0.00 0.04 + 0.02
676.7 N26:0 0.01 + 0.01 0.03 + 0.02 0.04 + 0.02 0.01 + 0.00 0.01 + 0.00 0.01 + 0.00 0.01 + 0.00
678.6 OH_N25:0 0.01 + 0.01 0.01 + 0.01 0.01 + 0.01
700.7 N28:2 0.04 + 0.01 0.06 + 0.01 0.02 + 0.04 0.04 + 0.07 0.07 + 0.06 0.01 + 0.01 0.02 + 0.01 0.05 + 0.03
702.7 N28:1 0.03 + 0.01 0.02 + 0.01 0.02 + 0.03 0.04 + 0.07 0.03 + 0.03 0.01 + 0.00 0.02 + 0.01 0.01 + 0.00
704.7 N28:0 0.01 + 0.01 0.00 + 0.00 0.01 + 0.01
Values are expressed as nmol/mg protein + S.D.M. of three independent samples
VM-NM1 VM-M2 VM-M3
In vivo In vitro
Table 39   Mass content of ceramide molecular species of mitochondria from VM brain, brain tumor, and cells
Brain VM-NM1 VM-M2 VM-M3 Microglia
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Figure 14.  Distribution of cardiolipin molecular species from mitochondria 
isolated from VM brain tumors grown in vivo and from VM brain.  Total mass 
content of molecular species is presented in Table 33.  All values are expressed 
as the mean of three independent samples (N = 3). 
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 Figure 15.  Distribution of cardiolipin molecular species from mitochondria 
isolated from transformed microglia and VM brain tumor cells grown in vitro.  
Total mass content of molecular species is presented in Table 33.  All values are 
expressed as the mean of three independent samples (N = 3). 
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 Figure 16.  Electron transport chain activities in isolated mitochondria from VM 
brain, brain tumors, and cells.  Mitochondria isolated from tissues are VM brain 
(B), VM-NM1 (NM1), VM-M2 (M2), and VM-M3 (M3).  The control cell line for in 
vitro was transformed microglia (BV2).  Significantly different values from VM 
brain or transformed microglia at *: P < 0.025; **: P < 0.001 using a two-tailed 
student t-test 
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CHAPTER SIX 
Alterations in the Mitochondrial Lipidome and Electron Transport Chain Activities 
in Experimental Murine Brain Tumors Grown in the C57BL/6J Mouse Strain 
 
INTRODUCTION 
Mitochondria and Cancer 
Over 80 years ago, Otto Warburg first noted that cancer cells exhibited 
elevated aerobic glycolysis, possibly due to defects in oxidative phosphorylation 
(Warburg 1931).  Interestingly, Warburg stated that these defects were 
irreversible, yet never defined the components or mechanisms causing these 
defects (Warburg 1956).  It is this hypothesis that has driven research to 
investigate the cause(s) for defective respiration in cancer. 
Brain Tumor Mitochondria 
 Brain tumors are commonly characterized as primarily driven by ATP 
produced from glycolysis (Oudard et al. 1997; Lichtor and Dohrmann 1986; 
Kirsch et al. 1972; Galarraga et al. 1986).  Defects in brain tumor mitochondrial 
ultrastructure have been extensively characterized, in which most brain tumors 
exhibit swollen, deformed, as well as partial cristolysis (Cervos-Navarro et al. 
1981; Floridi et al. 1989; Arismendi-Morillo and Castellano-Ramirez 2008).  
These defects suggest an impaired ability of mitochondria to effectively produce 
ATP via oxidative phosphorylation.  Tumor mitochondria can be altered at the 
protein or mtDNA level, yet little attention has focused on the role of alterations to 
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mitochondrial membrane lipids regarding their functional significance.  
Mitochondrial membrane lipids play a critical role in regulating membrane 
fluidity/stability, impermeability of the proton gradient, membrane potential, ETC 
activities, supercomplex formation, proton leak, as well as apoptosis (Daum 
1985; Zhang et al. 2002; McMillin and Dowhan 2002).  Also, the unique 
composition of mitochondrial lipids in both inner and outer membrane is required 
for efficient production ATP, which is conserved in energy transducing 
membranes (Mileykovskaya et al. 2005).  A change in the mitochondrial lipid 
composition will result in a severe impairment of mitochondrial function. 
Mitochondrial Lipids and Cancer  
The mitochondrial membrane is primarily composed of the EtnGpl and 
ChoGpl, which comprises 80% of the total phospholipids in the mitochondrial 
membrane.  Cardiolipin (1,3-diphosphatidyl-sn-glycerol, Ptd2Gro), PtdIns, PtdSer, 
PtdGro, CerPCho, LysoPtdCho, and Cer comprise the remaining portion and are 
listed in order of abundance (Kiebish et al. 2008).  Each phospholipid contains a 
unique distribution of molecular species comprised of specific fatty acids in the 
sn-1 and sn-2 positions.  Tumor mitochondrial membrane lipids are primarily 
composed of shorter chain, more saturated fatty acids compared to mitochondria 
isolated from the tissue of origin (Canuto et al. 1989; Hartz et al. 1982; Morton et 
al. 1976; Reitz et al. 1977).  These changes in fatty acids result in a decrease in 
fluidity of the mitochondrial membrane leading a loss of efficiency of the 
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mitochondrial membrane to produce ATP by oxidative phosphorylation.  Changes 
in Ptd2Gro, LysoPtdCho, PtdSer, CerPCho, as well as ether 
glycerophospholipids content has also been observed in neoplastic tissues 
(Bergelson et al. 1970; Bergelson et al. 1974; Hostetler et al. 1976).  The advent 
of shotgun lipidomics by ESI/MS now provides a rapid and detailed method for 
the analysis of the lipids from biological membranes (Han and Gross 2005b). 
Shotgun lipidomics characterizes all detectable lipid molecular species as well as 
provides evidence for abnormalities in lipid metabolism or modifications in 
disease state to determine functional alterations.  Recently, shotgun lipidomics 
has identified nearly 100 molecular species of brain Ptd2Gro (Kiebish et al. 
2008).  Ptd2Gro is almost exclusively localized in the mitochondria, where it is 
synthesized by the condensation of PtdGro and cytidine diphosphate-
diacylglycerol to form immature Ptd2Gro (Hoch 1992; Schlame et al. 2000).  
Ptd2Gro is remodeled by a deacylation and reacylation reaction using donor fatty 
acids from EtnGpl and ChoGpl to create mature Ptd2Gro (Hauff and Hatch 2006).  
The remodeling of Ptd2Gro molecular species synthesizes a predominant 
tetralinoleic Ptd2Gro species, which is believed to have functional significance in 
heart, liver, and muscle cardiolipins (Schlame et al. 2005).  Alterations in Ptd2Gro 
molecular species, as found in Barth syndrome, results in a severe bioenergetic 
impairment of oxidative phosphorylation (Schlame and Ren 2006; Schlame et al. 
2002).  Therefore, the maintainence of specific Ptd2Gro molecular species 
appears to be critical for bioenergetic capacity. 
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Cardiolipin Remodeling 
 Brain is composed of a unique distribution of Ptd2Gro molecular species, 
which appears to have an entirely different molecular species composition than 
any other tissue (Schlame et al. 2005; Kiebish et al. 2008).  This is due to brain 
cardiolipin’s broad distribution of molecular species as well as increase in 
arachidonic and docosahexaenoic containing species.  Also, it is still not known 
which acyltransferase(s) are involved in the remodeling of brain Ptd2Gro, which 
results in such a diverse number of molecular species.  Regardless, all cells 
derived from neural origin should contain similar Ptd2Gro remodeling machinery, 
resulting in the increased molecular species distribution as discovered for brain 
Ptd2Gro.  Hence, if lipid or fatty acid metabolism is altered in brain cancer, the 
resulting effects will be evident in Ptd2Gro remodeling due to utilization of donor 
fatty acids.  Altered Ptd2Gro remodeling will result in a decreased ability to 
produce ATP through oxidative phosphorylation. 
 Ours is the first study to analyze the mitochondrial lipidome of an 
experimental murine astrocytoma and ependymoblastoma using shotgun 
lipidomics to examine if lipid alterations exist, which would suggest defects in the 
mitochondrial membrane.  The ETC activities were measured in isolated 
mitochondria to determine if in fact these brain tumor mitochondria do have an 
impaired ability to produce ATP by oxidative phosphorylation.  The analysis of 
mitochondrial lipids and ETC activities of brain tumors grown in vivo and in vitro 
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also provides new insight into the alterations of mitochondrial metabolism as a 
result of the in vitro environment.   
 
 
MATERIALS AND METHODS 
Mice and Brain Tumors 
The inbred C57BL/6J (B6) mouse strain was obtained from the Jackson 
Laboratory (Bar Harbor, ME).  B6 mice were propagated at the Boston College 
Animal Facility and were housed in plastic cages with filter tops containing Sani-
Chip bedding (P.J. Murphy Forest Products Corp., Montville, NJ, USA).  The 
room was maintained at 22 ºC on a 12 hour light/dark cycle.  Food (Prolab RMH 
3000; PMI LabDiet, Richmond, IN, USA) and water were provided ad libitum.  
This study was conducted with the National Institutes of Health Guide for the 
Care and Use of Laboratory Animals and was approved by the Institutional 
Animal Care Committee. 
The CT-2A and EPEN brain tumors were originally produced from the 
implantation of 20-methylcholanthrene into the brains of B6 mice as previously 
described (Zimmerman and Arnould 1941; Seyfried et al. 1992).  The CT-2A 
tumor arose in the cerebral cortex and was characterized as a malignant 
anaplastic astrocytoma, whereas the EPEN tumor arose in the cerebral ventricle 
and was characterized as an ependymoblastoma (Seyfried et al. 1992; Rubin 
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and Sutton 1968).  Male B6 mice (8-12 weeks of age) were used as tumor 
recipients.  Tumor pieces from donor mice were diced and resuspended in cold 
phosphate buffered saline (PBS) at pH 7.4.  Mice were anesthetized with 
isoflurane (Halocarbon, N) and 0.1 mL of diced tumor tissue suspended in 0.2 
mL PBS, was implanted subcutaneously in the right flank by injection using a 1 
cc tuberculin syringe and an 18-gauge needle. 
Cell Culture 
Cultured cell lines were prepared from each tumor as we previously described 
(Bai and Seyfried 1997; el-Abbadi and Seyfried 1994).  CT-2A, EPEN, and 
transformed C57BL/6J astrocytes (C8-D30 cell line) were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma, St. Louis, MO, USA) 
supplemented with 10% fetal bovine serum (FBS) (Atlanta Biologicals, Atlanta, 
GA, USA) and 0.5% penicillin/streptomycin (Sigma) in a humidified atmosphere 
containing 95% air and 5% CO2 at 37 ºC.  Cells were grown to 90% confluency 
and removed using a BD Falcon cell scraper (Becton Dickinson, NJ, USA). 
 
Mitochondrial Isolation 
Mitochondria were isolated in a cold room (4 ºC) and all reagents were kept on 
ice.  Non-synaptic (NS) mouse brain mitochondria and brain tumor mitochondria 
were isolated as previously described utilizing a series of discontinuous Ficoll 
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and sucrose gradients (Kiebish et al 2008).  Briefly, the cerebral cortexes (a pool 
of 6/samples) or (a pool of 4 tumors/sample) were homogenized and differentially 
centrifuged to remove membrane contamination.  A crude mitochondrial pellet 
was layered on a 7.5%/12% Ficoll discontinuous gradient and centrifuged at 
73,000 x g for 36 min in a Sorval SW 28 rotor.  An enriched mitochondrial pellet 
was collected below the 12% Ficoll layer.  The enriched mitochondrial pellet was 
then layered on a 0.8M/ 1.0M/ 1.3M/ 1.6M discontinuous sucrose gradient and 
centrifuged at 50,000 x g for 2 hr in a Sorvall SW 28 rotor.  Purified NS brain or 
brain tumor mitochondria were collected at the interface between 1.3M and 1.6M 
sucrose. 
Mitochondria were isolated from the CT-2A, EPEN, and transformed astrocyte 
cell lines as a single enriched mitochondrial fraction as previously described 
(Yang et al. 1997; Pon and Schon 2001).  A pellet obtained from cells grown to 
90% confluency on 6 T150s was resuspended in mitochondrial isolation buffer 
(MIB; 0.32 M sucrose, 10 mM Tris-HCl, and 1 mM EDTA-K (pH 7.4)) and 
homogenized using a teflon coated homogenizer attached to a hand-held drill.  
Samples were homogenized using 10 up and down strokes at 500 rpm.  The 
homogenate was then centrifuged at 800 x g for 5 min.  The supernatant was 
collected and centrifuged at 1,000 x g for 5 min.  The pellet was discarded and 
the supernatant was collected and centrifuged at 14,000 g for 10 min.  The pellet 
was collected and resuspended in MIB and recentrifuged at 8,600 x g for 10 min.   
The supernatant was discarded and the pellet was resuspended in MIB and 
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layered on a 0.8M/ 1.0M/ and 1.7M discontinuous sucrose gradient and 
centrifuged at 80,000 x g for 2 hr in a Sorvall SW 55 Ti rotor.  Purified 
mitochondria were collected at the 1.0M/1.7M sucrose interface.  The collected 
band was suspended in MIB and centrifuged at 19,000 x g for 15 min.  The pellet 
was resuspended in MIB and centrifuged at 10,200 x g for 10 min.  The pellet 
was resuspended twice more in MIB and recentrifuged at 8,200 x g for 10 min.  
The collected pellet contained purified mitochondria. 
 
Materials for Mass Spectrometry 
Materials for mass spectrometry are described in methods in Chapter 3. 
 
Sample Preparation for Mass Spectrometric Analysis 
Samples were prepared for Mass spectrometry as described in methods in 
Chapter 3. 
 
Instrumentation and Mass Spectrometry 
Mass spectrometry was performed as described in methods in Chapter 3. 
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Electron Transport Chain Enzyme Activities 
ETC enzyme analysis for Complex I (NADH-ubiquinone oxidoreductase), 
Complex II (succinate decylubiquinone DCIP oxidoreductase), Complex III 
(ubiquinol cytochrome c reductase), Complex IV (cytochrome c oxidase), 
Complex I/III (NADH cytochrome c reductase), and Complex II/III (succinate 
cytochrome c reductase) was performed as described in methods in Chapter 3.  
 
 
 
RESULTS 
Lipid Composition of C57BL/6J Brain Tumors and Controls 
We used shotgun lipidomics to evaluate lipid content and distribution of 
molecular species in brain tumors as well as controls.  The lipid classes are 
arranged according to their relative abundance in C57BL/6J control brain 
mitochondria (Table 40).   
In Vivo Analysis of Mitochondrial Lipids 
The most abundant phospholipid in the brain mitochondrial membrane is EtnGpl, 
which is comprised of PtdEtn, PlsEtn, as well as PakEtn.  Total EtnGpl were 
increased by 31% and 97% for CT-2A and EPEN, respectively, compared to 
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brain mitochondria (Table 40).  Although, PtdEtn was lower in CT-2A compared 
to brain mitochondria, the significant increase in total EtnGpl was due to 
increases in PlsEtn and PakEtn content.  PlsEtn content was 4.5 and 6.5 fold 
higher in CT-2A and EPEN mitochondria, respectively, compared to brain 
mitochondria.  PakEtn molecular species were undetectable in brain 
mitochondria.  However, CT-2A and EPEN mitochondria contained 9.3 and 12.4 
nmol/mg protein of PakEtn.  Total ChoGpl were not different in CT-2A and EPEN 
compared to brain mitochondria.  However, PtdCho was lower and PlsCho and 
PakCho content was higher in CT-2A mitochondria compared to brain 
mitochondria. 
Ptd2Gro mass content was 2 and 4 fold lower in CT-2A and EPEN mitochondria, 
respectively, compared to brain mitochondria.  Interestingly enough, PtdGro (the 
precursor for Ptd2Gro) was increased by 38% and 131% in CT-2A and EPEN 
mitochondria, respectively, compared to brain mitochondria.  PtdIns was also 
increased in EPEN mitochondria compared to brain mitochondria.  PtdSer as well 
as Cer were also increased in brain tumor mitochondria compared to brain 
mitochondria.  Also, LysoPtdCho was increased in CT-2A mitochondria 
compared to brain mitochondria. 
In Vitro Analysis of Mitochondrial Lipids 
Since, most studies of cellular metabolism are investigated using cultured cells; 
we examined the mitochondrial lipids and ETC activities of cells grown in vitro.  
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Also, since comparison of proliferating brain tumors with non-proliferating brain 
tissue might result in a different interpretation of differences in mitochondrial 
lipids, we chose to compare transformed astrocytes with CT-2A and EPEN in 
culture.  This in vitro comparison would allow us to determine the effect of 
proliferation and differences in mitochondrial lipids from cells grown in culture. 
Total EtnGpl were similar in CT-2A and EPEN mitochondria compared to 
astrocyte mitochondria (Table 40).  However, PtdEtn content was lower in CT-2A 
and higher in EPEN compared to astrocyte mitochondria.  No differences were 
found in PlsEtn content, whereas PakEtn content was slightly higher in CT-2A 
compared to astrocyte mitochondria.  Total ChoGpl were lower in CT-2A 
mitochondria, primarily due to a lower PtdCho and PakCho content compared to 
astrocyte mitochondria.  EPEN mitochondria contain no differences in the total 
EtnGpl content, however PtdCho was higher and PakCho was lower compared 
to astrocyte mitochondria.  CerPCho as well as Cer content was higher in EPEN 
mitochondria compared to astrocyte mitochondria.  No differences were detected 
in Ptd2Gro, PtdIns, PtdGro, PtdSer, and LysoPtdCho content for CT-2A and 
EPEN grown in culture compared to astrocytes.   
Analysis of Lipid Molecular Species 
EtnGpl, ChoGpl, as well as Ptd2Gro comprise around 90% in vivo and close to 
85% in vitro of the total phospholipid content of examined mitochondria.  
Therefore discussion of difference in their molecular species will represent the 
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most significant changes to membrane dynamics.  Also, Ptd2Gro is remodeled 
using donor fatty acids from EtnGpl and ChoGpl, thus changes in these 
molecular species will result in an increase in altered molecular speciation of 
Ptd2Gro (Fig. 17).  All other molecular species can be found in Tables 41-49. 
Brain mitochondria contained a predominance of D18:1-22:6 and D18:0-
20:4/D16:0-22:4 in EtnGpl, with 12 other molecular species being detected at 
varying concentrations (Fig. 18A).  However, CT-2A contained predominantly 
D18:0-18:1/D16:0-20:1 and EPEN contained predominantly D18:0-18:1/D16:0-
20:1 as well as lesser amounts of D18:0-20:4/D16:0-22:4.  The distribution of 
molecular species of CT-2A and EPEN grown in vivo had more of an abundance 
of molecular species with lower mass to charge ratios representing an increase 
in saturated and shorter chain fatty acids as compared to brain mitochondrial 
EtnGpl.  Analysis of mitochondrial EtnGpl of cells grown in vitro revealed a lack 
of predominant species (Fig 18B).  The distribution of EtnGpl molecular species 
in astrocytes did not differ from CT-2A or EPEN mitochondria. 
ChoGpl molecular species were predominantly D16:0-18:1, D18:2-18:2/D16:0-
20:4, D16:0-22:6/D18:2-20:4, and D18:2-20:2/D18:0-20:4 in brain mitochondria.  
These species also were present in CT-2A and EPEN, but were less abundant 
that those found in brain mitochondria (Fig. 19A).  The molecular species of 
ChoGpl were similar for mitochondria isolated from cells grown in vitro, with a 
predominance of D16:0-18:1, D16:1-16:0/D14:1-18:0, D18:0-18:2/D18:1-18:1, 
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and D18:0-18:1 species.  However, D18:2-20:2/D18:0-20:4 appeared to higher in 
EPEN mitochondria grown in vitro compared to astrocytes (Fig. 19B). 
Brain Ptd2Gro contains a unique distribution of molecular species represented by 
seven major species groups (Kiebish et al. 2008).  This brain cardiolipin pattern 
is the result of extensive remodeling (Kiebish et al. 2008). The conserved pattern 
for brain cardiolipin species (Cheng et al., unpublished observation), appears to 
be severely altered in CT-2A and EPEN mitochondria grown in vivo (Fig 20).  CT-
2A contained only 18 molecular species compared to 51 detected in brain 
Ptd2Gro as determined by mass to charge ratios.  The molecular species that 
were detected contains lower mass to charge ratios, thus representing shorter 
chain less unsaturated molecular species of Ptd2Gro.  These species likely 
represent newly synthesized cardiolipin.  Also, since there were not an abundant 
amount of molecular species of Ptd2Gro in CT-2A, it appears that Ptd2Gro is not 
extensively remodeled.  In contrast, EPEN contained a similar amount of Ptd2Gro 
molecular species, yet the distribution of molecular species contained a 
predominance of shorter chain less unsaturated molecular species as 
demonstrated by the relative mass to charge ratios.  The distribution of Ptd2Gro 
molecular is likely influenced by remodeling from EtnGpl and ChoGpl.  Tumor 
mitochondrial Ptd2Gro also contain hydroxylated Ptd2Gro molecular species, due 
to increased lipid peroxidation.  The distribution of Ptd2Gro molecular species 
was similar in tumor cells and control astrocytes grown in vitro (Fig. 21). 
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ETC Activities of Brain Tumor Mitochondria and Controls 
ETC activities were measured in mitochondria isolated from brain and brain 
tumors grown in vivo as well as cells grown in vitro.  Both unlinked and linked 
ETC enzyme activities were examined.  Isolated mitochondria from CT-2A and 
EPEN had a 60% and 80% lower Complex I activity, respectively, compared to 
mitochondria isolated from brain (Fig 22).  Complex I activity measured in 
mitochondria isolated in vitro revealed a lower activity compared to in vivo 
mitochondria.  Complex I activity from EPEN mitochondria isolated in vitro was 
60% lower than astrocyte mitochondria.  Complex II activities were 32% and 59% 
lower in CT-2A and EPEN, respectively, compared to brain mitochondria.  
Mitochondria isolated from cells in vitro revealed a 45% and 76% lower Complex 
II activities in CT-2A and EPEN, respectively, compared to astrocytes.  Complex 
III activity was 58% lower in vivo and in vitro in EPEN mitochondria compared to 
control mitochondria.  No differences were detected in Complex IV.  The linked 
Complex I/III enzyme activities were lower in CT-2A and EPEN mitochondria 
isolated both in vivo and in vitro.  Complex I/III activities in CT-2A mitochondria 
were 81% and 69% lower compared to brain and astrocyte mitochondria, 
respectively.  Also, Complex I/III activities in EPEN mitochondria were 69% and 
76% lower compared to controls for in vivo and in vitro mitochondria, 
respectively.   The linked Complex II/III activities were 67% and 76% lower in CT-
2A and EPEN mitochondria, respectively, compared to brain mitochondria.  
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Complex II/III activity was 69% lower in EPEN compared to astrocyte 
mitochondria. 
 
 
 
 
 
DISCUSSION 
Through the use of shotgun lipidomics, we were able to characterize the 
differences in mitochondrial membrane lipidome that exist between isolated 
mitochondria from brain, brain tumors, and cells.  Our study is the first to utilize 
this tool for lipid analysis of mitochondria isolated from neoplastic tissue.  A 
comprehensive assessment of fatty acid and lipid metabolism will determine if 
lipid alterations exist likely resulting in an impairment of the proton gradient.  The 
proton gradient utilizes the unique composition of mitochondrial lipids to create 
an impermeable mitochondrial membrane to effectively produce ATP through 
oxidative phosphorylation (Daum 1985; Mileykovskaya et al. 2005).  Defects in 
tumor mitochondria has long been considered a hallmark of cancer (Warburg 
1931; Warburg 1956).  However, the description of the exact mitochondrial defect 
has never been defined.  Since, membrane lipids are critical for metabolic 
processes in mitochondria, it can be hypothesized that alterations in these lipids 
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at the molecular species or content level will result in impairment of mitochondrial 
function. 
 Mitochondrial membrane lipids are critical for the maintenance of 
numerous enzyme activities (Daum 1985; Hoch 1992).  Ptd2Gro, in particular, 
regulates enzyme activities of Complex I, III, IV, and V of the ETC (Fry and 
Green 1981; Fry and Green 1980; Chicco and Sparagna 2007).  Ptd2Gro can 
regulate proton leak, adenine nucleotide, carnitine, pyruvate, phosphate transport 
as well as supercomplex formation (Chicco and Sparagna 2007).  The 
composition of Ptd2Gro molecular species also appears critical for bioenergetic 
efficiency, as demonstrated by Barth syndrome, the  α-synuclein model of 
parkinson’s disease, experimental diabetic myocardium, as well as experimental 
heart failure (Schlame and Ren 2006; Han et al. 2007; Sparagna et al. 2007; Ellis 
et al. 2005).  Therefore, changes in the molecular speciation of Ptd2Gro will result 
in a decrease in bioenergetic efficiency. 
 Ptd2Gro molecular speciation is the result of both newly synthesized as 
well as remodeled Ptd2Gro.  Newly synthesized Ptd2Gro will contain similar fatty 
acids species as PtdGro and CDP-DAG, which serve as precursors for Ptd2Gro 
(Hoch 1992).  However, as Ptd2Gro is remodeled, the fatty acid composition of 
Ptd2Gro molecular species will increase in its degree of unsaturated fatty acids, 
relative to saturated fatty acids.  This is due to a selection of the acyl 
transferase(s) involved in Ptd2Gro remodeling to preferentially use donor fatty 
170 
 
acids from ChoGpl and EtnGpl from the sn-2, which are primarily unsaturated.  
Defects in Ptd2Gro remodeling or a change in fatty acid metabolism will result a 
change in the molecular species of Ptd2Gro due to availability of donor fatty acids 
or loss of acyl specificity of acyltransferases.  Furthermore, in neoplastic cells 
Ptd2Gro remodeling may be limited based on the growth rate of cells. 
 A lower Ptd2Gro content as well as increase in saturated fatty acids with a 
corresponding decrease in polyunsaturated fatty acids has previously been 
shown for hepatoma compared to liver mitochondria (Bergelson et al. 1974; 
Bergelson et al. 1970; Canuto et al. 1989; Hartz et al. 1982; Morton et al. 1976; 
Reitz et al. 1977).  These studies also indicated similar alterations in the fatty 
acids of ChoGpl and EtnGpl.  This suggests that alterations in the fatty acid 
composition of hepatoma mitochondria might be due to alterations in the rate of 
synthesis/remodeling as well as the selection of donor fatty acids to be utilized 
for remodeling of Ptd2Gro.  We found a similar phenomenon regarding Ptd2Gro 
molecular species in the experimental brain tumors examined.  Ptd2Gro 
molecular species enriched in arachidonic and docosahexaenoic fatty acids were 
fewer in CT-2A and EPEN Ptd2Gro compared to brain Ptd2Gro.  Molecular 
species containing these fatty acids are likely the result of extensive remodeling 
for neurally derived cells (Kiebish et al. 2008).  In addition, arachidonic and 
docosahexaenoic fatty acids were found to be decreased in ChoGpl and EtnGpl 
of CT-2A and EPEN tumors grown in vivo.  This suggests both substrate as well 
as rate of remodeling could be decreased in tumor mitochondria.  CT-2A grows 
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faster than EPEN (Ranes et al. 2001), thus the rate of proliferation may influence 
the ability of Ptd2Gro remodeling enzymes to effectively create optimal Ptd2Gro 
molecular speciation in a time dependent manner.  Thus, the rate of proliferation 
could result in the observed shift in Ptd2Gro molecular species with shorter chain 
less unsaturated fatty acids, as viewed in CT-2A, compared to EPEN grown in 
vivo.  Interestingly enough, PtdGro was found to be increased in CT-2A and 
EPEN tumors grown in vivo.  This suggests inefficient utilization of PtdGro for the 
synthesis of Ptd2Gro, resulting in an accumulation of PtdGro in the mitochondrial 
membrane. 
 The Ptd2Gro composition of cells grown in vitro differed from tumors grown 
in vivo.  The composition as well as molecular species of Ptd2Gro in cells grown 
in culture did not differ.  This suggests that the remodeling of Ptd2Gro is affected 
by the culture environment and may not reflect the mitochondrial membrane 
lipids as found in tissue or cells grown in vivo.  These differences in Ptd2Gro 
molecular species could result in a differences in susceptibility to cytochrome c 
anchoring, apoptosis, or lipid peroxidation from in vitro experiments, which may 
not reflect the biological interactions that occur in vivo (Polcic et al. 2005; Kagan 
et al. 2006).   
 The plasmalogen content of ChoGpl and EtnGpl was also found to be 
elevated in the mitochondria of experimental brain tumors.  Plasmalogen 
glycerophospholipids are composed of a vinyl-ether linkage in the sn-1 position. 
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The vinyl-ether linkage has been proposed to facilitate membrane fusion as well 
as serve as an antioxidant (Gross 1984; Zoeller et al. 1988; Farooqui and 
Horrocks 2001).  Brain tumors as well as other tumors have been found to also 
have elevated plasmalogen content compared to whole tissue, however, the role 
of elevated plasmalogens in the mitochondria has not yet been investigated 
(Snyder and Wood 1969; Wood and Healy 1970; Yoshioka et al. 1985).  
Perhaps, the elevation of plasmalogens in tumor mitochondria might compensate 
for increased free radical production of tumors as well as facilitate mitochondrial 
fusion (Richard et al. 2000). 
 Cer as well as PtdSer were higher in CT-2A and EPEN mitochondria from 
tumors grown in vivo compared to brain mitochondria.  Cer has been suggested 
to inhibit complex I and III activities of the mitochondrial respiratory chain, thus an 
increase in mitochondrial Cer could result in an impairment of Complex I and III 
of the respiratory chain (Di Paola et al. 2000).  The higher PtdSer content in 
tumor mitochondria compared to brain mitochondria could be due to PtdSer 
dependence for the synthesis of PtdEtn (Zborowski et al. 1983).  Also, an 
increase in PtdSer or other anionic lipids, such as PtdIns or PtdGro, can balance 
membrane charged lipids due to the loss of Ptd2Gro in the mitochondrial 
membrane (Bergelson et al. 1970; Morton et al. 1977). 
 As Ptd2Gro is required for the activities of complex I, III, IV, and V, a lower 
mass content of Ptd2Gro as well as alteration to its conserved molecular species 
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composition will correspond to lower ETC activities (Fry and Green 1981; 
Abramovitch et al. 1990; Hoch 1992; Chicco and Sparagna 2007).  However, 
other lipid changes are also observed in tumor mitochondrial membranes, such a 
higher Cer and PtdSer content as well as alterations the fatty acid composition of 
ChoGpl and EtnGpl compared to control mitochondria can also influence the 
membrane environment.  All of these changes taken together will affect ETC 
activities since most lipids in the mitochondrial membrane interact with the 
complexes (Shinzawa-Itoh et al. 2007).  These differences in ETC activities are 
not due to mtDNA mutations, since CT-2A and EPEN due not harbor pathogenic 
mtDNA mutations (Kiebish and Seyfried 2005).   Complex I and II as well as the 
linked ETC activities (I/III and II/III) are lower in tumor mitochondria compared to 
controls.  This suggests that tumor mitochondria are impaired in the early steps 
of the ETC contributing protons and electrons to the gradient.  Also, linked 
activities can take into account the activity of the supercomplex or the span 
across the mitochondrial membrane in regards to efficiency of electron transport.  
Lower linked ETC activities suggest that the mitochondrial membrane is 
impaired, possibly due to altered mitochondrial membrane lipids. 
 Alterations in tumor mitochondrial membrane lipids will likely result in an 
impaired ability of tumor mitochondria to produce ATP through oxidative 
phosphorylation.  This impairment could be due to altered membrane fluidity, loss 
of ETC activity, increase in proton leak, or altered nucleotide exchange.  In 
addition, it appears that an impairment in the maintenance of Ptd2Gro content or 
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remodeling in neoplastic cells will also contribute to altered mitochondrial 
function.  Our study demonstrated that both lipid alterations as well as lower ETC 
activites in specific complexes existed in tumor mitochondria compared to control 
mitochondria.  These data provide new support for the Warburg hypothesis in 
regards to defective mitochondria in cancer cells. 
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Lipid
Ethanolamine glycerophospholipids 187.4 + 12.1 245.9 + 13.7** 368.4 + 46.4* 171.4 + 18.6 163.0 + 6.5 211.0 + 16.7
164.9 + 10.0 137.3 + 6.0* 259.4 + 45.7 85.9 + 3.4 69.7 + 3.0** 98.9 + 2.3*
22.5 + 2.2 99.3 + 7.1** 147.8 + 21.4** 80.5 + 15.0 87.5 + 9.4 106.9 + 14.4
9.3 + 0.7** 12.4 + 3.0* 5.0 + 0.3 5.7 + 0.1* 5.1 + 1.1
Choline glycerophospholipids 129.9 + 7.7 121.2 + 3.6 160.0 + 29.5 168.5 + 14.2 127.4 + 13.2* 194.4 + 15.7
119.6 + 5.3 81.4 + 3.4** 127.4 + 25.4 124.6 + 10.5 98.1 + 12.4* 174.3 + 13.9**
1.2 + 0.1 19.4 + 2.1*** 11.6 + 4.8 22.4 + 4.0 15.8 + 0.8 9.3 + 0.8*
9.1 + 3.2 20.4 + 2.6** 17.0 + 6.2 21.5 + 2.1 13.5 + 0.4* 10.8 + 1.1**
Cardiolipin 52.7 + 4.5 26.1 + 1.0** 13.5 + 2.7*** 28.3 + 4.3 24.6 + 3.7 31.1 + 4.2
Phosphatidylinositol 9.4 + 0.8 9.5 + 2.6 19.4 + 2.5* 18.5 + 2.4 18.4 + 1.6 20.5 + 3.3
Phosphatidylglycerol 7.1 + 0.5 9.8 + 0.5** 16.4 + 3.6* 7.7 + 2.6 7.6 + 1.5 4.7 + 0.3
Sphingomyelin 5.3 + 1.2 4.6 + 0.2 5.8 + 1.8 9.7 + 1.4 15.9 + 3.4 22.1 + 1.3**
Phosphatidylserine 4.6 + 1.5 9.1 + 0.6* 10.4 + 2.0* 17.8 + 0.4 28.7 + 5.7 24.1 + 3.6
Lysophosphatidylcholine 2.7 + 0.6 6.3 + 0.6** 2.8 + 0.4 1.5 + 0.1 2.2 + 0.4 2.4 + 0.6
Ceramide 0.7 + 0.2 2.3 + 0.2*** 1.7 + 0.2** 0.9 + 0.1 1.0 + 0.5 2.0 + 0.2**
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
C - B6 non-synaptic brain mitochondria or astrocyte (C8-D30) mitochondria were used as controls
Significantly different values from B6 NS or astrocyte mitochondria at *: P < 0.05; **: P < 0.01; ***: P < 0.001
N.D. - Not detected
Table 40 Lipid composition of mitochondria isolated from B6 brain, brain tumor, and cells
EPEN
In vivo
AstrocyteC CT-2A EPEN
In vitro
Plasmanylcholine
   N.D.
    BrainC CT-2A
Phosphatidylethanolamine
Plasmenylethanolamine
Plasmanylethanolamine
Phosphatidylcholine
Plasmenylcholine
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[M-H]- Molecular Species
698.5 P16:0-18:2 3.60 + 0.33 4.00 + 0.09 2.30 + 0.58 4.44 + 0.89 3.31 + 0.09
700.5 P18:1-16:0 5.77 + 0.25 7.02 + 1.03 5.66 + 1.29 8.75 + 1.41 5.70 + 1.15
P16:0-18:1
702.5 P18:0-16:0 5.41 + 0.62 5.55 + 1.50 2.08 + 0.50 2.81 + 0.48 2.93 + 1.11
P16:0-18:0
712.5 D16:1-18:2 2.74 + 0.26 3.80 + 0.89 1.62 + 0.12 1.71 + 0.36 1.60 + 0.18
714.5 D16:0-18:2 7.42 + 0.18 11.59 + 2.58 3.33 + 0.17 2.91 + 0.28 2.57 + 0.14
D16:1-18:1
716.5 D16:0-18:1 5.11 + 1.14 8.51 + 0.25 5.79 + 0.22 5.15 + 0.36 4.92 + 0.83 4.59 + 0.47
718.5 P14:0-22:6 10.64 + 0.88 4.63 + 1.14 0.91 + 0.20 0.89 + 0.08 1.75 + 0.13
720.5 P16:1-20:4 2.85 + 0.20 3.45 + 0.86 2.09 + 0.45 1.74 + 0.20 4.84 + 0.21
P14:0-22:5
722.5 P16:0-20:4 4.18 + 0.21 9.39 + 1.56 10.53 + 2.23 6.43 + 0.81 16.84 + 2.73
724.5 P16:0-20:3 3.33 + 0.30 5.73 + 1.12 3.35 + 0.82 4.19 + 0.73 2.83 + 0.32
P18:1-18:2
726.5 P18:1-18:1 4.32 + 0.19 5.62 + 0.85 2.76 + 0.79 6.17 + 1.46 3.30 + 0.66
P18:0-18:2
P16:0-20:2
728.6 P18:0-18:1 5.22 + 0.27 7.19 + 0.36 2.54 + 0.71 5.86 + 0.94 2.83 + 0.55
P16:0-20:1
730.6 A18:0-18:1 7.55 + 0.49 6.25 + 1.73 3.78 + 0.12 4.31 + 0.18 3.59 + 0.71
732.5 D14:1-22:6 3.76 + 0.30 5.09 + 1.00 0.73 + 0.16 0.79 + 0.04 1.09 + 0.24
734.5 D16:2-20:4 3.01 + 0.32 4.14 + 0.56 0.65 + 0.05 0.97 + 0.38 1.10 + 0.12
D14:1-22:5
736.5 D16:1-20:4 2.80 + 0.35 5.02 + 2.17 1.70 + 0.04 1.29 + 0.18 1.90 + 0.16
738.5 D16:0-20:4 2.91 + 0.07 6.15 + 1.26 3.36 + 0.22 1.88 + 0.13 3.04 + 0.04
D18:2-18:2
740.5 D18:1-18:2 4.19 + 0.27 5.08 + 0.44 1.57 + 0.17 1.34 + 0.13 1.05 + 0.18
D16:0-20:3
742.5 D18:0-18:2 5.07 + 0.62 10.67 + 0.22 9.68 + 1.73 3.75 + 0.42 4.55 + 0.35 3.80 + 0.64
D18:1-18:1
D16:0-20:2
744.6 D18:0-18:1 26.64 + 3.06 75.04 + 10.54 8.70 + 1.04 10.12 + 1.08 10.98 + 0.53
D16:0-20:1
746.5 P16:0-22:6 9.03 + 1.39 4.24 + 0.37 7.06 + 0.96 7.78 + 0.91 5.26 + 0.60 8.31 + 0.52
D18:0-18:0
P18:2-20:4
748.5 P18:1-20:4 8.32 + 0.52 16.59 + 3.20 14.43 + 2.16 12.25 + 1.02 20.43 + 2.41
P16:0-22:5
750.5 P18:0-20:4 5.29 + 0.27 11.69 + 3.40 7.63 + 1.44 6.29 + 0.88 12.42 + 2.16
P16:0-22:4
P18:1-20:3
752.6 P18:0-20:3 2.98 + 0.34 6.02 + 1.21 3.39 + 0.48 3.66 + 0.63 2.46 + 0.34
754.6 P20:1-18:1 2.85 + 0.34 4.09 + 0.37 1.45 + 0.30 2.28 + 0.52 0.99 + 0.07
P18:1-20:1
756.6 P18:1-20:0 3.45 + 0.28 4.98 + 0.36 0.81 + 0.25 1.48 + 0.26 0.86 + 0.18
758.5 P20:0-18:0 4.70 + 0.40 6.65 + 0.66 1.14 + 0.16 1.56 + 0.28 1.18 + 0.23
P18:0-20:0
760.5 D16:1-22:6 4.29 + 0.29 4.54 + 0.72 1.41 + 0.11 1.18 + 0.18 1.12 + 0.20
762.5 D16:0-22:6 9.39 + 0.81 3.41 + 0.27 4.96 + 0.67 2.28 + 0.17 1.26 + 0.27 2.84 + 0.18
764.5 D16:0-22:5 8.78 + 0.52 4.04 + 0.47 6.62 + 0.99 4.78 + 0.61 2.31 + 0.49 4.35 + 0.38
D18:1-20:4
766.5 D18:0-20:4 37.49 + 2.42 6.63 + 0.67 26.35 + 8.19 14.71 + 1.38 6.49 + 1.60 22.87 + 1.71
D16:0-22:4
768.6 D18:1-20:2 11.49 + 2.19 4.97 + 0.19 11.26 + 2.97 6.91 + 1.56 7.31 + 1.06 8.73 + 0.96
D16:0-22:3
D18:0-20:3
770.5 P18:2-22:6 3.87 + 0.30 5.18 + 0.62 0.85 + 0.23 1.29 + 0.10 0.91 + 0.11
D18:1-20:1
772.5 P18:1-22:6 5.24 + 0.48 7.32 + 1.24 3.19 + 0.45 2.53 + 0.50 3.17 + 0.06
D18:0-20:1
774.5 P18:0-22:6 10.37 + 1.44 7.31 + 0.62 9.00 + 1.75 4.51 + 1.00 4.96 + 0.73 5.04 + 0.48
P18:1-22:5
D18:0-20:0
776.6 P18:0-22:5 7.29 + 2.19 5.85 + 0.69 9.25 + 1.95 3.95 + 0.55 3.98 + 0.19 6.01 + 0.64
P18:1-22:4
778.6 P18:0-22:4 2.23 + 0.52 3.27 + 0.31 6.47 + 1.86 2.52 + 0.41 2.29 + 0.23 4.25 + 0.71
P20:0-20:4
P18:1-22:3
780.6 A20:0-20:4 3.52 + 0.41 12.35 + 4.21 2.47 + 0.39 2.87 + 0.60 3.10 + 0.70
P18:0-22:3
782.6 P18:0-22:2 3.24 + 0.26 6.32 + 0.98 1.53 + 0.45 2.24 + 0.40 1.51 + 0.27
786.5 D18:2-22:6 4.47 + 0.26 5.48 + 0.95 0.73 + 0.22 1.09 + 0.28 0.85 + 0.16
788.5 D18:1-22:6 5.95 + 0.44 5.94 + 0.46 5.65 + 1.14 2.65 + 0.15 2.11 + 0.26 2.01 + 0.37
790.5 D18:0-22:6 58.18 + 1.87 4.44 + 0.57 10.33 + 2.43 5.30 + 0.46 3.13 + 0.91 5.74 + 0.17
D18:1-22:5
792.6 D18:1-22:4 3.62 + 0.29 4.29 + 0.30 9.48 + 2.21 4.58 + 0.16 3.20 + 0.22 4.34 + 0.20
D18:0-22:5
794.6 D20:0-20:4 6.53 + 0.46 5.63 + 0.28 16.42 + 7.29 4.11 + 0.37 4.24 + 0.23 5.81 + 0.68
D18:1-22:3
D18:0-22:4
796.6 D20:0-20:3 6.85 + 1.34 4.18 + 0.35 9.51 + 2.42 1.74 + 0.41 1.64 + 0.14 2.09 + 0.18
D18:0-22:3
798.6 D20:0-20:2 4.02 + 0.50 5.83 + 0.60
D18:0-22:2
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
In vivo In vitro
Table 41   Mass content of ethanolamine glycerophospholipid molecular species of mitochondria isolated from B6 brain, brain tumor, and cells
Brain CT-2A EPEN Astrocyte CT-2A EPEN
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[M+Li]+ Molecular Species
698.6 A14:0-16:0 0.57 + 0.03 0.59 + 0.30 0.63 + 0.19 0.50 + 0.07 0.11 + 0.02
710.5 D14:0-16:1 2.63 + 0.11 2.43 + 1.24 4.55 + 0.83 5.54 + 0.72 5.14 + 0.64
712.5 D14:0-16:0 0.35 + 0.11 3.79 + 0.53 2.19 + 0.27 4.79 + 0.68 6.09 + 1.14 4.52 + 0.25
722.6 P16:0-16:1 0.04 + 0.07 0.40 + 0.07 0.52 + 0.18 0.40 + 0.09 0.17 + 0.01 0.09 + 0.03
P16:1-16:0
P18:1-14:0
724.6 P16:0-16:0 0.09 + 0.02 0.76 + 0.07 0.74 + 0.44 2.73 + 0.20 1.41 + 0.23 0.45 + 0.12
A16:0-16:1
726.6 A16:0-16:0 0.11 + 0.10 1.17 + 0.07 0.84 + 0.39 1.98 + 0.36 1.64 + 0.17 1.14 + 0.16
736.5 D16:1-16:1 0.31 + 0.15 0.98 + 0.31 1.72 + 0.58 2.82 + 0.92 0.79 + 0.13 0.68 + 0.04
D14:1-18:1
738.6 D16:1-16:0 2.39 + 0.44 6.83 + 0.06 9.44 + 2.65 19.79 + 2.15 11.95 + 1.72 8.52 + 0.57
D14:1-18:0
740.6 D16:0-16:0 10.00 + 1.27 4.14 + 0.62 4.56 + 1.63 4.55 + 0.85 6.56 + 1.01 11.67 + 1.74
748.6 P16:0-18:2 0.00 + 0.00 0.20 + 0.06 0.25 + 0.08 0.14 + 0.04 0.07 + 0.01 0.03 + 0.01
A16:0-18:3
750.6 P16:0-18:1 0.05 + 0.08 0.68 + 0.09 0.67 + 0.07 1.26 + 0.15 0.64 + 0.04 0.19 + 0.02
P18:1-16:0
752.6 P16:0-18:0 0.22 + 0.06 1.68 + 0.07 1.17 + 0.50 4.21 + 0.23 2.48 + 0.11 1.29 + 0.05
P18:0-16:0
A18:1-16:0
A16:0-18:1
760.5 D14:1-20:3 0.13 + 0.06 0.13 + 0.16 0.60 + 0.21 0.09 + 0.16 0.04 + 0.06 0.01 + 0.02
D16:2-18:2
D14:0-20:4
762.6 D16:1-18:2 0.15 + 0.10 0.56 + 0.36 1.25 + 0.15 0.73 + 0.42 0.20 + 0.06 0.21 + 0.05
764.6 D16:0-18:2 1.71 + 0.26 6.81 + 1.24 12.64 + 3.06 8.07 + 1.50 4.26 + 0.02 3.20 + 0.18
766.6 D16:0-18:1 33.31 + 1.31 15.43 + 0.14 19.67 + 4.31 27.74 + 4.55 23.21 + 3.65 30.82 + 2.08
768.6 D16:0-18:0 2.47 + 0.26 1.50 + 0.09 1.55 + 0.33 1.25 + 0.23 1.88 + 0.18 2.26 + 0.21
772.6 P18:2-18:2 0.03 + 0.05 0.16 + 0.16 0.28 + 0.09 0.56 + 0.07 0.72 + 0.33 0.27 + 0.04
P16:0-20:4
P20:4-16:0
774.6 A16:0-20:4 0.05 + 0.04 0.13 + 0.10 0.71 + 0.33 0.35 + 0.21 0.09 + 0.04 0.14 + 0.02
776.6 P18:1-18:1 0.00 + 0.00 0.42 + 0.08 0.53 + 0.10 0.67 + 0.09 0.33 + 0.08 0.15 + 0.02
778.6 P18:1-18:0 0.10 + 0.05 2.96 + 0.38 1.64 + 0.55 2.04 + 0.26 1.23 + 0.15 0.82 + 0.07
780.6 A18:0-18:1 0.59 + 0.05 6.20 + 0.48 5.70 + 1.80 4.17 + 0.73 2.17 + 0.27 1.84 + 0.24
P18:0-18:0
782.7 A16:0-20:0 7.42 + 2.81 10.50 + 2.02 7.83 + 3.11 8.03 + 1.41 5.02 + 0.55 5.39 + 0.78
786.6 D18:2-18:3 0.53 + 0.12 0.15 + 0.23 1.24 + 0.37 0.27 + 0.46 0.06 + 0.10 0.74 + 0.06
D16:1-20:4
788.6 D18:2-18:2 23.37 + 1.28 1.26 + 0.72 14.32 + 4.61 2.69 + 1.60 0.58 + 0.13 11.31 + 2.25
D16:0-20:4
790.6 D18:1-18:2 1.07 + 0.14 2.34 + 0.62 7.36 + 1.38 2.91 + 0.25 1.44 + 0.00 2.66 + 0.12
D16:0-20:3
792.6 D18:0-18:2 4.15 + 0.42 10.21 + 0.21 13.36 + 2.61 11.27 + 3.30 13.57 + 1.77 10.89 + 1.04
D18:1-18:1
794.6 D18:0-18:1 4.38 + 0.46 6.68 + 0.71 6.87 + 1.05 12.62 + 4.63 11.74 + 4.33 15.00 + 1.89
796.6 D18:0-18:0 0.08 + 0.07 3.69 + 0.74 1.12 + 0.52 1.14 + 0.37 0.68 + 0.16 0.68 + 0.17
798.6 P18:1-20:4 0.07 + 0.01 0.54 + 0.35 0.39 + 0.16 1.34 + 0.24 0.85 + 0.24 0.41 + 0.11
800.6 P18:0-20:4 0.07 + 0.01 0.36 + 0.04 0.68 + 0.30 5.61 + 2.88 4.71 + 0.18 0.93 + 0.23
802.6 P18:2-20:1 0.27 + 0.10 0.39 + 0.11 0.92 + 0.30 0.86 + 0.29 0.26 + 0.06 1.39 + 0.14
P20:1-18:2
A18:0-20:4
810.7 A18:0-20:0 0.91 + 0.23 3.12 + 1.66 2.65 + 1.24 2.53 + 1.48 1.39 + 0.50 1.33 + 0.03
812.6 D16:0-22:6 13.94 + 0.79 0.78 + 0.86 4.58 + 1.59 1.21 + 1.19 0.35 + 0.39 6.65 + 1.98
D18:2-20:4
814.6 D18:1-20:4 5.66 + 0.72 0.68 + 0.43 5.23 + 1.60 2.76 + 1.00 0.85 + 0.03 13.27 + 2.42
D16:0-22:5
816.6 D18:2-20:2 11.36 + 0.90 1.86 + 0.15 9.56 + 2.11 6.12 + 0.74 2.05 + 0.16 26.50 + 4.26
D18:0-20:4
818.6 D18:0-20:3 0.36 + 0.17 1.03 + 0.09 1.56 + 0.80 1.59 + 0.49 1.98 + 0.20 0.45 + 0.76
820.6 D18:0-20:2 0.16 + 0.03 2.17 + 0.31 1.21 + 0.70 0.57 + 0.11 1.89 + 0.19 0.43 + 0.37
P18:2-22:6
822.7 D18:0-20:1 0.10 + 0.09 3.14 + 0.63 0.89 + 0.82 0.12 + 0.10 0.08 + 0.14 0.00 + 0.00
P18:1-22:6
824.6 P18:0-22:6 0.02 + 0.02 1.63 + 0.63 0.36 + 0.34 0.87 + 0.19 0.44 + 0.08 0.35 + 0.08
P18:1-22:5
826.6 A18:0-22:6 0.05 + 0.05 0.70 + 0.12 0.25 + 0.19 4.23 + 2.12 3.37 + 0.57 0.88 + 0.42
P18:0-22:5
836.6 D18:2-22:6 0.12 + 0.11 0.58 + 0.75 0.75 + 0.69 0.66 + 0.15
838.6 D18:1-22:6 1.29 + 1.15 0.71 + 0.45 0.73 + 0.28 1.05 + 0.52 0.43 + 0.00 3.71 + 0.92
D18:2-22:5
840.6 D18:0-22:6 2.07 + 1.96 0.88 + 0.17 1.31 + 0.32 2.48 + 0.64 1.01 + 0.15 7.86 + 2.79
D20:2-20:4
842.6 D18:0-22:5 0.20 + 0.18 0.53 + 0.03 0.70 + 0.31 1.85 + 0.18 0.81 + 0.18 4.53 + 1.57
D20:2-20:3
844.6 D18:0-22:4 0.14 + 0.14 0.75 + 0.20 0.61 + 0.31 0.83 + 0.49 0.57 + 0.18 1.16 + 0.26
D20:0-20:4
D20:2-20:2
846.7 D18:0-22:3 0.84 + 0.36 0.31 + 0.33 0.22 + 0.12 0.12 + 0.09 0.02 + 0.02
D20:0-20:3
D18:2-22:1
848.7 D18:0-22:2 0.84 + 0.29 0.29 + 0.32 0.50 + 0.22 0.18 + 0.04 0.11 + 0.02
D20:0-20:2
850.6 P20:1-22:6 0.64 + 0.08 0.12 + 0.21 0.20 + 0.11 0.22 + 0.13 0.10 + 0.05
854.7 P20:1-22:4 0.63 + 0.29 0.12 + 0.20 0.38 + 0.10 0.35 + 0.08 0.34 + 0.11
860.7 P20:0-22:2 0.65 + 0.20 0.16 + 0.29 0.70 + 0.09
862.7 P20:0-22:1 0.86 + 0.18 0.19 + 0.33 0.45 + 0.09
864.6 P21:1-22:6 1.04 + 0.45 0.09 + 0.16 0.13 + 0.03 0.07 + 0.02 0.28 + 0.04
866.7 P21:1-22:5 0.51 + 0.14 0.06 + 0.10 0.14 + 0.03 0.09 + 0.03 0.42 + 0.08
868.7 P21:1-22:4 0.26 + 0.07 0.05 + 0.09 0.10 + 0.01 0.09 + 0.03 0.39 + 0.05
870.7 D20:0-22:5 0.36 + 0.13 0.05 + 0.09 0.31 + 0.11
D20:1-22:4
872.7 D20:0-22:4 0.23 + 0.05 0.06 + 0.10 0.14 + 0.02
D20:2-22:2
874.7 D20:0-22:3 0.29 + 0.05 0.06 + 0.11 0.12 + 0.08
D20:2-22:1
876.7 D20:0-22:2 0.40 + 0.12 0.07 + 0.12 0.30 + 0.12 0.12 + 0.02 0.10 + 0.05
D20:2-22:0
878.7 D20:0-22:1 0.44 + 0.06 0.10 + 0.16 0.11 + 0.06 0.07 + 0.02 0.13 + 0.05
880.7 D20:0-22:0 0.38 + 0.08 0.07 + 0.13 0.05 + 0.02
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
In vivo In vitro
Table 42  Mass content of choline glycerophospholipid molecular species of mitochondria isolated from B6 brain, brain tumor, and cells
Brain CT-2A EPEN Astrocyte CT-2A EPEN
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[M-2H]- Molecular Species
685.0 18:1-16:1-16:1-16:1 0.04 + 0.01 0.65 + 0.41 0.29 + 0.11 0.86 + 0.24
686.0 18:1-16:1-16:1-16:0 1.31 + 0.03 1.42 + 0.12 0.73 + 0.18 0.24 + 0.06
687.0 18:1-16:1-16:0-16:0 1.06 + 0.26 0.88 + 0.24 0.72 + 0.05 0.48 + 0.03
699.0 18:2-18:1-16:1-16:1 1.14 + 0.12 0.17 + 0.01 1.16 + 0.29 0.97 + 0.44 0.42 + 0.07
700.0 18:1-18:1-16:1-16:1 0.30 + 0.03 1.33 + 0.34 0.26 + 0.05 3.60 + 0.47 2.13 + 0.48 0.99 + 0.08
701.0 18:1-18:1-16:0-16:1        0.31 + 0.05 1.08 + 0.23 0.32 + 0.07 1.58 + 0.15 1.05 + 0.03 1.05 + 0.08
18:2-18:1-16:0-16:0
18:2-18:0-16:1-16:0
702.0 18:1-18:1-16:0-16:0     0.24 + 0.04 0.87 + 0.17 0.44 + 0.11 0.85 + 0.12 0.59 + 0.08 0.96 + 0.12
18:2-18:0-16:0-16:0 
18:1-18:0-16:0-16:1
710.0 20:4-18:2-16:1-16:1 0.09 + 0.01 0.17 + 0.07 0.25 + 0.02 0.12 + 0.03 0.16 + 0.03
711.0 20:4-18:1-16:1-16:1          0.41 + 0.06 1.25 + 0.17 0.24 + 0.01 0.58 + 0.12 0.31 + 0.10 0.30 + 0.01
20:4-18:2-16:1-16:0
712.0 20:4-18:1-16:1-16:0         0.45 + 0.06 1.62 + 0.11 0.46 + 0.09 0.82 + 0.15 0.84 + 0.37 0.65 + 0.06
18:2-18:2-18:1-16:1
713.0 18:2-18:1-18:1-16:1       0.71 + 0.02 1.91 + 0.07 0.73 + 0.17 2.31 + 0.57 2.26 + 0.66 1.92 + 0.18
18:1-18:1-18:1-16:2   
18:2-18:1-18:0-16:2  
18:2-18:2-18:0-16:1
714.0 18:1-18:1-18:1-16:1          1.47 + 0.23 2.00 + 0.63 0.75 + 0.15 2.55 + 0.42 2.32 + 0.36 2.38 + 0.37
18:2-18:1-18:1-16:0
715.0 18:1-18:1-18:1-16:0     0.68 + 0.04 1.57 + 0.30 0.39 + 0.08 0.59 + 0.04 0.64 + 0.06 1.33 + 0.13
18:0-18:1-18:1-16:1
716.0 18:0-18:1-18:1-16:0    0.09 + 0.02 0.17 + 0.05 0.24 + 0.02 0.21 + 0.03 0.24 + 0.05
18:0-18:0-18:1-16:1
720.0 O-20:4-18:1-16:1-16:0         0.28 + 0.06 0.29 + 0.10 0.33 + 0.04
O-18:2-18:2-18:1-16:1
721.0 O-18:2-18:1-18:1-16:1          0.42 + 0.16 0.37 + 0.03 0.52 + 0.08
O-18:1-18:1-18:1-16:2  
O-18:2-18:1-18:0-16:2
O-18:2-18:2-18:0-16:1
722.0 20:4-20:4-16:1-16:1 0.23 + 0.03 0.27 + 0.08 0.24 + 0.10 0.23 + 0.09 0.31 + 0.05
723.0 20:4-20:4-16:1-16:0               0.36 + 0.03 0.18 + 0.05 0.37 + 0.08 0.21 + 0.03 0.26 + 0.05
20:4-18:2-18:2-16:1
724.0 20:4-18:2-18:1-16:1 0.95 + 0.08 1.36 + 0.21 0.65 + 0.14 0.47 + 0.12 0.36 + 0.10 0.60 + 0.05
725.0 20:4-18:2-18:1-16:0                2.22 + 0.17 1.61 + 0.31 1.07 + 0.19 0.59 + 0.08 0.70 + 0.27 1.11 + 0.16
20:4-18:1-18:1-16:1
726.0 20:4-18:1-18:1-16:0          1.74 + 0.13 2.09 + 0.04 1.42 + 0.31 0.72 + 0.25 1.28 + 0.48 1.87 + 0.23
20:3-18:1-18:1-16:1
727.0 18:2-18:1-18:1-18:1 2.48 + 0.33 0.77 + 0.15 0.83 + 0.27 1.39 + 0.25 2.28 + 0.50
728.0 18:1-18:1-18:1-18:1 3.72 + 0.72 0.32 + 0.05 0.48 + 0.15 0.72 + 0.16 1.32 + 0.49
729.0 18:1-18:1-18:1-18:0 0.30 + 0.03 0.11 + 0.03 0.24 + 0.06 0.23 + 0.03 0.28 + 0.01
731.0 O-20:4-20:4-16:1-16:0        0.24 + 0.05 0.22 + 0.02 0.30 + 0.03
O-20:4-18:2-18:2-16:1
732.0 O-20:4-18:2-18:1-16:1 0.12 + 0.00 0.12 + 0.01 0.18 + 0.02
734.0 22:6-20:4-16:1-16:1 0.14 + 0.02 0.04 + 0.01 0.10 + 0.02 0.15 + 0.06 0.14 + 0.01
735.0 20:4-20:4-18:2-16:1 0.56 + 0.06 0.07 + 0.02 0.16 + 0.05 0.15 + 0.00 0.27 + 0.04
736.0 20:4-20:4-18:1-16:1 1.41 + 0.16 0.20 + 0.05 0.18 + 0.03 0.18 + 0.04 0.28 + 0.02
737.0 20:4-20:4-18:1-16:0          2.11 + 0.07 1.00 + 0.07 0.41 + 0.14 0.32 + 0.06 0.33 + 0.06 0.78 + 0.14
22:6-18:1-18:1-16:1
22:6-18:2-18:1-16:0
738.0 20:4-18:2-18:1-18:1           2.68 + 0.37 1.20 + 0.28 0.46 + 0.10 0.34 + 0.04 0.40 + 0.12 0.93 + 0.18
22:6-18:1-18:1-16:0
739.0 20:4-18:1-18:1-18:1 3.30 + 0.45 0.39 + 0.11 0.24 + 0.04 0.44 + 0.15 0.80 + 0.21
740.0 20:4-18:1-18:1-18:0               1.07 + 0.14 0.19 + 0.04 0.21 + 0.05 0.36 + 0.04 0.53 + 0.15
20:3-18:1-18:1-18:1
741.0 20:4-18:1-18:0-18:0               0.25 + 0.08 0.10 + 0.02 0.09 + 0.02 0.14 + 0.02 0.20 + 0.08
20:3-18:1-18:1-18:0
747.0 22:6-18:3-18:2-18:2 0.40 + 0.04 0.15 + 0.04 0.12 + 0.01 0.12 + 0.04
748.0 20:4-20:4-18:2-18:2                  1.38 + 0.09 0.25 + 0.04 0.43 + 0.13 0.31 + 0.03 0.29 + 0.09
20:4-20:4-20:4-16:0 
22:6-20:4-18:1-16:1 
22:6-22:6-16:0-16:0
22:6-18:2-18:2-18:2
749.0 20:4-20:4-18:2-18:1 1.99 + 0.19 0.19 + 0.03 0.15 + 0.10 0.11 + 0.02 0.22 + 0.08
750.0 20:4-20:4-18:1-18:1 3.24 + 0.24 0.26 + 0.04 0.25 + 0.05 0.28 + 0.04 0.47 + 0.09
751.0 22:6-18:1-18:1-18:1          2.74 + 0.10 0.17 + 0.02 0.15 + 0.04 0.21 + 0.02 0.40 + 0.13
20:4-20:3-18:1-18:1
752.0 22:6-18:1-18:1-18:0 0.54 + 0.17 0.12 + 0.04 0.24 + 0.05
753.0 20:4-20:2-18:1-18:0          0.15 + 0.04 0.07 + 0.01 0.21 + 0.04
20:4-20:1-18:1-18:1
754.0 20:4-20:1-18:1-18:0 0.09 + 0.02 0.05 + 0.02 0.12 + 0.01
755.0 20:4-20:1-18:0-18:0 + 0.04 + 0.01 0.14 + 0.02
759.0 22:6-20:4-20:4-16:1        0.32 + 0.04 0.05 + 0.02 0.17 + 0.05 0.17 + 0.05 0.20 + 0.02
22:6-22:6-18:2-16:1
760.0 22:6-20:4-18:2-18:2               0.76 + 0.05 0.07 + 0.03 0.10 + 0.03
22:6-20:4-20:4-16:0   
22:6-22:6-18:1-16:1
761.0 22:6-20:4-18:2-18:1 1.72 + 0.08 0.18 + 0.08 0.20 + 0.09 0.17 + 0.03 0.23 + 0.04
762.0 22:6-20:4-18:1-18:1 2.94 + 0.23 0.11 + 0.02 0.20 + 0.03
763.0 22:6-20:4-18:1-18:0         1.03 + 0.05 0.07 + 0.02 0.18 + 0.02
22:6-20:3-18:1-18:1
764.0 22:4-20:4-18:1-18:1         0.24 + 0.02 0.11 + 0.03 0.21 + 0.14
22:6-20:3-18:1-18:0
765.0 22:4-20:4-18:1-18:0 0.08 + 0.01 0.27 + 0.06
771.0 22:6-20:4-20:4-18:3 0.18 + 0.05 0.09 + 0.02 0.11 + 0.07 0.07 + 0.01 0.11 + 0.00
772.0 22:6-22:6-20:4-16:0          0.42 + 0.05 0.10 + 0.04 0.12 + 0.05 0.09 + 0.02 0.13 + 0.01
20:4-20:4-20:4-20:4   
22:6-20:4-20:4-18:2  
22:6-22:6-18:2-18:2
773.0 22:6-20:4-20:4-18:1 1.42 + 0.12 2.03 + 0.11 0.14 + 0.04 0.13 + 0.05 0.11 + 0.04 0.11 + 0.04
774.0 22:6-22:6-18:1-18:1          1.81 + 0.09 1.64 + 0.18 0.11 + 0.02 0.35 + 0.22 0.20 + 0.06 0.21 + 0.05
22:6-20:4-20:3-18:1
775.0 16:0-20:3-22:5-22:5             0.28 + 0.10
18:2-20:3-20:3-22:5  
18:0-18:1-22:6-22:6   
18:0-20:3-20:4-22:6
776.0 18:0-18:0-22:6-22:6 0.16 + 0.05
783.0 O-22:6-22:6-18:0-18:1   0.30 + 0.31 0.21 + 0.05 0.12 + 0.02
O-22:6-20:3-20:4-18:0
784.0 22:6-22:6-20:4-18:2 0.33 + 0.05
786.0 22:6-22:6-20:4-18:1             1.34 + 0.09
22:6-20:4-20:4-20:3
796.0 20:4-20:4-22:6-22:6 0.25 + 0.09 0.14 + 0.06 0.42 + 0.42 0.14 + 0.02 0.33 + 0.07
797.0 22:6-22:6-22:6-18:1          0.50 + 0.04 0.12 + 0.05 0.30 + 0.30 0.14 + 0.02 0.22 + 0.00
22:6-22:6-20:4-20:3
798.0 20:4-20:3-22:6-22:5   0.16 + 0.07 0.06 + 0.02 0.26 + 0.21 0.11 + 0.02 0.22 + 0.04
22:6-22:6-22:6-18:0   
22:6-22:6-22:5-18:1
808.0 20:4-22:6-22:6-22:6 0.07 + 0.03 0.28 + 0.22 0.22 + 0.06 0.22 + 0.04
809.0 20:4-22:6-22:6-22:5 0.30 + 0.22 0.27 + 0.09 0.32 + 0.06
813.0 22:6-22:6-22:6-22:5 0.06 + 0.02 0.17 + 0.03 0.18 + 0.01 0.20 + 0.03
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
In vivo In vitro
Table 43   Mass content of cardiolipin molecular species of mitochondria isolated from B6 brain, brain tumor, and cells
Brain CT-2A EPEN Astrocyte CT-2A EPEN
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[M-H]- Molecular Species
807.5 16:0-16:1 0.04 + 0.02 0.07 + 0.04 0.06 + 0.02 0.11 + 0.03 0.08 + 0.02
809.5 16:0-16:0 0.07 + 0.02 0.03 + 0.01 0.07 + 0.05 0.02 + 0.01 0.03 + 0.01 0.07 + 0.02
821.6 A16:0-18:1 0.04 + 0.02 0.06 + 0.05 0.04 + 0.02 0.08 + 0.03 0.04 + 0.02
831.5 16:1-18:2 0.07 + 0.06 0.18 + 0.14 0.09 + 0.03 0.04 + 0.02 0.06 + 0.02
16:0-18:3
833.5 16:0-18:2 0.02 + 0.01 0.09 + 0.04 0.25 + 0.08 0.26 + 0.10 0.31 + 0.04 0.20 + 0.04
835.5 16:0-18:1 0.18 + 0.08 0.11 + 0.03 0.15 + 0.09 0.29 + 0.15 0.96 + 0.20 0.60 + 0.04
837.5 16:0-18:0 0.05 + 0.02 0.03 + 0.02 0.06 + 0.03 0.02 + 0.01 0.08 + 0.01 0.12 + 0.04
843.5 P18:1-18:2 0.05 + 0.03 0.10 + 0.10 0.15 + 0.06 0.05 + 0.01 0.04 + 0.01
845.6 P18:1-18:1 0.05 + 0.02 0.10 + 0.10 0.12 + 0.07 0.08 + 0.02 0.04 + 0.02
847.6 P18:0-18:1 0.06 + 0.03 0.09 + 0.04 0.11 + 0.04 0.31 + 0.07 0.06 + 0.01
849.6 A18:0-18:1 0.07 + 0.03 0.11 + 0.06 0.08 + 0.06 0.19 + 0.06 0.09 + 0.02
857.5 16:0-20:4 1.12 + 0.09 0.21 + 0.04 0.64 + 0.16 1.23 + 0.18 0.36 + 0.07 1.04 + 0.19
859.5 18:1-18:2 0.03 + 0.02 0.21 + 0.04 0.42 + 0.25 0.87 + 0.08 0.84 + 0.25 0.29 + 0.06
861.5 18:0-18:2 0.03 + 0.01 0.36 + 0.06 0.56 + 0.22 0.91 + 0.27 3.16 + 0.53 0.85 + 0.13
863.6 18:0-18:1 0.06 + 0.03 0.14 + 0.06 0.19 + 0.17 0.25 + 0.14 1.62 + 0.49 0.88 + 0.13
865.6 18:0-18:0 0.03 + 0.01 0.11 + 0.04 0.15 + 0.18 0.02 + 0.01 0.10 + 0.06 0.13 + 0.06
869.6 P18:0-20:4 0.12 + 0.04 0.20 + 0.13 0.46 + 0.01 0.16 + 0.02 0.12 + 0.06
873.6 A18:0-20:3 0.05 + 0.01 0.24 + 0.19 0.37 + 0.08 0.29 + 0.03 0.09 + 0.02
P18:0-20:2
875.6 A18:0-20:2 0.05 + 0.01 0.07 + 0.04 0.07 + 0.04 0.24 + 0.02 0.03 + 0.02
P18:0-20:1
877.6 A18:0-20:1 0.05 + 0.01 0.06 + 0.06 0.02 + 0.00 0.06 + 0.04 0.02 + 0.01
P18:0-20:0
881.5 18:2-20:4 0.23 + 0.01 0.05 + 0.01 0.21 + 0.08 0.13 + 0.02 0.08 + 0.02 0.12 + 0.01
16:0-22:6
883.5 18:1-20:4 0.26 + 0.11 0.40 + 0.22 1.79 + 0.24 0.95 + 0.28 1.52 + 0.22
885.5 18:0-20:4 6.68 + 0.41 3.08 + 0.55 8.77 + 1.90 7.80 + 1.21 3.82 + 0.81 11.74 + 2.52
887.6 18:0-20:3 0.17 + 0.15 0.69 + 0.18 2.41 + 0.50 1.94 + 0.45 2.92 + 0.27 1.09 + 0.15
889.6 18:0-20:2 0.03 + 0.01 0.16 + 0.03 0.39 + 0.14 0.17 + 0.07 0.93 + 0.11 0.15 + 0.03
893.6 18:0-20:0 0.09 + 0.02 0.15 + 0.06 0.17 + 0.10 0.05 + 0.02 0.09 + 0.05 0.11 + 0.01
897.6 A18:0-22:5 0.17 + 0.18 0.19 + 0.10 0.08 + 0.02 0.03 + 0.02 0.05 + 0.03
P18:0-22:4
899.6 A18:0-22:4 0.24 + 0.10 0.47 + 0.07 0.10 + 0.02 0.04 + 0.03 0.04 + 0.03
901.6 A18:0-22:3 0.13 + 0.06 0.24 + 0.12 0.12 + 0.00 0.06 + 0.05 0.04 + 0.01
905.5 18:2-22:6 0.14 + 0.06 0.25 + 0.21 0.04 + 0.02 0.02 + 0.02 0.03 + 0.01
907.5 18:1-22:6 0.05 + 0.03 0.09 + 0.01 0.06 + 0.08 0.05 + 0.01 0.01 + 0.01 0.04 + 0.03
909.5 18:0-22:6 0.37 + 0.02 0.09 + 0.04 0.28 + 0.16 0.09 + 0.04 0.08 + 0.10 0.16 + 0.08
911.6 18:0-22:5 0.12 + 0.05 0.37 + 0.25 0.18 + 0.04 0.11 + 0.09 0.27 + 0.16
913.6 18:0-22:4 0.19 + 0.09 0.56 + 0.20 0.17 + 0.04 0.11 + 0.10 0.16 + 0.08
915.6 18:0-22:3 0.15 + 0.05 0.22 + 0.07 0.02 + 0.01 0.03 + 0.03 0.03 + 0.02
937.6 20:0-22:6 0.08 + 0.06 0.13 + 0.04 0.01 + 0.01
937.5 P22:6-22:6 0.09 + 0.07 0.14 + 0.05 0.01 + 0.01
953.5 22:6-22:6 0.08 + 0.03 1.43 + 1.05 0.22 + 0.11 0.20 + 0.17 0.03 + 0.05
Values are expressed as mean nmol.mg protein + S.D. (N = 3)
In vivo In vitro
Table 44  Mass content of phosphatidylinositol molecular species of mitochondria isolated from B6 brain, brain tumor, and cells
Brain CT-2A EPEN Astrocyte CT-2A EPEN
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[M-H]- Molecular Species
707.5 A16:0-16:0  0.88 + 0.31 2.41 + 2.04 0.36 + 0.04
719.5 16:0-16:1 0.29 + 0.02 0.89 + 0.01 1.47 + 0.43 0.41 + 0.07 0.40 + 0.01 0.30 + 0.03
721.5 16:0-16:0 0.49 + 0.04 0.34 + 0.09 1.13 + 0.35 0.27 + 0.04 0.50 + 0.45 0.86 + 0.14
743.5 16:1-18:2 0.22 + 0.04 0.89 + 0.42 1.30 + 0.38 0.27 + 0.09 0.14 + 0.02 0.14 + 0.03
745.5 16:0-18:2 0.54 + 0.10 1.07 + 0.03 3.99 + 0.71 0.95 + 0.34 0.52 + 0.17 0.44 + 0.01
747.5 16:0-18:1 3.41 + 0.13 3.35 + 0.15 2.30 + 0.26 2.23 + 0.69 1.82 + 0.23 1.21 + 0.15
769.5 18:2-18:2 0.82 + 0.04 0.38 + 0.02 1.15 + 0.36 0.37 + 0.16 0.16 + 0.02 0.27 + 0.04
771.5 18:1-18:2 0.29 + 0.03 0.65 + 0.07 1.29 + 0.20 0.45 + 0.18 0.23 + 0.06 0.27 + 0.03
773.5 18:1-18:1 0.47 + 0.12 1.49 + 0.04 2.24 + 0.49 1.41 + 0.85 0.88 + 0.39 0.54 + 0.10
775.5 18:0-18:1 0.55 + 0.10 0.77 + 0.03 1.47 + 0.48 0.44 + 0.15 0.47 + 0.12 0.33 + 0.05
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
In vivo In vitro
Table 45  Mass content of phosphatidylglycerol molecular species of mitochondria isolated from B6 brain, brain tumor, and cells
Brain CT-2A EPEN Astrocyte CT-2A EPEN
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[M+Li]+ Molecular Species
691.5 N15:2 0.01 + 0.00 0.01 + 0.00 0.01 + 0.01
693.6 N15:1 0.01 + 0.00 0.01 + 0.00 0.02 + 0.00
695.6 N15:0 0.25 + 0.03 0.34 + 0.12 0.32 + 0.04
707.6 N16:1 0.22 + 0.01 0.94 + 0.55 0.47 + 0.01 0.58 + 0.19 1.27 + 0.04
709.6 N16:0 0.27 + 0.32 1.53 + 0.04 2.41 + 0.73 4.22 + 0.74 8.32 + 2.46 11.72 + 0.53
721.6 N17:1 0.04 + 0.00 0.02 + 0.01 0.03 + 0.01
723.6 N17:0 0.19 + 0.00 0.21 + 0.05 0.26 + 0.01
733.6 N18:2 0.04 + 0.01 0.01 + 0.00 0.02 + 0.01
735.6 N18:1 0.26 + 0.02 0.09 + 0.04 0.34 + 0.19 0.32 + 0.03 0.14 + 0.01 0.85 + 0.11
737.6 N18:0 1.99 + 0.38 0.52 + 0.08 0.47 + 0.12 1.07 + 0.15 1.00 + 0.11 2.13 + 0.14
749.6 N19:1 0.04 + 0.01 0.01 + 0.01 0.02 + 0.01
751.6 N19:0 0.08 + 0.01 0.09 + 0.05 0.13 + 0.02
761.6 N20:2 0.03 + 0.04 0.04 + 0.04 0.05 + 0.02 0.01 + 0.01 0.01 + 0.01
763.6 N20:1 0.07 + 0.00 0.41 + 0.10 0.52 + 0.34 0.34 + 0.05 0.26 + 0.03 0.24 + 0.03
765.6 N20:0 2.33 + 0.41 0.34 + 0.02 0.50 + 0.07 0.66 + 0.09 0.83 + 0.08 1.23 + 0.05
775.6 N21:2 0.00 + 0.00 0.00 + 0.00 0.01 + 0.01
777.6 N21:1 0.03 + 0.02 0.05 + 0.01 0.04 + 0.03
779.7 N21:0 0.04 + 0.01 0.06 + 0.03 0.09 + 0.01
789.6 N22:2 0.15 + 0.18 0.31 + 0.39 0.00 + 0.00 0.03 + 0.04 0.00 + 0.00
791.7 N22:1 0.55 + 0.09 0.01 + 0.01 0.35 + 0.15 0.60 + 0.15 0.39 + 0.04
793.7 N22:0 0.16 + 0.27 0.26 + 0.13 0.56 + 0.12 0.73 + 0.11
805.7 N23:1 0.08 + 0.01 0.10 + 0.03 0.10 + 0.04
807.7 N23:0 0.02 + 0.02 0.08 + 0.01 0.11 + 0.01
817.7 N24:2 0.14 + 0.04 0.12 + 0.03 0.36 + 0.15 0.05 + 0.09
819.7 N24:1 0.65 + 0.08 0.24 + 0.21 0.62 + 0.20 1.73 + 0.54 1.34 + 0.21
821.7 N24:0 0.20 + 0.14 0.06 + 0.08 0.13 + 0.05 0.24 + 0.04 0.57 + 0.22
833.7 N25:1 0.11 + 0.05 0.07 + 0.02 0.25 + 0.05
835.7 N25:0 0.13 + 0.02 0.22 + 0.12 0.21 + 0.04
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
In vivo In vitro
Table 46  Mass content of sphingomyelin molecular species of mitochondria isolated from B6 brain, brain tumor, and cells
Brain CT-2A EPEN Astrocyte CT-2A EPEN
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[M-H]- Molecular Species
706.5 14:0-16:0 0.01 + 0.01
732.5 16:0-16:1 0.02 + 0.00 0.01 + 0.00 0.12 + 0.03 0.62 + 0.33 0.01 + 0.01
734.5 16:0-16:0 0.03 + 0.02 0.01 + 0.00 0.02 + 0.01 0.03 + 0.02 0.02 + 0.01
744.5 P16:0-18:1   0.02 + 0.01 0.01 + 0.01 0.02 + 0.00 0.03 + 0.01 0.02 + 0.01
746.5 P16:0-18:0   0.03 + 0.01 0.03 + 0.01 0.10 + 0.04 0.21 + 0.07 0.03 + 0.02
758.5 16:0-18:2 0.08 + 0.01 0.03 + 0.02 0.16 + 0.05 0.31 + 0.11 0.05 + 0.02
760.5 16:0-18:1 0.07 + 0.02 0.55 + 0.08 0.20 + 0.05 2.35 + 0.37 4.78 + 1.46 0.37 + 0.15
762.5 16:0-18:0 0.05 + 0.04 0.02 + 0.00 0.03 + 0.01 0.05 + 0.04 0.10 + 0.07
772.5 P18:0-18:1   0.03 + 0.01 0.05 + 0.01 0.05 + 0.02 0.10 + 0.05 0.03 + 0.01
774.6 P18:0-18:0   0.09 + 0.01 0.04 + 0.01 0.36 + 0.09 0.68 + 0.17 0.12 + 0.04
782.5 18:2-18:2 0.03 + 0.02 0.04 + 0.02 0.05 + 0.02 0.06 + 0.01 0.01 + 0.01
784.5 18:1-18:2 0.02 + 0.01 0.05 + 0.02 0.03 + 0.00 0.08 + 0.02 0.21 + 0.01 0.05 + 0.02
786.5 18:0-18:2 0.29 + 0.07 0.93 + 0.02 0.74 + 0.23 1.01 + 0.09 2.66 + 0.88 0.64 + 0.23
788.5 18:0-18:1 0.24 + 0.21 4.56 + 0.92 3.14 + 0.65 6.86 + 0.80 10.46 + 2.05 10.75 + 2.21
790.6 18:0-18:0 0.01 + 0.01 0.01 + 0.02 0.13 + 0.18 0.17 + 0.15 0.17 + 0.05 0.17 + 0.11
794.5 P18:0-20:4  0.01 + 0.01 0.02 + 0.02 0.04 + 0.03 0.06 + 0.02 0.05 + 0.01
800.6 P18:0-20:1  0.07 + 0.03 0.03 + 0.01 0.03 + 0.01 0.10 + 0.04 0.02 + 0.01
802.6 P18:0-20:0  0.17 + 0.11 0.04 + 0.01 0.08 + 0.02 0.11 + 0.03 0.08 + 0.01
806.5 18:2-20:4 0.05 + 0.03 0.03 + 0.01 0.06 + 0.03 0.08 + 0.01 0.13 + 0.03 0.04 + 0.01
808.5 18:1-20:4 0.04 + 0.04 0.04 + 0.02 0.06 + 0.06 0.09 + 0.04 0.14 + 0.03 0.13 + 0.03
810.5 18:0-20:4 0.10 + 0.08 0.32 + 0.06 0.94 + 0.17 0.58 + 0.13 0.68 + 0.10 1.82 + 0.39
812.5 18:0-20:3 0.22 + 0.07 0.77 + 0.25 0.65 + 0.06 1.33 + 0.32 1.26 + 0.26
814.6 18:0-20:2 0.08 + 0.01 0.11 + 0.05 0.16 + 0.06 0.63 + 0.19 0.10 + 0.05
816.6 18:0-20:1 0.13 + 0.07 0.13 + 0.06 0.08 + 0.02 0.29 + 0.05 0.16 + 0.09
818.6 18:0-20:0 0.05 + 0.03 0.01 + 0.02 0.01 + 0.01 0.07 + 0.01 0.02 + 0.02
820.5 P18:0-22:5   0.04 + 0.03 0.04 + 0.04 0.06 + 0.02 0.10 + 0.02 0.03 + 0.01
822.6 P20:0-20:4   0.02 + 0.01 0.03 + 0.01 0.06 + 0.00 0.07 + 0.03 0.03 + 0.02
P18:0-22:4
824.6 P20:0-20:3   0.04 + 0.05 0.03 + 0.04 0.03 + 0.02 0.03 + 0.01 0.02 + 0.01
P18:0-22:3
826.6 P20:0-20:2   0.08 + 0.03 0.02 + 0.03 0.09 + 0.01 0.08 + 0.03 0.05 + 0.04
P18:0-22:2
828.6 P20:0-20:1   0.04 + 0.04 0.01 + 0.01 0.01 + 0.01 0.04 + 0.02 0.02 + 0.02
P18:0-22:1
832.5 18:1-22:6 0.05 + 0.01 0.06 + 0.05 0.04 + 0.03 0.08 + 0.01 0.07 + 0.01 0.09 + 0.05
834.5 18:0-22:6 3.13 + 1.22 0.33 + 0.17 1.31 + 0.34 1.71 + 0.12 1.84 + 0.46 3.01 + 0.54
836.5 18:0-22:5 0.22 + 0.27 0.14 + 0.09 0.67 + 0.05 1.42 + 0.15 1.39 + 0.36 2.20 + 0.06
838.6 20:0-20:4 0.28 + 0.07 0.21 + 0.04 0.91 + 0.18 0.82 + 0.24 0.43 + 0.11 1.80 + 0.61
18:0-22:4
840.6 20:0-20:3 0.12 + 0.02 0.06 + 0.06 0.17 + 0.05 0.15 + 0.04 0.12 + 0.08
18:0-22:3
842.6 20:0-20:2 0.13 + 0.08 0.09 + 0.14 0.06 + 0.03 0.19 + 0.12 0.16 + 0.10
18:0-22:2
844.6 20:0-20:1 0.06 + 0.04 0.17 + 0.04 0.04 + 0.01 0.17 + 0.02 0.15 + 0.02
18:0-22:1
860.5 20:1-22:6 0.04 + 0.03 0.02 + 0.03 0.01 + 0.01 0.02 + 0.00 0.02 + 0.01
862.6 20:0-22:6 0.06 + 0.04 0.04 + 0.01 0.05 + 0.02 0.08 + 0.05
864.6 20:0-22:5 0.06 + 0.02 0.07 + 0.03 0.01 + 0.01 0.01 + 0.01 0.07 + 0.06
870.6 20:0-22:2 0.05 + 0.03 0.06 + 0.02 0.02 + 0.01 0.05 + 0.03 0.05 + 0.02
872.6 20:0-22:1 0.02 + 0.01 0.13 + 0.10 0.01 + 0.01 0.06 + 0.00 0.13 + 0.06
878.5 22:6-22:6 0.07 + 0.01
882.5 22:6-22:4 0.06 + 0.07
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
In vivo In vitro
Table 47  Mass content of phosphatidylserine molecular species of mitochondria isolated from B6 brain, brain tumor, and cells
Brain CT-2A EPEN Astrocyte CT-2A EPEN
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[M+Na]+ Molecular Species
490.3 14:0 0.06 + 0.01 0.19 + 0.02 0.12 + 0.01 0.06 + 0.01 0.05 + 0.01 0.11 + 0.07
504.3 A16:0    0.06 + 0.03 0.25 + 0.02 0.14 + 0.10 0.28 + 0.02 0.53 + 0.17 0.15 + 0.03
516.3 16:1 0.09 + 0.04
518.3 16:0 0.89 + 0.21 2.23 + 0.27 0.93 + 0.38 0.48 + 0.04 0.86 + 0.06 0.82 + 0.15
542.3 18:2 0.06 + 0.02 0.24 + 0.02 0.10 + 0.01 0.02 + 0.01 0.02 + 0.01 0.02 + 0.01
544.3 18:1 0.41 + 0.13 1.33 + 0.06 0.39 + 0.09 0.15 + 0.00 0.26 + 0.09 0.25 + 0.09
546.4 18:0 0.32 + 0.08 1.38 + 0.29 0.68 + 0.19 0.38 + 0.07 0.48 + 0.05 0.65 + 0.05
566.3 20:4 0.16 + 0.09 0.06 + 0.00 0.08 + 0.03 0.02 + 0.02 0.08 + 0.05
568.3 20:3 0.02 + 0.00 0.05 + 0.01 0.05 + 0.00 0.01 + 0.01 0.02 + 0.01
570.4 20:2 0.03 + 0.01 0.10 + 0.04 0.10 + 0.04 0.01 + 0.01 0.02 + 0.02
572.4 20:1 0.04 + 0.02 0.34 + 0.14 0.09 + 0.05 0.03 + 0.01 0.04 + 0.02 0.30 + 0.24
574.4 20:0 0.04 + 0.02 0.06 + 0.03 0.04 + 0.02
590.3 22:6 0.24 + 0.12 0.03 + 0.01 0.08 + 0.00 0.02 + 0.01 0.02 + 0.02
592.3 22:5 0.08 + 0.03
594.4 22:4 0.04 + 0.02
596.4 22:3 0.03 + 0.03
598.4 22:2 0.01 + 0.01
600.4 22:1 0.04 + 0.03
602.4 22:0 0.02 + 0.02
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
In vivo In vitro
Table 48   Mass content of lysophosphatidylcholine molecular species of mitochondria isolated from B6 brain, brain tumors, and cells
Brain CT-2A EPEN Astrocyte CT-2A EPEN
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[M-H]- Molecular Species
536.5 N16:0 0.01 + 0.01 0.54 + 0.11 0.32 + 0.10 0.16 + 0.04 0.35 + 0.19 0.67 + 0.06
562.5 N18:1 0.02 + 0.02 0.01 + 0.01 0.01 + 0.00
564.5 N18:0 0.66 + 0.15 0.15 + 0.03 0.11 + 0.01 0.03 + 0.01 0.04 + 0.02 0.19 + 0.04
592.6 N20:0 0.04 + 0.02 0.06 + 0.01 0.03 + 0.01 0.01 + 0.00 0.02 + 0.00 0.03 + 0.00
606.6 N21:0 0.01 + 0.01 0.01 + 0.00
616.6 N22:2 0.01 + 0.00 0.00 + 0.01
618.6 N22:1 0.06 + 0.02 0.01 + 0.01 0.01 + 0.01 0.01 + 0.00 0.01 + 0.00
620.6 N22:0 0.15 + 0.05 0.17 + 0.03 0.11 + 0.02 0.10 + 0.06 0.17 + 0.03
632.6 N23:1 0.02 + 0.01 0.02 + 0.00 0.01 + 0.01 0.01 + 0.00
634.6 N23:0 0.02 + 0.00 0.02 + 0.01 0.03 + 0.01 0.02 + 0.00 0.03 + 0.01
644.6 N24:2 0.09 + 0.02 0.07 + 0.02 0.02 + 0.00 0.01 + 0.01 0.02 + 0.00
646.6 N24:1 0.02 + 0.02 0.71 + 0.08 0.51 + 0.03 0.23 + 0.01 0.25 + 0.12 0.36 + 0.04
648.6 N24:0 0.02 + 0.00 0.17 + 0.07 0.41 + 0.08 0.23 + 0.04 0.15 + 0.07 0.42 + 0.05
660.6 OH_N24:2 0.03 + 0.01 0.01 + 0.01
662.6 OH_N24:1 0.01 + 0.00 0.01 + 0.01 0.01 + 0.00
664.6 OH_N24:0 0.02 + 0.02 0.01 + 0.01 0.01 + 0.00 0.01 + 0.00
674.6 N26:1 0.03 + 0.01 0.01 + 0.00 0.01 + 0.00 0.01 + 0.00 0.01 + 0.00
676.7 N26:0 0.01 + 0.01 0.01 + 0.00
678.6 OH_N25:0 0.01 + 0.01
700.7 N28:2 0.04 + 0.00 0.01 + 0.00 0.01 + 0.00 0.04 + 0.00
702.7 N28:1 0.04 + 0.01 0.01 + 0.00 0.01 + 0.00 0.01 + 0.00
704.7 N28:0 0.02 + 0.02 0.01 + 0.00
Values are expressed as mean nmol/mg protein + S.D. (N = 3)
In vivo In vitro
Table 49   Mass content of ceramide molecular species of mitochondria isolated from B6 brain, brain tumor, and cells
Brain CT-2A EPEN Astrocyte CT-2A EPEN
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Figure 17.  Cardiolipin synthesis and remodeling.  Cardiolipin is synthesized by 
the condensation of phosphatidylglycerol and CDP-DAG to form immature 
cardiolipin.  Immature cardiolipin is the deacylation to form monolysocardiolipin 
and then uses the deacylated sn-2 position fatty acid tails of choline and 
ethanolamine glycerophospholipids for the reacylation of monolysocardiolipin.  
This remodeling process forms mature cardiolipin with a specific fatty acid 
molecular species. 
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 Figure 18.  Distribution of fatty acid molecular species of ethanolamine 
glycerophospholipids from B6 mitochondria isolated in vivo (A) or in vitro (B).  
Molar percentages less than 2% of total ethanolamine glycerophospholipids are 
not shown.  Glycerophospholipid subclasses include D (phosphatidyl), P 
(plasmenyl), and A (plasmanyl).  Total mass content is presented in Table 41.  All 
values are expressed as the mean of three independent samples (N = 3). 
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 Figure 19.  Distribution of fatty acid molecular species of choline 
glycerophospholipids from B6 mitochondria isolated in vivo (A) or in vitro (B).  
Molar percentages less than 2% of total ethanolamine glycerophospholipids are 
not shown.  Glycerophospholipid subclasses include D (phosphatidyl), P 
(plasmenyl), and A (plasmanyl).  Total mass content is presented in Table 41.  All 
values are expressed as the mean of three independent samples (N = 3). 
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Figure 20.  Distribution of fatty acid molecular species of cardiolipin from 
mitochondria isolated from B6 brain and brain tumors grown in vivo.  Total mass 
content is presented in Table 43.  All values are expressed as the mean of three 
independent samples (N = 3). 
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 Figure 21.  Distribution of fatty acid molecular species of cardiolipin from 
mitochondria isolated from B6 transformed astrocytes and brain tumors grown in 
vitro.  Total mass content is presented in Table 43.  All values are expressed as 
the mean of three independent samples (N = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
194 
 
0%
5%
10%
0%
5%
10%
0%
5%
10%
m
ol
e 
%
Astrocyte
CT-2A
EPEN
 
 
 
 
195 
 
Figure  22.  Electron transport chain activities in isolated mitochondria from B6 
brain, brain tumors, and cells.  Mitochondria isolated from tissue in vivo are brain 
(B), CT-2A (C), and EPEN (E).  The control cell line for in vitro measurements is 
transformed astrocytes (A).  Significantly different values from brain or 
transformed astrocytes at *: P < 0.03 or **: P < 0.005 as determined from the 
two-tailed t-test. 
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 CHAPTER SEVEN 
 
CONCLUSION 
 
The role and function of mitochondria in multicellular organisms is well 
established (Lane 2005; Scheffler 1999).  Mitochondria are the key component, 
which maintain and regulate the bioenergetic state of the cell.  Alterations in 
mitochondrial functionality results in a severe impairment of ATP production, 
which may lead to apoptosis.  In this thesis, I investigated multiple aspects of 
mitochondrial biology that contributed to the understanding of metabolic 
compartmentation in the brain, the role of mtDNA mutations in experimental brain 
cancer, the critical importance of the maintenance of the brain mitochondrial 
lipidome and corresponding ETC, as well as the role of mitochondrial lipid 
alterations in experimental brain cancer.  The majority of the research conducted 
for this thesis was to refute or support one of the key tenets of altered 
metabolism in cancer.  In the 1920’s, Otto Warburg, conducted key experiments 
establishing that cancer contained alterations in metabolism, due to a 
dependence on aerobic glycolysis in tumor tissue slices compared to control 
tissue (Warburg 1931).  In Warburg’s 1956 paper, he stated that ‘damage to 
respiration in cancer was irreversible’ (Warburg 1956).  This statement has 
driven research for decades on establishing the cause of irreversibly damaged 
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respiration at the same time it has been the ultimate goal of providing evidence 
that defective respiration can restored in cancer, which has yet to proven (Fantin 
et al. 2006; Chance 2005; Kroemer 2006; Pedersen 2007). 
 The Warburg theory of cancer metabolism has yet to be proven incorrect, 
since Otto Warburg never defined the defect that existed in tumor mitochondria.  
Could it be a simple upregulation of glycolytic enzymes, a loss of cellular 
mitochondrial content, mutations in mtDNA, altered metabolite transporters, or 
loss of energy sensing mechanism in cancer, to name a few possible 
explanations (Pelicano et al. 2006; Pedersen 1978; Wallace 2005)?  All of these 
possibilities seem feasible, however, there has yet to be an epiphenomenon that 
universally explains altered metabolism in most tumors.  Recent focus has been 
placed on the role of mtDNA mutations in cancer.  This seemed like an attractive 
idea, since mtDNA contains primarily coding sequence, is co-localized in a region 
containing high quantities of damaging free radicals, and has a reduced fidelity of 
its DNA polymerase (Kunkel and Loeb 1981; Croteau and Bohr 1997; Bianchi et 
al. 2001).  At the present time, there are over 1,000 articles investigating mtDNA 
mutations in cancer, however, there is little evidence to support the pathological 
significance of these mutations.  I investigated the mitochondrial genome in five 
spontaneous and chemically induced murine brain tumors and found no 
pathogenic mtDNA mutations.  Upon researching all published papers claiming 
mtDNA mutations in cancer, I learned that almost all mutations detected were not 
likely to be pathogenic as well.  A recent investigation by Salas et al 2005, 
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revealed that most mtDNA ‘mutations’ detected in various studies naturally exist 
in the human population due to genetic variation and that most mutations 
reported were likely due to experimental error and laboratory mishandling (Salas 
et al. 2005).  This reassessment of the role of mtDNA mutations in cancer, as 
well as utmost frustration with the field, resulted in a derivatization of a novel 
hypothesis regarding the role of mitochondrial membrane lipids in altered 
mitochondrial metabolism in brain cancer.   
 Mitochondrial membrane lipids comprise 20 to 45% of the total 
mitochondrial membrane, including both inner and outer membrane (Daum 1985; 
Goldhor 1968; Stoffel and Schiefer 1968; Comte et al. 1976).  These 
concentrations vary depending on isolation technique, experimental procedure 
for quantitation, as well as purity of mitochondria.  Mitochondrial lipids are critical 
for membrane fluidity, permeability, ETC activities, adenine nucleotide transport, 
phosphate transport, respiratory supercomplex formation, proton leak, creatine 
kinase activity, proton trapping, anchoring of cytochrome c, apoptosis, as well as 
numerous other enzyme activities associated with metabolism (Chicco and 
Sparagna 2007; Daum 1985).  Based on this list, as well as other functions, it 
seemed more likely that the investigation of the mitochondrial lipidome would 
seem  logical in terms of investigating a global change in mitochondria than 
investigating a few proteins or ‘tilling’ to find random mutations in cancer.  A 
change in the mitochondrial membrane lipid composition at the level of content, 
glycerophospholipids subclass, or molecular species would likely have a 
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significant effect on mitochondrial functionality, since energy transducing 
membranes require an evolutionarily selected composition of lipids in its inner 
and outer membrane to produce an efficient proton gradient and metabolic state 
(Mileykovskaya et al. 2005; Domenech et al. 2006). 
The advent of shotgun lipidomics allows for rapid analysis of the lipidome 
of an organelle (Han and Gross 2005b).  Through a collaboration with Xianlin 
Han, from Washington University School of Medicine, St. Louis, who developed 
this technology and  is a leading expert in the analysis of cardiolipin, I was able to 
analyze the mitochondrial lipidome in brain as well as brain tumor.  However, 
analysis of mitochondrial lipids was not the difficult part of this experiment; it was 
the purification of mitochondria, suitable for lipid analysis that was the most 
difficult aspect of this undertaking.  Even more so, the tissue of origin used for my 
control (brain), contained multiple populations of mitochondria as well as were 
found to be extremely contaminated with myelin and cellular components using 
previously described procedures.  Previous studies using isolated mitochondria 
from brain solely examined enzyme activities or oxygen consumption and these 
experiments did not require mitochondria that were greater than 95% pure 
(Brown et al. 2006; Lai and Clark 1976; Hamberger et al. 1970; Dagani et al. 
1988; Billups and Forsythe 2002).  Therefore, these isolation procedures were 
not developed to enrich for highly purified brain mitochondria.   
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One of the primary goals of my thesis was to establish a technique that 
would be able to isolated brain mitochondria (non-synaptic and synaptic) for the 
purpose of lipid analysis, which was free from any detectable contamination.  I 
tested numerous different types of discontinuous gradients (Percoll, Nycodenz, 
Ficoll, and sucrose) and through critical evaluation of the literature was able to 
devise a combination of protocols that were able to obtain highly enriched 
mitochondrial fractions for lipid analysis.    In the process of doing so for a 
comparison as a control for tumor mitochondrial lipid analysis, I discovered that 
non-synaptic and synaptic brain mitochondria contained differences in lipid 
content as well as unique molecular species, particularly in Ptd2Gro.  Also, these 
lipid differences could explain the lower in ETC activities in Syn compared to NS 
mitochondria.  This investigation led to the conclusion that differences in 
mitochondrial lipid and ETC activities likely contribute to metabolic 
compartmentation in the brain. 
The unique distribution of Ptd2Gro molecular species in brain mitochondria 
differed from Ptd2Gro in almost all other tissues, which primarily contain 
tetralinoleic Ptd2Gro (18:2-18:2-18:2-18:2) (Schlame et al. 2005; Schlame 2007).  
This was an important discovery, since the current opinion regarding Ptd2Gro 
was that tetralinoleic Ptd2Gro had functional significance and if the pattern 
deviated from a predominance of this species, it would result in a loss of 
mitochondrial functionality (Schlame et al. 2000; Chicco and Sparagna 2007).  
However, how could this be true in relationship to the brain Ptd2Gro distribution, 
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which contained a unique distribution consisting of seven symmetrically oriented 
molecular species groups and no tetralinoleic Ptd2Gro?  Based on the 
combinations of molecular species as well as distribution, I hypothesized that if 
remodeling of Ptd2Gro did not specify any of the four acyl chains based on the 
concentration of fatty acids found in Ptd2Gro, it could possible to create the same 
pattern of brain Ptd2Gro by random incorporation of remodeled fatty acids.  In 
addition, I was able to determine where the likely fatty acids were originating in 
Ptd2Gro remodeling since ChoGpl and EtnGpl sn-2 positions were used as donor 
fatty acids.  A PERL script was devised by Jeffrey Chuang and Hwi Moon, 
utilizing these parameters as well as outputting the data as viewed by mass 
spectrometry.  Surprisingly, a random incorporation model was able to determine 
the exact same pattern as viewed in brain Ptd2Gro.  The model produced 1800 
possible molecular species, however, when molecular species were combined 
based on their carbon:double bond values, which would be represented by mass 
to charge ratios, as well as all the species below 0.2% of the total distribution 
were eliminated, we were able to obtain 56 values with similar arrangement as 
that observed in brain Ptd2Gro.  Thus, Ptd2Gro remodeling enzymes in brain may 
have phospholipid specificity, but lack fatty acyl specificity that occurs in Ptd2Gro 
remodeling in other tissues. 
After establishing the ability to isolate brain mitochondria for the purpose 
of lipid analysis, I devised an approach to determine if the mitochondrial lipidome 
was altered in brain tumor mitochondria compared to controls.  In doing so, I 
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realized that most researchers use cells grown in vitro to analyze the metabolism 
of tumors.  I determined that it would be interesting to investigate if the 
mitochondrial lipidome as well as corresponding ETC activities were different 
depending on whether tumors were grown in vivo versus in vitro.  I isolated and 
purified mitochondria from chemically induced brain tumors in the B6 mouse (CT-
2A and EPEN) as well as those that arose spontaneously in the VM mouse strain 
(VM-NM1, VM-M2, and VM-M3). 
These tumor models are commonly used in the Seyfried lab and represent 
an astrocytoma, ependymoblastoma, a non-metastatic tumor with stem cell like 
characteristics, and two metastatic tumors with macrophage/microglia 
characteristics.  In doing so, I compared NS mitochondria from B6 and VM 
mouse strains to their syngeneic tumors.  NS mitochondria would represent both 
glial and neuronal mitochondria from brain, thus would be the representative 
control to compare to brain tumors. I used the transformed astrocyte cell line (C8-
D30) to compared B6 brain tumors as well as the transformed microglia cell line 
(BV2) to compare VM brain tumors for cells grown in vitro. 
   Before comparing brain tumor mitochondria with their corresponding NS 
brain mitochondrial controls, I made an interesting discovery regarding B6 NS 
mitochondria compared to VM NS mitochondria.  After comparing the entire brain 
mitochondrial lipidome as well as ETC activities between these two strains, I 
determined that the VM strain of mouse had significant differences in the 
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distribution of lipids as well as alterations in their brain Ptd2Gro molecular 
species.  This corresponded with a decrease in specific ETC activities that could 
be explained by alterations in the lipid composition.  This provoked an interesting 
hypothesis.  Could alterations in the brain mitochondrial lipidome, likely 
contribute to a decrease in metabolic efficiency, resulting in an increase in 
spontaneous brain tumor formation?  Since, VM mice have a 210 fold increase in 
spontaneous brain tumor incidence compared to the B6 mice, it could be 
possible that this metabolic deficiency could predispose VM to increased brain 
tumorigenesis (Fraser 1971). 
Analysis of the lipidome in isolated mitochondria grown in vivo and in vitro 
revealed significant differences in lipid content compared to controls.  Most 
notably, Ptd2Gro appeared to have a different molecular species distribution 
depending on growth conditions.  Since, Ptd2Gro molecular species are 
determined by a complex balance of synthesis as well as remodeling using fatty 
acid donor tails from ChoGpl and EtnGpl, changes in the growth conditions 
demonstrated control over the overall Ptd2Gro molecular species.  Regardless, 
since tumors grown in vivo represent the more likely comparison, I discovered 
significantly lower Ptd2Gro content in almost all tumors as well as abnormalities 
in Ptd2Gro molecular speciation, likely the result of abnormal cardiolipin 
remodeling.  In addition, some tumor mitochondria contained higher PtdGro, in 
addition to low Ptd2Gro, which would be indicative of an inability to efficiently 
synthesize Ptd2Gro, resulting in an accumulation of its precursor, PtdGro.  Also, 
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changes in ChoGpl and EtnGpl content as well as glycerophospholipid 
subclasses would likely result in altered fluidity as well as functional changes in 
the mitochondrial membrane.  Interestingly, Cer was also found to be elevated in 
the mitochondrial membrane in some tumors, which corresponded to lower 
specific ETC activities with known inhibition by Cer (Di Paola et al. 2000).  PtdSer 
was elevated in most tumor mitochondria, likely due to a requirement to balance 
anionic lipids in the mitochondrial membrane to restore charge due to a loss of 
Ptd2Gro or due to its use as a precursor in PtdEtn synthesis by the mitochondria 
(Morton et al. 1976; Zborowski et al. 1983; Daum and Vance 1997). 
Ptd2Gro molecular species distribution in tumors appears to be 
significantly altered due to Ptd2Gro remodeling.  In most tumors, the vast majority 
of Ptd2Gro molecular species could represent newly synthesized Ptd2Gro, due to 
fatty acid similarities with the PtdGro.  The mathematical algorithm used to 
explain random incorporation of fatty acids into brain Ptd2Gro did not function for 
brain tumor mitochondria, since Ptd2Gro remodeling might not occur in 
equilibrium as it does in brain.  Hence, a new algorithmic approach is being 
developed, in collaboration with Jeffrey Chuang, to allow for real time analysis of 
Ptd2Gro remodeling.  A computer visualization program will allow the 
mathematical model’s output to be display newly synthesized Ptd2Gro from the 
condensation of PtdGro molecular species based on designated concentrations.  
Then based on the calculation of ChoGpl and EtnGpl sn-2 fatty acids as well as 
phospholipid specificity, a selection of calculated fatty acids will be determined to 
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be utilized for remodeling.  At this stage, modifications of fatty acid 
concentrations will allow for determination of fatty acid specificity.  A specified 
rate of cardiolipin remodeling will be determined and remain constant.   A 
simulation will be initiated and the rate as well as groups of newly remodeled 
Ptd2Gro will be visualized as would be viewed from mass spectrometry data.  
This approach will allow for the comparison of the rate of Ptd2Gro remodeling, 
fatty acid specificity, phospholipid specificity, as well as a direct comparison with 
data obtained from experimental samples determined by mass spectrometry.  
This model can also be utilized to determine abnormalities in Ptd2Gro metabolism 
in other cancers, diabetic cardiomyopathies, sudden heart failure, 
neurodegenerative diseases, as well as Barth syndrome (Hartz et al. 1982; Han 
et al. 2007; Sparagna et al. 2007; Valianpour et al. 2002; Guan et al. 1994). 
Taken together, I determined that differences in the mitochondrial lipidome 
of NS and Syn mitochondria likely contribute to metabolic compartmentation in 
brain.  In addition, my findings for brain Ptd2Gro will result in a reevaluation of the 
importance of Ptd2Gro molecular species as well as Ptd2Gro remodeling.  I 
determined that mtDNA mutations do not contribute to altered metabolism in 
experimental brain cancer, however, differences in the mitochondrial lipidome in 
brain tumors contribute to abnormal metabolism likely due to alterations in ETC 
activities.  The determination of an altered mitochondrial lipidome in brain cancer 
as well as connection with ETC functionality is a novel interpretation of the 
Warburg theory that fully supports the tenet that mitochondria are altered in 
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cancer.  Furthermore, future experiments regarding mathematically predicting 
Ptd2Gro remodeling in cancer, neurodegenerative disease, diabetic myocardium, 
as well as other neurological disorders could have significant impact on 
understanding the role of Ptd2Gro regarding its bioenergetic impact on these 
disease states. 
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